Represent

Lobbying
Lobbying by Bayer Corporation (consolidated report)

Lobbying Relationship

Client

Bayer Corporation (consolidated report)

More records

Lobbying firm

Bayer Corporation (consolidated report)

More records

Monitor and engage on legislative and administrative action related to pollinator health and habitat promotion. Monitor and engage on legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor and engage on legislative and administrative action related to the Endangered Species Act and related reforms. Monitor and engage on legislative and administrative action related to 7 CFR Part 340. Monitor and engage on the implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor and engage on legislative and administrative action related to biotech innovation and regulation. Monitor and engage on legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor and engage on legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor and engage on legislative and administrative action related to food security and nutrition. Monitor and engage on legislative and administrative action related to the International Union for the Protection of New Varieties of Plants (UPOV). Monitor and engage on legislative and administrative action related to the reauthorization of the Pesticide Registration Improvement Act. Monitor and engage on legislative and administrative action related to biofuels, including ethanol, the RFS, and sustainable aviation fuel. Monitor and engage on legislative and administrative action related to Pesticides: Exemptions of Certain Plant-Incorporated Protectants Derived from Newer Technologies (Final Rule). Monitor and engage on legislative and administrative action related to reauthorization of Foundation for Food and Agriculture Research (FFAR). Monitor and engage on legislative and administrative action related to the Farm Bill. H.R. 1472, Plant Biostimulant Act. H.R. 3935, Securing Growth and Robust Leadership in American Aviation Act. H.R. 4288, Agricultural Labeling Uniformity Act. S. 802, Plant Biostimulant Act.
Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on the implementation of the Infrastructure Investment and Jobs Act (P.L. 117-58), and the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on a FY 2025 National Defense Authorization Act (NDAA). H.R. 4288, Labeling Uniformity Act. H.R. 4366, Consolidated Appropriations Act, 2024 (Pub. Law 118-42). H.R. 4368, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024. H.R. 4821, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2024, including Section 461. S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024. S. 2605, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2024.
Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform.
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. Monitor and engage on legislative and administrative action related to DEA-determined pseudoephedrine quotas. H.R. 3086, Find It Early Act.
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169).
Monitor and engage on legislative and administrative action related to Miscellaneous Tariff Bill (MTB) petitions. Monitor and engage on legislative and administrative action related to Section 301 tariffs. Monitor and engage on legislative and administrative action related to tariff deferment. Monitor and engage on legislative and administrative action related to tariff suspensions.
Monitor and engage on legislative and federal activity related to tax reform. Monitor and engage on legislative and administrative action related to corporate and international tax, including issues related to tax code sections 245A, 951A, 59A, 163(j), 174, and 965. Monitor and engage on legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor and engage on legislative and administrative action related to including dietary supplements as reimbursable expenses in tax-preferred savings accounts. Monitor and engage on legislative and administrative issues related to foreign tax credit regulations. Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169), including the section 45Z tax credit and the sustainable aviation fuel tax credit.
Monitor and engage on legislative and administrative action related to trade. Monitor and engage on legislative and administrative action related to foreign regulation of chemicals, pesticides, pharmaceuticals, and health care products. Monitor and engage on legislative and administrative action related to China import approvals, and foreign direct investment prohibitions and restrictions. Monitor and engage in administrative action related to maximum residue levels (MRLs) in the EU, EU biotech import approvals, and EU Green Deal. Monitor and engage on legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor and engage on legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor and engage on legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor and engage on legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor and engage on the administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor and engage on legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor and engage on legislative and administrative action related to Russian and Ukraine food security. Monitor and engage on legislative and administrative action related to Ukraine reconstruction and investment. Monitor and engage on legislative and administrative action related to World Trade Organization (WTO) digital trade rules.
Monitor and engage on legislative and administrative action related to Biofuels and the Renewable Fuel Standard. Monitor and engage on the implementation of the Infrastructure Investment and Jobs Act (P.L. 117-58). Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169).
Monitor and engage on legislative and administrative action related to phosphate mining operations and permits. Monitor and engage on legislative and administrative action related to Caldwell Canyon permitting. Monitor and engage on legislative and administrative action related to proposed Conservation and Landscape Health Rule and Greater Sage Grouse Habitat Conservation Plans.
Monitor and engage on legislative and administrative action related to climate change, including sustainable agriculture. Monitor and engage on legislative and administrative action related to FIFRA Regulations, including voluntary carbon markets.
Monitor and engage on legislative and administrative action related to antitrust and competition.
S. 1939, FAA Reauthorization Act of 2023.
Resolution expressing a commitment to strengthen science, technology, and innovation R&D for economic development in Africa, and the importance for US engagement with Africa to address global challenges.

Duration: January 1, 2008 to present

General Issues: Agriculture, Budget/Appropriations, Copyright/Patent/Trademark, Health Issues, Medicare/Medicaid, Miscellaneous Tariff Bills, Taxation/Internal Revenue Code, Trade (Domestic & Foreign), Energy/Nuclear, Natural Resources, Environmental/Superfund, Labor Issues/Antitrust/Workplace, Transportation, Foreign Relations, Defense, Civil Rights/Civil Liberties, Immigration, Telecommunications, Financial Institutions/Investments/Securities, Government Issues, Chemicals/Chemical Industry, Pharmacy, Banking, Homeland Security, Education, Animals, Food Industry (Safety, Labeling, etc.), Manufacturing, Medical/Disease Research/Clinical Labs, Railroads, Aviation/Aircraft/Airlines, Consumer Issues/Safety/Protection, Alcohol & Drug Abuse, Clean Air & Water (Quality), Insurance, Economics/Economic Development, Science/Technology, Automotive Industry, Aerospace, Housing, Indian/Native American Affairs, Law Enforcement/Crime/Criminal Justice, Roads/Highway

Spending: about $109,599,903 (But it's complicated. Here's why.)

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), U.S. Trade Representative (USTR), Council on Environmental Quality (CEQ), Patent & Trademark Office (PTO), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Treasury - Dept of, Natl Economic Council (NEC), Agriculture - Dept of (USDA), Natl Security Council (NSC), Commerce - Dept of (DOC), Executive Office of the President (EOP), State - Dept of (DOS), U.S. Agency for International Development (USAID), Homeland Security - Dept of (DHS), Interior - Dept of (DOI), Bureau of Land Management (BLM), Office of Management & Budget (OMB), White House Office, Small Business Administration (SBA), U.S. Copyright Office, Commerce - Dept of (DOC), U.S. Senate,, House of Representatives,

Bills mentioned

S.322: Pet and Women Safety Act of 2017

Sponsor: Gary Peters (D-Mich.)

S.629: Preventing Antibiotic Resistance Act of 2017

Sponsor: Dianne Feinstein (D-Calif.)

H.R.909: Pet and Women Safety Act of 2017

Sponsor: Katherine Clark (D-Mass.)

H.R.953: Reducing Regulatory Burdens Act of 2017

Sponsor: Bob Gibbs (R-Ohio)

H.R.1029: Pesticide Registration Improvement Extension Act of 2018

Sponsor: Rodney Davis (R-Ill.)

H.R.3040: Saving America's Pollinators Act of 2017

Sponsor: John Conyers Jr. (D-Mich.)

S.CON.RES.3: A concurrent resolution setting forth the congressional budget for the...

Sponsor: Michael B. Enzi (R-Wyo.)

S.1603: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: John Hoeven (R-N.D.)

H.R.3268: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Robert B. Aderholt (R-Ala.)

S.404: A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the...

Sponsor: Johnny Isakson (R-Ga.)

S.469: Affordable and Safe Prescription Drug Importation Act

Sponsor: Bernard Sanders (ID-Vt.)

S.934: FDA Reauthorization Act of 2017

Sponsor: Lamar Alexander (R-Tenn.)

H.R.749: Lower Drug Costs through Competition Act

Sponsor: Kurt Schrader (D-Ore.)

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

H.R.2009: Fostering Innovation in Medical Imaging Act of 2017

Sponsor: Ryan Costello (R-Pa.)

H.R.2118: Medical Device Servicing Safety and Accountability Act

Sponsor: Ryan Costello (R-Pa.)

H.R.2164: Medical Device Safety Act

Sponsor: Brian Fitzpatrick (R-Pa.)

H.R.2430: FDA Reauthorization Act of 2017

Sponsor: Greg Walden (R-Ore.)

H.R.3921: HEALTHY KIDS Act

Sponsor: Michael C. Burgess (R-Texas)

H.R.849: Protecting Seniors Access to Medicare Act

Sponsor: Phil Roe (R-Tenn.)

S.251: Protecting Medicare from Executive Action Act of 2017

Sponsor: Ron Wyden (D-Ore.)

S.260: Protecting Seniors' Access to Medicare Act of 2017

Sponsor: John Cornyn (R-Texas)

S.85: Restoring Access to Medication Act of 2017

Sponsor: Pat Roberts (R-Kan.)

S.108: Medical Device Access and Innovation Protection Act

Sponsor: Orrin G. Hatch (R-Utah)

H.R.184: Protect Medical Innovation Act of 2018

Sponsor: Erik Paulsen (R-Minn.)

H.R.394: Restoring Access to Medication Act of 2017

Sponsor: Lynn Jenkins (R-Kan.)

H.R.1268: Veterinary Medicine Loan Repayment Program Enhancement Act

Sponsor: Adrian Smith (R-Neb.)

S.119: Sunshine for Regulatory Decrees and Settlements Act of 2017

Sponsor: Charles E. Grassley (R-Iowa)

H.R.469: Congressional Article I Powers Strengthening Act

Sponsor: Doug Collins (R-Ga.)

H.R.1430: HONEST Act

Sponsor: Lamar Smith (R-Texas)

H.R.1431: EPA Science Advisory Board Reform Act of 2017

Sponsor: Frank D. Lucas (R-Okla.)

S.951: Regulatory Accountability Act of 2017

Sponsor: Rob Portman (R-Ohio)

S.1794: HONEST Act

Sponsor: Mike Rounds (R-S.D.)

S.511: Genetically Engineered Food Right-to-Know Act

Sponsor: Barbara Boxer (D-Calif.)

S.621: Preventing Antibiotic Resistance Act of 2015

Sponsor: Dianne Feinstein (D-Calif.)

S.1559: Pet and Women Safety Act of 2015

Sponsor: Kelly Ayotte (R-N.H.)

S.2609: An original bill to amend the Agricultural Marketing Act of 1946 to...

Sponsor: Pat Roberts (R-Kan.)

H.R.897: Zika Vector Control Act

Sponsor: Bob Gibbs (R-Ohio)

H.R.913: Genetically Engineered Food Right-to-Know Act

Sponsor: Peter A. DeFazio (D-Ore.)

H.R.1258: Pet and Women Safety Act of 2015

Sponsor: Katherine Clark (D-Mass.)

H.R.1284: Saving America's Pollinators Act of 2015

Sponsor: John Conyers Jr. (D-Mich.)

H.R.1599: Safe and Accurate Food Labeling Act of 2015

Sponsor: Mike Pompeo (R-Kan.)

H.R.3714: Small Agriculture Producer Size Standards Improvements Act of 2015

Sponsor: Mike Bost (R-Ill.)

H.R.4974: Military Construction and Veterans Affairs and Related Agencies...

Sponsor: Charlie Dent (R-Pa.)

H.R.4909: National Defense Authorization Act for Fiscal Year 2017

Sponsor: William M. Thornberry (R-Texas)

H.R.5293: Department of Defense Appropriations Act, 2017

Sponsor: Rodney Frelinghuysen (R-N.J.)

S.1878: Advancing Hope Act of 2016

Sponsor: Bob Casey (D-Pa.)

S.1890: Defend Trade Secrets Act of 2016

Sponsor: Orrin G. Hatch (R-Utah)

S.2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act

Sponsor: Al Franken (D-Minn.)

H.R.6: 21st Century Cures Act

Sponsor: Fred Upton (R-Mich.)

H.R.34: 21st Century Cures Act

Sponsor: Suzanne Bonamici (D-Ore.)

H.R.771: Protecting Access to Diabetes Supplies Act of 2015

Sponsor: Diana DeGette (D-Colo.)

H.R.1537: Advancing Hope Act of 2015

Sponsor: G. K. Butterfield (D-N.C.)

H.R.2459: Delivering Antimicrobial Transparency in Animals Act of 2015

Sponsor: Louise M. Slaughter (D-N.Y.)

H.R.3299: Strengthening Public Health Emergency Response Act of 2016

Sponsor: Susan Brooks (R-Ind.)

H.R.3326: Defend Trade Secrets Act of 2015

Sponsor: Doug Collins (R-Ga.)

H.R.3920: E-Free Act

Sponsor: Michael G. Fitzpatrick (R-Pa.)

S.2011: Offshore Production and Energizing National Security Act of 2015

Sponsor: Lisa Murkowski (R-Alaska)

S.148: Medicare DMEPOS Competitive Bidding Improvement Act of 2015

Sponsor: Rob Portman (R-Ohio)

H.R.2: Medicare Access and CHIP Reauthorization Act of 2015

Sponsor: Michael C. Burgess (R-Texas)

H.R.5122: To prohibit further action on the proposed rule regarding testing of...

Sponsor: Larry Bucshon (R-Ind.)

S.2794: American Manufacturing Competitiveness Act of 2016

Sponsor: Orrin G. Hatch (R-Utah)

H.R.4923: American Manufacturing Competitiveness Act of 2016

Sponsor: Kevin Brady (R-Texas)

H.R.160: Protect Medical Innovation Act of 2015

Sponsor: Erik Paulsen (R-Minn.)

S.149: Medical Device Access and Innovation Protection Act

Sponsor: Orrin G. Hatch (R-Utah)

S.440: Veterinary Medicine Loan Repayment Program Enhancement Act

Sponsor: Michael D. Crapo (R-Idaho)

S.1015: Enforcing Orders and Reducing Customs Evasion Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

S.1200: Fairness to Pet Owners Act of 2015

Sponsor: Richard Blumenthal (D-Conn.)

H.R.644: Trade Facilitation and Trade Enforcement Act of 2015

Sponsor: Tom Reed (R-N.Y.)

H.R.1891: To extend the African Growth and Opportunity Act, the Generalized System...

Sponsor: Paul D. Ryan (R-Wis.)

H.R.1907: Trade Facilitation and Trade Enforcement Act of 2015

Sponsor: Pat Tiberi (R-Ohio)

H.R.2146: Defending Public Safety Employees' Retirement Act

Sponsor: Dave Reichert (R-Wash.)

H.R.3174: Fairness to Pet Owners Act of 2015

Sponsor: Jason Chaffetz (R-Utah)

S.337: FOIA Improvement Act of 2016

Sponsor: John Cornyn (R-Texas)

S.378: Sunshine for Regulatory Decrees and Settlements Act of 2015

Sponsor: Charles E. Grassley (R-Iowa)

H.R.653: FOIA Act

Sponsor: Darrell Issa (R-Calif.)

S.998: American Manufacturing Competitiveness Act of 2015

Sponsor: Rob Portman (R-Ohio)

H.R.2576: Frank R. Lautenberg Chemical Safety for the 21st Century Act

Sponsor: John Shimkus (R-Ill.)

S.1137: PATENT Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.9: Innovation Act

Sponsor: Robert W. Goodlatte (R-Va.)

H.R.2029: Consolidated Appropriations Act, 2016

Sponsor: Charlie Dent (R-Pa.)

H.R.1890: Bipartisan Congressional Trade Priorities and Accountability Act of 2015

Sponsor: Paul D. Ryan (R-Wis.)

S.995: Bipartisan Congressional Trade Priorities and Accountability Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

S.1009: AGOA Extension and Enhancement Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

H.R.3651: Positive Train Control Enforcement and Implementation Act of 2015

Sponsor: Bill Shuster (R-Pa.)

S.650: Railroad Safety and Positive Train Control Extension Act

Sponsor: Roy Blunt (R-Mo.)

S.1006: Positive Train Control Safety Act

Sponsor: Dianne Feinstein (D-Calif.)

S.535: Energy Efficiency Improvement Act of 2015

Sponsor: Rob Portman (R-Ohio)

H.R.896: Regulatory Certainty Act of 2015

Sponsor: Bob Gibbs (R-Ohio)

H.R.1270: Restoring Access to Medication and Improving Health Savings Act of 2016

Sponsor: Lynn Jenkins (R-Kan.)

S.709: Restoring Access to Medication Act of 2015

Sponsor: Pat Roberts (R-Kan.)

S.CON.RES.11: An original concurrent resolution setting forth the congressional budget...

Sponsor: Michael B. Enzi (R-Wyo.)

H.CON.RES.27: Establishing the budget for the United States Government for fiscal year...

Sponsor: Tom Price (R-Ga.)

S.809: Genetically Engineered Food Right-to-Know Act

Sponsor: Barbara Boxer (D-Calif.)

S.1256: Preventing Antibiotic Resistance Act of 2013

Sponsor: Dianne Feinstein (D-Calif.)

H.R.1150: Preservation of Antibiotics for Medical Treatment Act of 2013

Sponsor: Louise M. Slaughter (D-N.Y.)

H.R.4432: Safe and Accurate Food Labeling Act of 2014

Sponsor: Mike Pompeo (R-Kan.)

H.R.2692: Saving America's Pollinators Act of 2013

Sponsor: John Conyers Jr. (D-Mich.)

H.R.5447: To amend the Federal Insecticide, Fungicide, and Rodenticide Act to...

Sponsor: Austin Scott (R-Ga.)

H.R.2217: Department of Homeland Security Appropriations Act, 2014

Sponsor: John Carter (R-Texas)

H.R.2725: Food and Drug Administration Safety Over Sequestration Act of 2013

Sponsor: Leonard Lance (R-N.J.)

S.696: Safe Chemicals Act of 2013

Sponsor: Frank R. Lautenberg (D-N.J.)

S.1009: Chemical Safety Improvement Act

Sponsor: Frank R. Lautenberg (D-N.J.)

H.R.3309: Innovation Act

Sponsor: Robert W. Goodlatte (R-Va.)

S.761: Energy Savings and Industrial Competitiveness Act of 2013

Sponsor: Jeanne Shaheen (D-N.H.)

S.1020: All-Of-The-Above Federal Building Energy Conservation Act of 2013

Sponsor: John Hoeven (R-N.D.)

S.1392: Energy Savings and Industrial Competitiveness Act of 2013

Sponsor: Jeanne Shaheen (D-N.H.)

S.2074: Energy Savings and Industrial Competitiveness Act of 2014

Sponsor: Jeanne Shaheen (D-N.H.)

S.2262: Energy Savings and Industrial Competitiveness Act of 2014

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.1616: Energy Savings and Industrial Competitiveness Act of 2013

Sponsor: David McKinley (R-W.Va.)

H.R.3080: Water Resources Reform and Development Act of 2014

Sponsor: Bill Shuster (R-Pa.)

S.601: Water Resources Development Act of 2013

Sponsor: Barbara Boxer (D-Calif.)

H.R.935: Reducing Regulatory Burdens Act of 2014

Sponsor: Bob Gibbs (R-Ohio)

H.R.5078: Waters of the United States Regulatory Overreach Protection Act of 2014

Sponsor: Steve Southerland (R-Fla.)

S.2011: Stop Targeting of Political Beliefs by the IRS Act of 2014

Sponsor: Jeff Flake (R-Ariz.)

H.R.4302: Protecting Access to Medicare Act of 2014

Sponsor: Joe Pitts (R-Pa.)

S.1871: SGR Repeal and Medicare Beneficiary Access Act of 2013

Sponsor: Max Baucus (D-Mont.)

H.R.4771: Designer Anabolic Steroid Control Act of 2014

Sponsor: Joe Pitts (R-Pa.)

S.2012: Designer Anabolic Steroid Control Act of 2014

Sponsor: Sheldon Whitehouse (D-R.I.)

H.R.1295: Medical Device Tax Elimination Act

Sponsor: Dan Maffei (D-N.Y.)

S.2917: Adding Ebola to the FDA Priority Review Voucher Program Act

Sponsor: Tom Harkin (D-Iowa)

H.R.3969: PACT Act

Sponsor: Bill Johnson (R-Ohio)

S.644: PACT Act

Sponsor: Bob Casey (D-Pa.)

H.R.2708: United States Job Creation and Manufacturing Competitiveness Act of 2013

Sponsor: Dave Camp (R-Mich.)

H.R.523: Protect Medical Innovation Act of 2013

Sponsor: Erik Paulsen (R-Minn.)

H.R.2835: Restoring Access to Medication Act of 2013

Sponsor: Lynn Jenkins (R-Kan.)

S.1647: Restoring Access to Medication Act

Sponsor: Pat Roberts (R-Kan.)

S.232: Medical Device Access and Innovation Protection Act

Sponsor: Orrin G. Hatch (R-Utah)

S.1900: Bipartisan Congressional Trade Priorities Act of 2014

Sponsor: Max Baucus (D-Mont.)

H.R.3830: Bipartisan Congressional Trade Priorities Act of 2014

Sponsor: Dave Camp (R-Mich.)

S.954: Agriculture Reform, Food, and Jobs Act of 2013

Sponsor: Debbie Stabenow (D-Mich.)

H.R.2642: Agricultural Act of 2014

Sponsor: Frank D. Lucas (R-Okla.)

H.R.1947: Federal Agriculture Reform and Risk Management Act of 2013

Sponsor: Frank D. Lucas (R-Okla.)

S.1106: Sensible Accounting to Value Energy Act of 2013

Sponsor: Michael Bennet (D-Colo.)

H.R.3204: Drug Quality and Security Act

Sponsor: Fred Upton (R-Mich.)

S.959: Pharmaceutical Quality, Security, and Accountability Act

Sponsor: Tom Harkin (D-Iowa)

H.R.1528: Veterinary Medicine Mobility Act of 2014

Sponsor: Kurt Schrader (D-Ore.)

H.R.1699: Genetically Engineered Food Right-to-Know Act

Sponsor: Peter A. DeFazio (D-Ore.)

S.553: Veterinary Medicine Loan Repayment Program Enhancement Act

Sponsor: Tim Johnson (D-S.D.)

H.R.1125: Veterinary Medicine Loan Repayment Program Enhancement Act

Sponsor: Kurt Schrader (D-Ore.)

H.R.1407: Animal Drug User Fee Amendments of 2013

Sponsor: John Shimkus (R-Ill.)

H.R.1408: Animal Generic Drug User Fee Amendments of 2013

Sponsor: Cory Gardner (R-Colo.)

S.622: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013

Sponsor: Tom Harkin (D-Iowa)

H.R.933: Consolidated and Further Continuing Appropriations Act, 2013

Sponsor: Harold Rogers (R-Ky.)

H.R.527: Helium Stewardship Act of 2013

Sponsor: Doc Hastings (R-Wash.)

S.10: Agriculture Reform, Food, and Jobs Act of 2013

Sponsor: Harry Reid (D-Nev.)

S.175: A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act...

Sponsor: Pat Roberts (R-Kan.)

H.R.8:

Sponsor: John A. Boehner (R-Ohio)

H.R.525: Veterinary Public Health Amendments Act of 2011

Sponsor: Tammy Baldwin (D-Wis.)

S.518: Veterinary Medicine Loan Repayment Program Enhancement Act

Sponsor: Tim Johnson (D-S.D.)

H.R.5973: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Jack Kingston (R-Ga.)

H.R.5250: To suspend temporarily the rate of duty on 1,6-Hexanediol-dimethyl...

Sponsor: Tim Murphy (R-Pa.)

S.2763: A bill to suspend temporarily the duty on dimethyl carbonate polymer...

Sponsor: Bob Casey (D-Pa.)

H.R.5251: To suspend temporarily the rate of duty on 1,6-Hexanediol-dimethyl...

Sponsor: Tim Murphy (R-Pa.)

S.2765: A bill to suspend temporarily the duty on copoly(dimethyl...

Sponsor: Bob Casey (D-Pa.)

S.2767: A bill to suspend temporarily the duty on dimethyl carbonate polymer...

Sponsor: Bob Casey (D-Pa.)

H.R.5253: To suspend temporarily the duty on reaction product of...

Sponsor: Tim Murphy (R-Pa.)

S.2770: A bill to suspend temporarily the duty on reaction product of...

Sponsor: Bob Casey (D-Pa.)

S.2778: A bill to suspend temporarily the duty on reaction product of...

Sponsor: Bob Casey (D-Pa.)

H.R.5236: To suspend temporarily the duty on Desmodur BL 1100/1.

Sponsor: Tim Murphy (R-Pa.)

S.2772: A bill to suspend temporarily the duty on oxirane, 2-methyl-, polymer...

Sponsor: Bob Casey (D-Pa.)

H.R.5235: To suspend temporarily the duty on Bayhydur BL 5335.

Sponsor: Tim Murphy (R-Pa.)

S.2773: A bill to suspend temporarily the duty on hexanedioic acid, dihydrazide,...

Sponsor: Bob Casey (D-Pa.)

H.R.5233: To suspend temporarily the duty on Desmodur VP LS 2078/2.

Sponsor: Tim Murphy (R-Pa.)

S.2775: A bill to suspend temporarily the duty on...

Sponsor: Bob Casey (D-Pa.)

H.R.5229: To suspend temporarily the duty on 1,6-Diisocyanato-hexane homopolymer,...

Sponsor: Tim Murphy (R-Pa.)

S.2779: A bill to suspend temporarily the duty on...

Sponsor: Bob Casey (D-Pa.)

H.R.5234: To suspend temporarily the duty on Bayhydur XP 2547.

Sponsor: Tim Murphy (R-Pa.)

S.2781: A bill to suspend temporarily the duty on water-dispersible...

Sponsor: Bob Casey (D-Pa.)

H.R.5246: To extend the temporary suspension of duty on 2-Oxepanone polymer with...

Sponsor: Tim Murphy (R-Pa.)

S.2783: A bill to extend the temporary suspension of duty on 2-oxepanone polymer...

Sponsor: Bob Casey (D-Pa.)

H.R.5247: To extend and modify the temporary suspension of duty on Desmodur R-E.

Sponsor: Tim Murphy (R-Pa.)

S.2788: A bill to extend and modify the temporary suspension of duty on...

Sponsor: Bob Casey (D-Pa.)

H.R.5230: To extend the temporary suspension of duty on Desmodur E 14.

Sponsor: Tim Murphy (R-Pa.)

S.2784: A bill to extend the temporary suspension of duty on 1,2,3-propanetriol,...

Sponsor: Bob Casey (D-Pa.)

H.R.5248: To extend and modify the temporary suspension of duty on Poly(toluene...

Sponsor: Tim Murphy (R-Pa.)

S.2760: A bill to extend and modify the temporary suspension of duty on...

Sponsor: Bob Casey (D-Pa.)

H.R.5249: To extend and modify the temporary suspension of duty on Desmodur RF-E.

Sponsor: Tim Murphy (R-Pa.)

S.2762: A bill to extend and modify the temporary suspension of duty on mixtures...

Sponsor: Bob Casey (D-Pa.)

H.R.5231: To extend and modify the temporary suspension of duty on Desmodur HL BA.

Sponsor: Tim Murphy (R-Pa.)

S.2786: A bill to extend and modify the temporary suspension of duty on...

Sponsor: Bob Casey (D-Pa.)

H.R.5276: To extend and modify the temporary reduction of duty on...

Sponsor: Bill Pascrell Jr. (D-N.J.)

S.2758: A bill to extend the temporary reduction of duty on Aspirin.

Sponsor: Bob Casey (D-Pa.)

H.R.5277: To extend the temporary suspension of duty on D-Mannose.

Sponsor: Bill Pascrell Jr. (D-N.J.)

S.3028: A bill to extend the temporary suspension of duty on D-Mannose.

Sponsor: Frank R. Lautenberg (D-N.J.)

H.R.5278: To extend the temporary suspension of duty on propoxur...

Sponsor: Bill Pascrell Jr. (D-N.J.)

S.3026: A bill to extend the temporary suspension of duty on Propoxur.

Sponsor: Robert Menendez (D-N.J.)

S.3292: Temporary Duty Suspension Process Act of 2012

Sponsor: Claire McCaskill (D-Mo.)

H.R.6727: United States Job Creation and Manufacturing Competitiveness Act of 2013

Sponsor: Dave Camp (R-Mich.)

H.R.4459: To suspend temporarily the duty on Thidiazuron.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.2725: A bill to suspend temporarily the duty on thidiazuron.

Sponsor: Bob Casey (D-Pa.)

H.R.4460: To extend the suspension of duty on Fenamidone.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.3135: A bill to extend the temporary suspension of duty on Fenamidone.

Sponsor: Kay Hagan (D-N.C.)

H.R.4461: To extend the suspension of duty on Spirodiclofen.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.2702: A bill to extend the temporary suspension of duty on Spirodiclofen.

Sponsor: Bob Casey (D-Pa.)

H.R.4462: To extend the suspension of duty on 2,4-dichloroaniline.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.3137: A bill to extend the temporary suspension of duty on 2,4-dichloroaniline.

Sponsor: Kay Hagan (D-N.C.)

H.R.4463: To suspend temporarily the duty on Thiacloprid.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.2723: A bill to suspend temporarily the duty on thiacloprid.

Sponsor: Bob Casey (D-Pa.)

H.R.4464: To extend the suspension of duty on Pyrimethanil.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.2700: A bill to extend the temporary suspension of duty on pyrimethanil.

Sponsor: Bob Casey (D-Pa.)

H.R.4465: To suspend temporarily the duty on Pyrasulfotole.

Sponsor: Blaine Luetkemeyer (R-Mo.)

H.R.4466: To suspend temporarily the duty on Fosetyl-Al.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.2704: A bill to extend the temporary suspension of duty on Fosetyl-Al.

Sponsor: Bob Casey (D-Pa.)

H.R.4538: To extend the temporary suspension of duty on Permethrin.

Sponsor: Renee Ellmers (R-N.C.)

S.3020: A bill to extend the temporary suspension of duty on Permethrin.

Sponsor: Robert Menendez (D-N.J.)

H.R.4575: To modify and extend the temporary reduction of duty on Isoxaflutole.

Sponsor: Blaine Luetkemeyer (R-Mo.)

H.R.4576: To modify and extend the temporary reduction of duty on Clothianidin.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.3015: A bill to extend and modify the temporary suspension of duty on...

Sponsor: Robert Menendez (D-N.J.)

H.R.4578: To supsend temporarily the duty on Triadimefon.

Sponsor: Blaine Luetkemeyer (R-Mo.)

S.3016: A bill to extend and modify the temporary reduction of duty on Triadimefon.

Sponsor: Robert Menendez (D-N.J.)

H.R.4657: To suspend temporarily the duty on mixtures containing ß-cyfluthrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4658: To extend the temporary reduction of duty on Deltamethrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4660: To reduce temporarily the duty on Thiencarbazone-methyl.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4661: To extend the temporary suspension of duty on Spiromesifen.

Sponsor: Emanuel Cleaver II (D-Mo.)

S.3017: A bill to extend the temporary suspension of duty on Spiromesifen.

Sponsor: Robert Menendez (D-N.J.)

H.R.4662: To suspend temporarily the duty on Trifloxystrobin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4663: To modify and extend the temporary reduction of duty on...

Sponsor: Emanuel Cleaver II (D-Mo.)

S.2703: A bill to extend the temporary suspension of duty on 2-acetylbutyrolactone.

Sponsor: Bob Casey (D-Pa.)

H.R.4664: To suspend temporarily the duty on 1,3-Cyclohexanedione.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4665: To suspend temporarily the duty on Flubendiamide.

Sponsor: Emanuel Cleaver II (D-Mo.)

S.3132: A bill to suspend temporarily the duty on flubendiamide.

Sponsor: Kay Hagan (D-N.C.)

H.R.4666: To suspend temporarily the duty on Spirotetramat.

Sponsor: Emanuel Cleaver II (D-Mo.)

S.2722: A bill to suspend temporarily the duty on spirotetramat.

Sponsor: Bob Casey (D-Pa.)

H.R.4667: To extend the temporary suspension of duty on Isoxadifen-Ethyl.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4668: To extend the temporary suspension of duty on Cyfluthrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

S.3024: A bill to extend the temporary suspension of duty on Cyfluthrin.

Sponsor: Robert Menendez (D-N.J.)

H.R.4669: To modify and extend the temporary reduction of duty on ß-cyfluthrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4670: To reduce temporarily the duty on mixtures contaning Trifloxystrobin and...

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4671: To suspend temporarily the rate of duty on certain mixtures containing...

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4672: To reduce temporarily the duty on mixtures containing Spirotetramat.

Sponsor: Emanuel Cleaver II (D-Mo.)

S.2726: A bill to suspend temporarily the duty on mixtures of cyprosulfamide.

Sponsor: Bob Casey (D-Pa.)

H.R.4673: To suspend temporarily the duty on mixtures containing Trifloxystrobin...

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4675: To reduce temporarily the duty on 1H-[1,2,4]Triazole.

Sponsor: Jim Costa (D-Calif.)

S.2678: A bill to suspend temporarily the duty on 1,2,4 Triazole.

Sponsor: Bob Casey (D-Pa.)

H.R.4676: To suspend temporarily the duty on mixtures of Indaziflam.

Sponsor: Jim Costa (D-Calif.)

S.3161: A bill to suspend temporarily the duty on Indaziflam.

Sponsor: Kay Hagan (D-N.C.)

H.R.4677: To suspend temporarily the duty on mixtures of Flubendiamide.

Sponsor: Jim Costa (D-Calif.)

S.3162: A bill to suspend temporarily the duty on Flubendiamide.

Sponsor: Kay Hagan (D-N.C.)

H.R.4678: To suspend temporarily the duty on mixtures containing Fluopyram.

Sponsor: Jim Costa (D-Calif.)

S.2681: A bill to suspend temporarily the duty on mixtures containing flupyram...

Sponsor: Bob Casey (D-Pa.)

H.R.4679: To suspend temporarily the duty on mixtures containing Fluopyram and...

Sponsor: Jim Costa (D-Calif.)

S.2719: A bill to suspend temporarily the duty on mixtures containing fluopyram...

Sponsor: Bob Casey (D-Pa.)

H.R.4680: To suspend temporarily the duty on mixtures containing Fluopyram and...

Sponsor: Jim Costa (D-Calif.)

S.2720: A bill to suspend temporarily the duty on mixtures containing fluopyram...

Sponsor: Bob Casey (D-Pa.)

H.R.4681: To suspend temporarily the duty on mixtures containing Fluopyram and...

Sponsor: Jim Costa (D-Calif.)

S.2721: A bill to suspend temporarily the duty on mixtures containing fluopyram...

Sponsor: Bob Casey (D-Pa.)

H.R.4682: To suspend temporarily the duty on Fenhexamid.

Sponsor: Jim Costa (D-Calif.)

S.3133: A bill to suspend temporarily the duty on fenhexamid.

Sponsor: Kay Hagan (D-N.C.)

H.R.4683: To suspend temporarily the duty on Fluopicolide.

Sponsor: Jim Costa (D-Calif.)

S.3134: A bill to suspend temporarily the duty on fluopicolide.

Sponsor: Kay Hagan (D-N.C.)

H.R.4684: To suspend temporarily the duty on Fluopyram.

Sponsor: Jim Costa (D-Calif.)

S.3130: A bill to suspend temporarily the duty on Fluopyram.

Sponsor: Kay Hagan (D-N.C.)

H.R.4685: To suspend temporarily the duty on Indaziflam.

Sponsor: Jim Costa (D-Calif.)

S.3131: A bill to suspend temporarily the duty on imdaziflam.

Sponsor: Kay Hagan (D-N.C.)

H.R.4686: To extend the temporary suspension of duty on 4-Chlorobenzaldehyde.

Sponsor: Jim Costa (D-Calif.)

S.3021: A bill to extend the temporary suspension of duty on 4-chlorobenzaldehyde.

Sponsor: Robert Menendez (D-N.J.)

H.R.4687: To extend the temporary suspension of duty on Phenmedipham.

Sponsor: Jim Costa (D-Calif.)

S.2701: A bill to extend the temporary suspension of duty on Phenmedipham.

Sponsor: Bob Casey (D-Pa.)

H.R.4694: To reduce temporarily the duty on product mixtures containing Spiromesifen.

Sponsor: Sam Graves (R-Mo.)

S.3160: A bill to extend the temporary suspension of duty on Spiromesifen.

Sponsor: Kay Hagan (D-N.C.)

H.R.4696: To suspend temporarily the duty on product mixtures containing...

Sponsor: Sam Graves (R-Mo.)

H.R.4698: To extend the suspension of duty on product mixtures containing...

Sponsor: Sam Graves (R-Mo.)

H.R.4699: To suspend temporarily the duty on cyprosulfamide.

Sponsor: Sam Graves (R-Mo.)

H.R.4735: To extend and modify the temporary reduction of duty on ACM.

Sponsor: Bill Huizenga (R-Mich.)

S.2355: A bill to extend and modify the temporary reduction of duty on...

Sponsor: Carl Levin (D-Mich.)

H.R.4736: To reduce temporarily the duty on Glufosinate-Ammonium (GA).

Sponsor: Bill Huizenga (R-Mich.)

S.2356: A bill to reduce temporarily the duty of Glufosinate-ammonium.

Sponsor: Carl Levin (D-Mich.)

H.R.4737: To extend and modify the temporary reduction of duty on Oxadiazon.

Sponsor: Bill Huizenga (R-Mich.)

S.2354: A bill to extend and modify the temporary reduction of duty on Oxadiazon.

Sponsor: Carl Levin (D-Mich.)

H.R.4876: To extend the temporary reduction of duty on Imidacloprid.

Sponsor: Shelley Moore Capito (R-W.Va.)

S.3136: A bill to extend the temporary reduction of duty on Imidacloprid.

Sponsor: Kay Hagan (D-N.C.)

H.R.4878: To suspend temporarily the duty on 1-Naphthyl, N-methylcarbamate.

Sponsor: Shelley Moore Capito (R-W.Va.)

S.2587: A bill to extend the temporary suspension of duty on Carbaryl.

Sponsor: Joe Manchin III (D-W.Va.)

H.R.4879: To reduce temporarily the duty on Penflufen.

Sponsor: Shelley Moore Capito (R-W.Va.)

S.2386: A bill to reduce temporarily the duty on Penflufen.

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.4883: To suspend temporarily the duty on IMIDACLOPRID.

Sponsor: Shelley Moore Capito (R-W.Va.)

S.2385: A bill to suspend temporarily the duty on Imidacloprid.

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.4914: To suspend temporarily the duty on mixtures containing Fluopyram and...

Sponsor: Jim Costa (D-Calif.)

S.2680: A bill to suspend temporarily the duty on mixtures containing fluopyram...

Sponsor: Bob Casey (D-Pa.)

H.R.5592: To suspend temporarily the duty on mixtures containing beta-cyfluthrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

S.3023: A bill to suspend temporarily the duty on B-Cyfluthrin.

Sponsor: Robert Menendez (D-N.J.)

H.R.5591: To modify and extend the temporary reduction of duty on beta-cyfluthrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

S.3025: A bill to extend and modify the temporary reduction of duty on...

Sponsor: Robert Menendez (D-N.J.)

H.R.4695: To reduce temporarily the duty on product mixtures containing...

Sponsor: Sam Graves (R-Mo.)

S.3008: A bill to reduce temporarily the duty on product mixtures containing...

Sponsor: Robert Menendez (D-N.J.)

S.136: Ban Poisonous Additives Act of 2011

Sponsor: Dianne Feinstein (D-Calif.)

H.R.432: Ban Poisonous Additives Act of 2011

Sponsor: Edward J. Markey (D-Mass.)

H.R.840: SECURE Act

Sponsor: Tim Murphy (R-Pa.)

S.352: American Energy Independence and Security Act of 2011

Sponsor: Lisa Murkowski (R-Alaska)

S.629: Hydropower Improvement Act of 2011

Sponsor: Lisa Murkowski (R-Alaska)

S.630: Marine and Hydrokinetic Renewable Energy Promotion Act of 2011

Sponsor: Lisa Murkowski (R-Alaska)

S.631: Hydropower Renewable Energy Development Act of 2011

Sponsor: Lisa Murkowski (R-Alaska)

S.398: Implementation of National Consensus Appliance Agreements Act of 2011

Sponsor: Jeff Bingaman (D-N.M.)

H.R.2962: Roofing Efficiency Jobs Act of 2011

Sponsor: Tom Reed (R-N.Y.)

S.1575: Energy-Efficient Cool Roof Jobs Act

Sponsor: Benjamin L. Cardin (D-Md.)

S.1737: Sensible Accounting to Value Energy Act of 2011

Sponsor: Michael Bennet (D-Colo.)

H.R.2599: PACE Assessment Protection Act of 2011

Sponsor: Nan Hayworth (R-N.Y.)

S.3591: Commercial Building Modernization Act

Sponsor: Olympia J. Snowe (R-Maine)

S.847: Safe Chemicals Act of 2011

Sponsor: Frank R. Lautenberg (D-N.J.)

S.709: Secure Chemical Facilities Act

Sponsor: Frank R. Lautenberg (D-N.J.)

H.R.908: Full Implementation of the Chemical Facility Anti-Terrorism Standards Act

Sponsor: Tim Murphy (R-Pa.)

H.R.5855: Department of Homeland Security Appropriations Act, 2013

Sponsor: Robert B. Aderholt (R-Ala.)

H.R.872: Reducing Regulatory Burdens Act of 2011

Sponsor: Bob Gibbs (R-Ohio)

S.3605: Restoring Effective Environmental Protection Act of 2012

Sponsor: Kay Hagan (D-N.C.)

S.3240: Agriculture Reform, Food, and Jobs Act of 2012

Sponsor: Debbie Stabenow (D-Mich.)

S.1053: Veterinary Services Investment Act

Sponsor: Debbie Stabenow (D-Mich.)

H.R.965: Preservation of Antibiotics for Medical Treatment Act of 2011

Sponsor: Louise M. Slaughter (D-N.Y.)

S.1211: Preservation of Antibiotics for Medical Treatment Act of 2011

Sponsor: Dianne Feinstein (D-Calif.)

H.R.4223: SAFE DOSES Act

Sponsor: F. James Sensenbrenner (R-Wis.)

H.R.3668: Counterfeit Drug Penalty Enhancement Act of 2012

Sponsor: Pat Meehan (R-Pa.)

H.R.4216: Foreign Counterfeit Prevention Act

Sponsor: Ted Poe (R-Texas)

S.365: Budget Control Act of 2011

Sponsor: Tom Harkin (D-Iowa)

S.3552: Pesticide Registration Improvement Extension Act of 2012

Sponsor: Debbie Stabenow (D-Mich.)

H.R.4874: To suspend temporarily the duty on mixtures containing...

Sponsor: Shelley Moore Capito (R-W.Va.)

S.2382: A bill to suspend temporarily the duty on mixtures containing methyl...

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.4659: To suspend temporarily the duty on...

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4877: To reduce temporarily the duty on mixtures containing Imidacloprid and...

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.5565: To reduce temporarily the duty on mixtures containing Imidacloprid and...

Sponsor: Shelley Moore Capito (R-W.Va.)

S.2384: A bill to reduce temporarily the duty on mixtures containing...

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.4875: To modify and extend the temporary reduction of duty on mixtures of...

Sponsor: Shelley Moore Capito (R-W.Va.)

S.2383: A bill to modify and extend the temporary reduction of duty on mixtures...

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.4873: To suspend temporarily the duty on mixtures containing Imidacloprid and...

Sponsor: Shelley Moore Capito (R-W.Va.)

S.2381: A bill to suspend temporarily the duty on mixtures containing...

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.4577: To extend and modify the temporary reduction of duty on mixtures...

Sponsor: Blaine Luetkemeyer (R-Mo.)

H.R.5257: To extend the temporary suspension of duty on product mixtures...

Sponsor: Randy Neugebauer (R-Texas)

S.3009: A bill to extend the temporary suspension of duty on Mesosulfuron-methyl.

Sponsor: Robert Menendez (D-N.J.)

H.R.4537: To suspend temporarily the duty on Methyl...

Sponsor: Renee Ellmers (R-N.C.)

S.3019: A bill to suspend temporarily the duty on propoxycarbazone-sodium.

Sponsor: Robert Menendez (D-N.J.)

H.R.4536: To extend the temporary suspension of duty on 2-Chlorobenzyl chloride.

Sponsor: Renee Ellmers (R-N.C.)

S.3018: A bill to extend the temporary suspension of duty on 2-chlorobenzyl...

Sponsor: Robert Menendez (D-N.J.)

H.R.5258: To suspend temporarily the rate of duty on certain mixtures containing...

Sponsor: Randy Neugebauer (R-Texas)

S.3022: A bill to reduce temporarily the duty on product mixtures containing...

Sponsor: Robert Menendez (D-N.J.)

H.R.4697: To reduce temporarily the duty on product mixtures containing...

Sponsor: Sam Graves (R-Mo.)

H.R.4574: To modify and extend the temporary reduction of duty on AE 0172747 Ether.

Sponsor: Blaine Luetkemeyer (R-Mo.)

H.R.4579: To suspend temporarily the duty on mixtures containing...

Sponsor: Blaine Luetkemeyer (R-Mo.)

H.R.4580: To suspend temporarily the duty on mixtures containing Trifloxystrobin,...

Sponsor: Blaine Luetkemeyer (R-Mo.)

H.R.2779: To exempt inter-affiliate swaps from certain regulatory requirements put...

Sponsor: Steve Stivers (R-Ohio)

H.R.436: Health Care Cost Reduction Act of 2012

Sponsor: Erik Paulsen (R-Minn.)

H.R.4850: Enabling Energy Saving Innovations Act

Sponsor: Robert B. Aderholt (R-Ala.)

H.R.2245: Preserving Access to Life-Saving Medications Act of 2011

Sponsor: Diana DeGette (D-Colo.)

S.2375: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Herb Kohl (D-Wis.)

H.R.1733: Interstate Horseracing Improvement Act of 2011

Sponsor: Edward Whitfield (R-Ky.)

S.886: Interstate Horseracing Improvement Act of 2011

Sponsor: Tom Udall (D-N.M.)

H.R.1406: Fairness to Pet Owners Act of 2011

Sponsor: Jim Matheson (D-Utah)

H.R.901: Chemical Facility Anti-Terrorism Security Authorization Act of 2011

Sponsor: Dan Lungren (R-Calif.)

H.R.1249: Leahy-Smith America Invents Act

Sponsor: Lamar Smith (R-Texas)

S.23: America Invents Act

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.480: Gulf of Mexico Economic and Environmental Restoration Act of 2011

Sponsor: Kathy Castor (D-Fla.)

S.231: EPA Stationary Source Regulations Suspension Act

Sponsor: John D. Rockefeller IV (D-W.Va.)

S.3187: Food and Drug Administration Safety and Innovation Act

Sponsor: Tom Harkin (D-Iowa)

H.R.916: Continuing Chemical Facilities Antiterrorism Security Act of 2011

Sponsor: Charlie Dent (R-Pa.)

S.473: Continuing Chemical Facilities Antiterrorism Security Act of 2011

Sponsor: Susan Collins (R-Maine)

S.158: Surface Transportation Board Reauthorization Act of 2011

Sponsor: John D. Rockefeller IV (D-W.Va.)

S.49: Railroad Antitrust Enforcement Act of 2011

Sponsor: Herb Kohl (D-Wis.)

H.R.524: Restoring Consumer-driven Health Care Act of 2011

Sponsor: Ben Quayle (R-Ariz.)

H.R.527: Regulatory Flexibility Improvements Act of 2011

Sponsor: Lamar Smith (R-Texas)

H.R.658: FAA Modernization and Reform Act of 2012

Sponsor: John L. Mica (R-Fla.)

S.223: FAA Air Transportation Modernization and Safety Improvement Act

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.488: Save Our Medical Devices Act of 2011

Sponsor: Jim Gerlach (R-Pa.)

H.R.734: To amend the Internal Revenue Code of 1986 to repeal the medical device...

Sponsor: Brian P. Bilbray (R-Calif.)

S.17: Medical Device Access and Innovation Protection Act

Sponsor: Orrin G. Hatch (R-Utah)

S.262: A bill to repeal the excise tax on medical device manufacturers.

Sponsor: Scott Brown (R-Mass.)

H.R.4: Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy...

Sponsor: Dan Lungren (R-Calif.)

H.R.60: To repeal the expansion of information reporting requirements for...

Sponsor: Steve Scalise (R-La.)

H.R.144: Small Business Paperwork Mandate Elimination Act of 2011

Sponsor: Dan Lungren (R-Calif.)

H.R.584: To repeal the information reporting requirements added by the Patient...

Sponsor: Joe Courtney (D-Conn.)

H.R.705: Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy...

Sponsor: Dave Camp (R-Mich.)

S.18: Small Business Paperwork Mandate Elimination Act

Sponsor: Mike Johanns (R-Neb.)

S.72: Small Business Paperwork Mandate Elimination Act of 2011

Sponsor: Max Baucus (D-Mont.)

H.R.141: To repeal the Patient Protection and Affordable Care Act and the Health...

Sponsor: Steve King (R-Iowa)

H.R.145: Revoke Excessive Policies that Encroach on American Liberties (REPEAL) Act

Sponsor: Connie Mack (R-Fla.)

H.R.215: To repeal the Patient Protection and Affordable Care Act and title I of...

Sponsor: Don Young (R-Alaska)

H.R.429: To repeal the Patient Protection and Affordable Care Act and the health...

Sponsor: Darrell Issa (R-Calif.)

H.R.636: Affordable Health Care Expansion Act of 2011

Sponsor: Kay Granger (R-Texas)

S.16: Patient Choice Restoration Act

Sponsor: David Vitter (R-La.)

S.193: USA PATRIOT Act Sunset Extension Act of 2011

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.3209: Premarket Predictability Act of 2011

Sponsor: John Shimkus (R-Ill.)

H.R.3204: Guidance Accountability and Transparency Act of 2011

Sponsor: Brett Guthrie (R-Ky.)

S.1700: Medical Device Regulatory Improvement Act

Sponsor: Amy Klobuchar (D-Minn.)

H.R.3010: Regulatory Accountability Act of 2011

Sponsor: Lamar Smith (R-Texas)

H.R.3765: Temporary Payroll Tax Cut Continuation Act of 2011

Sponsor: Dave Camp (R-Mich.)

H.R.2055: Consolidated Appropriations Act, 2012

Sponsor: John Culberson (R-Texas)

H.R.2112: Consolidated and Further Continuing Appropriations Act, 2012

Sponsor: Jack Kingston (R-Ga.)

H.R.2584: Department of the Interior, Environment, and Related Agencies...

Sponsor: Mike Simpson (R-Idaho)

H.R.1610: Business Risk Mitigation and Price Stabilization Act of 2011

Sponsor: Mike Grimm (R-N.Y.)

H.R.2017: Continuing Appropriations Act, 2012

Sponsor: Robert B. Aderholt (R-Ala.)

H.R.942: American Research and Competitiveness Act of 2011

Sponsor: Kevin Brady (R-Texas)

H.R.23: Belated Thank You to the Merchant Mariners of World War II Act of 2011

Sponsor: Bob Filner (D-Calif.)

S.1000: Energy Savings and Industrial Competitiveness Act of 2011

Sponsor: Jeanne Shaheen (D-N.H.)

S.937: American Alternative Fuels Act of 2011

Sponsor: John Barrasso (R-Wyo.)

S.963: Reducing Federal Energy Dollars Act of 2011

Sponsor: Thomas R. Carper (D-Del.)

H.R.43: To amend the Immigration and Nationality Act to eliminate the diversity...

Sponsor: Darrell Issa (R-Calif.)

H.R.2818: No Child Left Outside Act of 2011

Sponsor: Marcia L. Fudge (D-Ohio)

H.R.452: Medicare Decisions Accountability Act of 2011

Sponsor: Phil Roe (R-Tenn.)

H.R.605: Patients' Freedom to Choose Act

Sponsor: Erik Paulsen (R-Minn.)

H.R.1041: FIMBA

Sponsor: Glenn Thompson (R-Pa.)

H.R.1: Disaster Relief Appropriations Act, 2013

Sponsor: Harold Rogers (R-Ky.)

S.4: Make America the World's Leader in Clean Energy Act

Sponsor: Harry Reid (D-Nev.)

H.R.910: Energy Tax Prevention Act of 2011

Sponsor: Fred Upton (R-Mich.)

H.R.1549: Preservation of Antibiotics for Medical Treatment Act of 2009

Sponsor: Louise M. Slaughter (D-N.Y.)

S.619: Preservation of Antibiotics for Medical Treatment Act of 2009

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.2749: Food Safety Enhancement Act of 2009

Sponsor: John D. Dingell (D-Mich.)

S.510: FDA Food Safety Modernization Act

Sponsor: Richard J. Durbin (D-Ill.)

H.R.2400: Strategies to Address Antimicrobial Resistance Act

Sponsor: Jim Matheson (D-Utah)

H.R.2868: Continuing Chemical Facilities Antiterrorism Security Act of 2010

Sponsor: Bennie Thompson (D-Miss.)

S.2996: Continuing Chemical Facilities Antiterrorism Security Act of 2010

Sponsor: Susan Collins (R-Maine)

S.787: Clean Water Restoration Act

Sponsor: Russ Feingold (D-Wis.)

H.R.5504: Improving Nutrition for America's Children Act

Sponsor: George Miller (D-Calif.)

S.3307: Healthy, Hunger-Free Kids Act of 2010

Sponsor: Blanche Lincoln (D-Ark.)

S.3606: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Herb Kohl (D-Wis.)

H.R.6273: To amend the Federal Insecticide, Fungicide, and Rodenticide Act to...

Sponsor: Collin C. Peterson (D-Minn.)

S.3735: A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act...

Sponsor: Blanche Lincoln (D-Ark.)

H.R.6087: To amend the Federal Insecticide, Fungicide, and Rodenticide Act to...

Sponsor: Frank D. Lucas (R-Okla.)

H.R.2818: Methamphetamine Education, Treatment, and Hope Act of 2010

Sponsor: Jerry McNerney (D-Calif.)

H.R.2999: Veterinary Public Health Amendments Act of 2010

Sponsor: Tammy Baldwin (D-Wis.)

H.R.3519: Veterinarian Services Investment Act

Sponsor: Adrian Smith (R-Neb.)

S.1709: Veterinary Services Investment Act

Sponsor: Debbie Stabenow (D-Mich.)

H.RES.1531: Expressing support for designation of 2011 as "World Veterinary Year" to...

Sponsor: Kurt Schrader (D-Ore.)

S.RES.583: A resolution expressing support for designation of 2011 as "World...

Sponsor: John Ensign (R-Nev.)

S.515: Patent Reform Act of 2009

Sponsor: Patrick J. Leahy (D-Vt.)

S.1462: American Clean Energy Leadership Act of 2009

Sponsor: Jeff Bingaman (D-N.M.)

H.R.2454: American Clean Energy and Security Act of 2009

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1749: Energy Efficient Manufactured Housing Act of 2009

Sponsor: Baron P. Hill (D-Ind.)

H.R.5476: Building Star Energy Efficiency Act of 2010

Sponsor: Peter Welch (D-Vt.)

S.3079: Building Star Energy Efficiency Act of 2010

Sponsor: Jeff Merkley (D-Ore.)

H.R.5019: Home Star Energy Retrofit Act of 2010

Sponsor: Peter Welch (D-Vt.)

H.R.5210: Endocrine Disruptor Screening Enhancement Act of 2010

Sponsor: Edward J. Markey (D-Mass.)

H.R.1523: Ban Poisonous Additives Act of 2009

Sponsor: Edward J. Markey (D-Mass.)

S.593: Ban Poisonous Additives Act of 2009

Sponsor: Dianne Feinstein (D-Calif.)

S.753: BPA-Free Kids Act of 2009

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.4341: BPA Consumer Information Act of 2009

Sponsor: Tim Ryan (D-Ohio)

H.R.2789: To confer certain Federal jurisdiction on the High Court of American...

Sponsor: Eni F. H. Faleomavaega (D-American Samoa)

H.R.1332: Safe FEAST Act of 2009

Sponsor: Jim Costa (D-Calif.)

H.R.4994: Medicare and Medicaid Extenders Act of 2010

Sponsor: John Lewis (D-Ga.)

S.3653: Health Care Bureaucrats Elimination Act

Sponsor: John Cornyn (R-Texas)

H.R.2751: FDA Food Safety Modernization Act

Sponsor: Betty Sutton (D-Ohio)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.4872: Health Care and Education Reconciliation Act of 2010

Sponsor: John M. Spratt Jr. (D-S.C.)

S.3806: SECURE Facilities Act of 2010

Sponsor: Joseph I. Lieberman (I-Conn.)

H.R.1409: Employee Free Choice Act of 2009

Sponsor: George Miller (D-Calif.)

S.560: Employee Free Choice Act of 2009

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.1260: Patent Reform Act of 2009

Sponsor: John Conyers Jr. (D-Mich.)

S.146: Railroad Antitrust Enforcement Act of 2009

Sponsor: Herb Kohl (D-Wis.)

S.2889: Surface Transportation Board Reauthorization Act of 2009

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.233: Railroad Antitrust Enforcement Act of 2009

Sponsor: Tammy Baldwin (D-Wis.)

H.R.6517: Omnibus Trade Act of 2010

Sponsor: Sander M. Levin (D-Mich.)

H.R.2438: To amend the Internal Revenue Code of 1986 to provide a temporary bonus...

Sponsor: John B. Larson (D-Conn.)

H.R.4678: Foreign Manufacturers Legal Accountability Act of 2010

Sponsor: Betty Sutton (D-Ohio)

S.1733: Clean Energy Jobs and American Power Act

Sponsor: John Kerry (D-Mass.)

H.R.4159: School Environment Protection Act of 2009

Sponsor: Rush Holt (D-N.J.)

H.R.299: National Digital Television Consumer Education Act

Sponsor: Eliot L. Engel (D-N.Y.)

S.369: Preserve Access to Affordable Generics Act

Sponsor: Herb Kohl (D-Wis.)

H.R.6228: LEVEL Act

Sponsor: Michael C. Burgess (R-Texas)

H.R.4213: Unemployment Compensation Extension Act of 2010

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.4380: United States Manufacturing Enhancement Act of 2010

Sponsor: Sander M. Levin (D-Mich.)

S.269: Retooling America's Workers for a Green Economy Act

Sponsor: Patty Murray (D-Wash.)

S.1972: A bill to extend the temporary suspension of duty on mixtures of methyl...

Sponsor: Michael D. Crapo (R-Idaho)

S.2689: A bill to reduce the temporary suspension of duty on B-Cyfluthrin.

Sponsor: Richard M. Burr (R-N.C.)

S.1903: A bill to suspend temporarily the duty on 1,3-Dimethyl-1H-pyrazol-5-ol...

Sponsor: Pat Roberts (R-Kan.)

S.2489: A bill to suspend temporarily the duty on 2-Chloro-6-(methylthio)toluene.

Sponsor: Lindsey Graham (R-S.C.)

S.2252: A bill to extend the temporary suspension of duty on Clothianidin.

Sponsor: Dianne Feinstein (D-Calif.)

S.1902: A bill to reduce temporarily the duty on Corvus herbicide.

Sponsor: Pat Roberts (R-Kan.)

S.2686: A bill to extend and modify the temporary reduction of duty on...

Sponsor: Richard M. Burr (R-N.C.)

S.2257: A bill to extend the temporary suspension of duty on Deltamethrin.

Sponsor: Dianne Feinstein (D-Calif.)

S.1901: A bill to reduce temporarily the duty on Evergol.

Sponsor: Pat Roberts (R-Kan.)

S.2684: A bill to extend the temporary suspension of duty on Fenamidone.

Sponsor: Richard M. Burr (R-N.C.)

S.2069: A bill to extend the temporary suspension of duty on flutolanil.

Sponsor: Thomas R. Carper (D-Del.)

S.2687: A bill to extend and modify the temporary suspension of duty on Aluminum...

Sponsor: Richard M. Burr (R-N.C.)

S.1900: A bill to reduce temporarily the duty on Liberty, Rely, and Ignite...

Sponsor: Pat Roberts (R-Kan.)

S.1971: A bill to extend the suspension of duty on Mesosulfuronmethyl.

Sponsor: Michael D. Crapo (R-Idaho)

S.2253: A bill to extend the temporary suspension of duty on Permethrin.

Sponsor: Dianne Feinstein (D-Calif.)

S.2683: A bill to suspend temporarily the duty on Pyrasulfotole.

Sponsor: Richard M. Burr (R-N.C.)

S.2262: A bill to extend the temporary suspension of duty on Resmethrin.

Sponsor: Dianne Feinstein (D-Calif.)

S.2690: A bill to reduce and modify the temporary suspension of duty on Iprodione.

Sponsor: Richard M. Burr (R-N.C.)

S.2688: A bill to extend the temporary suspension of duty on Triadimefon.

Sponsor: Richard M. Burr (R-N.C.)

S.1970: A bill to suspend temporarily the duty on mixtures containing ethyl...

Sponsor: Michael D. Crapo (R-Idaho)

S.2109: A bill to reduce temporarily the duty on mixtures of imidacloprid...

Sponsor: Christopher S. Bond (R-Mo.)

S.2110: A bill to reduce temporarily the duty on Fluopyram.

Sponsor: Christopher S. Bond (R-Mo.)

S.2111: A bill to suspend temporarily the duty on Indaziflam.

Sponsor: Christopher S. Bond (R-Mo.)

S.2712: A bill to extend the temporary suspension of duty on D-Mannose.

Sponsor: Frank R. Lautenberg (D-N.J.)

S.2169: A bill to extend the temporary suspension of duty on trimethylopropane...

Sponsor: Arlen Specter (D-Pa.)

S.2187: A bill to extend the temporary suspension of duty on benzene,...

Sponsor: Arlen Specter (D-Pa.)

S.2189: A bill to extend the temporary suspension of duty on 1,2,3-Propanetriol,...

Sponsor: Arlen Specter (D-Pa.)

S.2188: A bill to extend the temporary suspension of duty on poly(toluene...

Sponsor: Arlen Specter (D-Pa.)

S.2190: A bill to extend the temporary suspension of duty on polyisocyanate...

Sponsor: Arlen Specter (D-Pa.)

S.2185: A bill to extend the temporary suspension of duty on mixtures of...

Sponsor: Arlen Specter (D-Pa.)

S.2167: A bill to extend the temporary suspension of duty on hexane,...

Sponsor: Arlen Specter (D-Pa.)

S.2186: A bill to extend the temporary suspension of duty on copolymer of methyl...

Sponsor: Arlen Specter (D-Pa.)

S.2165: A bill to extend the temporary suspension of duty on 2-Oxepanone polymer...

Sponsor: Arlen Specter (D-Pa.)

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

S.1142: Informed Health Care Decision Making Act

Sponsor: Jack Reed (D-R.I.)

H.R.1321: Healthy Americans Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...

Sponsor: John D. Dingell (D-Mich.)

S.1796: America's Healthy Future Act of 2009

Sponsor: Max Baucus (D-Mont.)

S.1679: Affordable Health Choices Act

Sponsor: Tom Harkin (D-Iowa)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

H.R.3790: To amend title XVIII of the Social Security Act to repeal the Medicare...

Sponsor: Kendrick B. Meek (D-Fla.)

H.R.4394: Decabromine Elimination and Control Act of 2009

Sponsor: Chellie Pingree (D-Maine)

H.R.598: To provide for a portion of the economic recovery package relating to...

Sponsor: Charles B. Rangel (D-N.Y.)

S.1631: Customs Facilitation and Trade Enforcement Reauthorization Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.4899: Supplemental Appropriations Act, 2010

Sponsor: David R. Obey (D-Wis.)

S.2166: A bill to extend the temporary suspension of duty on polyfunctional...

Sponsor: Arlen Specter (D-Pa.)

S.2691: A bill to reduce temporarily the duty on AE 0172747 Ether.

Sponsor: Richard M. Burr (R-N.C.)

S.3535: Next Generation Energy Security Act of 2010

Sponsor: Richard M. Burr (R-N.C.)

S.3464: Practical Energy and Climate Plan Act of 2010

Sponsor: Richard G. Lugar (R-Ind.)

S.RES.174: A resolution recognizing the region from Manhattan, Kansas to Columbia,...

Sponsor: Christopher S. Bond (R-Mo.)

H.R.3183: Energy and Water Development and Related Agencies Appropriations Act, 2010

Sponsor: Ed Pastor (D-Ariz.)

S.1436: Energy and Water Development and Related Agencies Appropriations Act, 2010

Sponsor: Byron L. Dorgan (D-N.D.)

H.R.2892: Department of Homeland Security Appropriations Act, 2010

Sponsor: David E. Price (D-N.C.)

H.R.2996: Department of the Interior, Environment, and Related Agencies...

Sponsor: Norman D. Dicks (D-Wash.)

S.1298: Department of Homeland Security Appropriations Act, 2010

Sponsor: Robert C. Byrd (D-W.Va.)

H.R.21: Ocean Conservation, Education, and National Strategy for the 21st...

Sponsor: Sam Farr (D-Calif.)

H.R.2997: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Rosa DeLauro (D-Conn.)

S.1406: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Herb Kohl (D-Wis.)

H.RES.317: Recognizing the region from Manhattan, Kansas, to Columbia, Missouri, as...

Sponsor: Dennis Moore (D-Kan.)

H.R.1105: Omnibus Appropriations Act, 2009

Sponsor: David R. Obey (D-Wis.)

H.R.1: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

H.R.679: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

H.R.1346: Medical Device Safety Act of 2009

Sponsor: Frank Pallone (D-N.J.)

S.540: Medical Device Safety Act of 2009

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.1085: Health Insurance Coverage Protection Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.1548: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.J.RES.18: Providing for congressional disapproval of the rule submitted by the...

Sponsor: Nick J. Rahall II (D-W.Va.)

H.R.759: Food and Drug Administration Globalization Act of 2009

Sponsor: John D. Dingell (D-Mich.)

S.1695: A bill to authorize the award of a Congressional gold medal to the...

Sponsor: Roland W. Burris (D-Ill.)

S.726: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

S.1213: Patient-Centered Outcomes Research Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.2824: Doctor-Patient Relationship and Research Protection Act

Sponsor: Donna M.C. Christensen (D-Virgin Islands)

H.R.2502: Comparative Effectiveness Research Act of 2009

Sponsor: Kurt Schrader (D-Ore.)

H.R.1256: Family Smoking Prevention and Tobacco Control Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1584: Flexibility in Rebuilding American Fisheries Act of 2009

Sponsor: Frank Pallone (D-N.J.)

H.R.5301: To extend the period during which the Administrator of the Environmental...

Sponsor: Frank A. LoBiondo (R-N.J.)

H.R.5303: To amend title 38, United States Code, to improve housing stipends for...

Sponsor: Timothy H. Bishop (D-N.Y.)

H.R.5073: To repeal the Patient Protection and Affordable Care Act and the Health...

Sponsor: Paul Broun (R-Ga.)

H.R.5074: National Institute of Standards and Technology Authorization Act of 2010

Sponsor: David Wu (D-Ore.)

H.R.5078: Higher Education Affordability and Equity Act of 2010

Sponsor: Brian Higgins (D-N.Y.)

H.R.5080: To amend the Internal Revenue Code of 1986 to provide unemployment...

Sponsor: Patrick J. Kennedy (D-R.I.)

H.R.5071: ESEA Fiscal Fairness Act

Sponsor: Chaka Fattah (D-Pa.)

H.R.5083: Promoting Fair Work Opportunities for Persons with Disabilities Act

Sponsor: Gwen Moore (D-Wis.)

H.R.5075: Middle Class Tax Relief Act

Sponsor: John Adler (D-N.J.)

H.R.5081: Broadband for First Responders Act of 2010

Sponsor: Peter T. King (R-N.Y.)

H.R.5077: To amend the Internal Revenue Code of 1986 to increase the alternative...

Sponsor: John Hall (D-N.Y.)

H.R.5079: To amend title II of the Elementary and Secondary Education Act of 1965...

Sponsor: Steve Israel (D-N.Y.)

H.R.5070: Smart Electronics Act

Sponsor: Michael M. Honda (D-Calif.)

H.CON.RES.85: Setting forth the congressional budget for the United States Government...

Sponsor: John M. Spratt Jr. (D-S.C.)

H.R.1902: PRO-VETS Act of 2009

Sponsor: Ginny Brown-Waite (R-Fla.)

S.316: Timber Revitalization and Economic Enhancement Act II of 2009

Sponsor: Blanche Lincoln (D-Ark.)

S.610: Patent Reform Act of 2009

Sponsor: Jon Kyl (R-Ariz.)

H.R.977: Derivatives Markets Transparency and Accountability Act of 2009

Sponsor: Collin C. Peterson (D-Minn.)

S.301: Physician Payments Sunshine Act of 2009

Sponsor: Charles E. Grassley (R-Iowa)

H.R.5304: Byrne/JAG Program Accountability Act

Sponsor: Steve Cohen (D-Tenn.)

H.R.5072: FHA Reform Act of 2010

Sponsor: Maxine Waters (D-Calif.)

H.R.5302: State Small Business Credit Initiative Act of 2010

Sponsor: Gary Peters (D-Mich.)

H.R.2419: Food, Conservation, and Energy Act of 2008

Sponsor: Collin C. Peterson (D-Minn.)

H.RES.829: Recognizing the region from Manhattan, Kansas, to Columbia, Missouri, as...

Sponsor: Nancy E. Boyda (D-Kan.)

S.3289: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Herb Kohl (D-Wis.)

S.3385: FDA Food Safety Modernization Act

Sponsor: Richard J. Durbin (D-Ill.)

H.R.1232: Veterinary Public Health Workforce Expansion Act of 2007

Sponsor: Tammy Baldwin (D-Wis.)

S.746: Veterinary Public Health Workforce Expansion Act of 2007

Sponsor: Wayne A. Allard (R-Colo.)

H.R.21: Oceans Conservation, Education, and National Strategy for the 21st...

Sponsor: Sam Farr (D-Calif.)

S.2191: Lieberman-Warner Climate Security Act of 2007

Sponsor: Joseph I. Lieberman (I-Conn.)

H.R.5577: Chemical Facility Anti-Terrorism Act of 2008

Sponsor: Bennie Thompson (D-Miss.)

H.R.6049: Energy Improvement and Extension Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.1887: Superfund Equity and Megasite Remediation Act of 2007

Sponsor: Maurice D. Hinchey (D-N.Y.)

S.1179: Superfund Equity and Megasite Remediation Act of 2007

Sponsor: Bob Casey (D-Pa.)

H.R.1148: Safe Food Act of 2007

Sponsor: Rosa DeLauro (D-Conn.)

H.R.6819: To amend the Medicare Improvements for Patients and Providers Act of...

Sponsor: Kevin McCarthy (R-Calif.)

S.2029: Physician Payments Sunshine Act of 2007

Sponsor: Charles E. Grassley (R-Iowa)

H.R.970: Dextromethorphan Distribution Act of 2007

Sponsor: Fred Upton (R-Mich.)

S.1378: Dextromethorphan Distribution Act of 2007

Sponsor: Patty Murray (D-Wash.)

H.R.1038: Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

S.623: Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.3700: Fair Medicaid Drug Payment Act of 2007

Sponsor: Frank Pallone (D-N.J.)

S.1951: Fair Medicaid Drug Payment Act of 2007

Sponsor: Max Baucus (D-Mont.)

H.R.4: Medicare Prescription Drug Price Negotiation Act of 2007

Sponsor: John D. Dingell (D-Mich.)

S.2928: BPA-Free Kids Act of 2008

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.4040: Consumer Product Safety Improvement Act of 2008

Sponsor: Bobby L. Rush (D-Ill.)

H.R.962: Preservation of Antibiotics for Medical Treatment Act of 2007

Sponsor: Louise M. Slaughter (D-N.Y.)

S.549: Preservation of Antibiotics for Medical Treatment Act of 2007

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.3697: Strategies to Address Antimicrobial Resistance Act

Sponsor: Jim Matheson (D-Utah)

S.2313: Strategies to Address Antimicrobial Resistance Act

Sponsor: Sherrod Brown (D-Ohio)

H.R.3610: Food and Drug Import Safety Act of 2007

Sponsor: John D. Dingell (D-Mich.)

H.R.5533: Chemical Facilities Security Act of 2008

Sponsor: Albert Russell Wynn (D-Md.)

H.R.1908: Patent Reform Act of 2007

Sponsor: Howard L. Berman (D-Calif.)

S.1145: Patent Reform Act of 2007

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.4083: Non-Prescription Drug Modernization Act of 2007

Sponsor: Henry A. Waxman (D-Calif.)

S.2311: Non-Prescription Drug Modernization Act of 2007

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.1650: Railroad Antitrust Enforcement Act of 2008

Sponsor: Tammy Baldwin (D-Wis.)

S.772: Railroad Antitrust Enforcement Act of 2007

Sponsor: Herb Kohl (D-Wis.)

H.R.2125: Railroad Competition and Service Improvement Act of 2007

Sponsor: James L. Oberstar (D-Minn.)

S.953: Railroad Competition and Service Improvement Act of 2007

Sponsor: John D. Rockefeller IV (D-W.Va.)

S.1125: Freight Rail Infrastructure Capacity Expansion Act of 2007

Sponsor: Trent Lott (R-Miss.)

H.R.1830: To extend the authorities of the Andean Trade Preference Act until...

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.5301: To extend the temporary suspension of duty on o-Acetylsalicylic acid.

Sponsor: Bill Pascrell Jr. (D-N.J.)

H.R.5302: To extend the temporary suspension of duty on D-Mannose.

Sponsor: Bill Pascrell Jr. (D-N.J.)

H.R.5303: To suspend temporarily the duty on Sedran Technical.

Sponsor: Bill Pascrell Jr. (D-N.J.)

H.R.5073: To extend the suspension of duty on Crelan VP LS 2147.

Sponsor: Tim Murphy (R-Pa.)

H.R.5074: To extend the suspension of duty on Desmodur RF-E.

Sponsor: Tim Murphy (R-Pa.)

H.R.5078: To extend the suspension of duty on Desmodur BL XP 2468.

Sponsor: Tim Murphy (R-Pa.)

H.R.5080: To extend the suspension of duty on Desmodur HL BA.

Sponsor: Tim Murphy (R-Pa.)

H.R.5083: To extend the suspension of duty on Desmodur E 14.

Sponsor: Tim Murphy (R-Pa.)

H.R.5075: To extend the suspension of duty on Desmodur R-E.

Sponsor: Tim Murphy (R-Pa.)

H.R.5081: To extend the suspension of duty on Desmodur VP LS 2253.

Sponsor: Tim Murphy (R-Pa.)

H.R.5077: To extend the suspension of duty on TSME.

Sponsor: Tim Murphy (R-Pa.)

H.R.5079: To extend the suspension of duty on Trimethylopropane...

Sponsor: Tim Murphy (R-Pa.)

H.R.5070: To extend the suspension of duty on Polyfunctional aziridine.

Sponsor: Tim Murphy (R-Pa.)

H.R.4653: To extend the temporary suspension of duty on ACM.

Sponsor: Peter Hoekstra (R-Mich.)

H.R.4654: To extend the temporary suspension of duty on Oxadiazon.

Sponsor: Peter Hoekstra (R-Mich.)

H.R.4635: To suspend temporarily the duty on Product mixtures containing...

Sponsor: Sam Graves (R-Mo.)

H.R.4636: To suspend temporarily the duy on Cyprosulfamide: N-(...

Sponsor: Sam Graves (R-Mo.)

H.R.4630: To suspend temporarily the duty on 2-Chloro-6-(methylthio)toluene.

Sponsor: Sam Graves (R-Mo.)

H.R.4629: To suspend temporarily the duty on 2-(Methylthio)-4-(trifluoromethyl)...

Sponsor: Sam Graves (R-Mo.)

H.R.4633: To suspend temporarily the duty on 1,3-Dimethyl-1H-pyrazol-5-ol and...

Sponsor: Sam Graves (R-Mo.)

H.R.4631: To suspend temporarily the duty on products containing...

Sponsor: Sam Graves (R-Mo.)

H.R.4632: To suspend temporarily the duty on mixtures containing Pyrasulfotole:...

Sponsor: Sam Graves (R-Mo.)

H.R.4634: To suspend temporarily the duty on Products containing ( )...

Sponsor: Sam Graves (R-Mo.)

H.R.4628: To suspend temporarily the duty on products containing...

Sponsor: Sam Graves (R-Mo.)

H.R.4591: To suspend temporarily the duty on 1,3-Cyclohexanedione.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4599: To extend the temporary suspension of duty on 2-Acetylbutyrolactone.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4590: To suspend temporarily the duty on AE 0172747 Ether.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4595: To suspend temporarily the duty on Mixtures containing...

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4600: To extend the temporary suspension of duty on -Cyfluthrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4602: To extend the temporary suspension of duty on Clothianidin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4601: To extend the temporary suspension of duty on Cyfluthrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4604: To extend the temporary suspension of duty on product mixtures...

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4603: To extend the temporary suspension of duty on Ethoprop.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4589: To suspend temporarily the duty on Flubendiamide.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4609: To extend the temporary suspension of duty on FOE Hydroxy.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4605: To extend the temporary suspension of duty on Isoxadifen-Ethyl.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4597: To suspend temporarily the duty on Isoxaflutole.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4587: To suspend temporarily the duty on Olympus WG70.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4594: To extend the temporary suspension of duty on 4-Chlorobenzaldehyde.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4598: To extend the temporary suspension of duty on Iprodione.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4607: To extend the temporary suspension of duty on Spiromesifen.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4588: To suspend temporarily the duty on Spirotetramat.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4610: To suspend temporarily the duty on Tembotrione.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4608: To suspend temporarily the duty on Thiencarbazone-methyl.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4606: To extend the temporary suspension of duty on Trifloxystrobin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.5117: To extend the temporary suspension of duty on 2,4-Dichloroaniline.

Sponsor: Kenny C. Hulshof (R-Mo.)

H.R.5398: To suspend temporarily the duty on certain mixtures containing...

Sponsor: Kenny C. Hulshof (R-Mo.)

H.R.5121: To extend the temporary reduction of duty on...

Sponsor: Kenny C. Hulshof (R-Mo.)

H.R.5118: To extend the temporary suspension of duty on Aluminum tris...

Sponsor: Kenny C. Hulshof (R-Mo.)

H.R.5122: To suspend temporarily the duty on Pyrasulfotole.

Sponsor: Kenny C. Hulshof (R-Mo.)

H.R.5123: To extend the temporary suspension of duty on Pyrimethanil.

Sponsor: Kenny C. Hulshof (R-Mo.)

H.R.5278: To extend the temporary suspension of duty on Option and Revolver...

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.5274: To reduce temporarily the duty on Imidacloprid Pesticides.

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.5277: To extend the temporary suspension of duty on Imidacloprid Technical.

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.5039: To suspend temporarily the duty on 1,2,4 Triazole.

Sponsor: Jim Costa (D-Calif.)

H.R.5042: To suspend temporarily the duty on Belt & Synapse.

Sponsor: Jim Costa (D-Calif.)

H.R.5041: To suspend temporarily the duty on Fenhexamid.

Sponsor: Jim Costa (D-Calif.)

H.R.5040: To suspend temporarily the duty on Fluopicolide.

Sponsor: Jim Costa (D-Calif.)

H.R.5045: To extend the temporary suspension of duty on Previcur.

Sponsor: Jim Costa (D-Calif.)

H.R.5044: To extend the temporary suspension of duty on Propiconazole.

Sponsor: Jim Costa (D-Calif.)

H.R.5419: To suspend temporarily the duty on product mixtures containing...

Sponsor: Bob Etheridge (D-N.C.)

H.R.5418: To extend the temporary suspension of duty on 2-Chloro benzyl chloride.

Sponsor: Bob Etheridge (D-N.C.)

H.R.5417: To extend the temporary suspension of duty on Permethrin.

Sponsor: Bob Etheridge (D-N.C.)

H.R.5414: To suspend temporarily the duty on Phosphorus Thiochloride.

Sponsor: Bob Etheridge (D-N.C.)

H.R.5120: To extend the temporary suspension of duty on Fenamidone.

Sponsor: Kenny C. Hulshof (R-Mo.)

H.R.5119: To suspend temporarily the duty on 2,2-Dimethylbutanoic acid...

Sponsor: Kenny C. Hulshof (R-Mo.)

H.R.5333: To extend the temporary suspension of duty on 2,6-dibromo-4-cyanophenyl...

Sponsor: David E. Price (D-N.C.)

H.R.5332: To extend the temporary suspension of duty on Desmedipham in bulk or...

Sponsor: David E. Price (D-N.C.)

H.R.5043: To extend the temporary suspension of duty on Phenmedipham.

Sponsor: Jim Costa (D-Calif.)

H.R.4998: To extend the temporary suspension of duty on mixtures of methyl...

Sponsor: Randy Neugebauer (R-Texas)

H.R.4999: To extend the temporary suspension of duty on Mesosulfuronmethyl.

Sponsor: Randy Neugebauer (R-Texas)

H.R.5000: To suspend temporarily the duty on mixtures containing...

Sponsor: Randy Neugebauer (R-Texas)

H.R.5421: To extend the temporary suspension of duty on...

Sponsor: Bob Etheridge (D-N.C.)

H.R.5420: To extend the temporary suspension of duty on Resmethrin.

Sponsor: Bob Etheridge (D-N.C.)

H.R.5422: To extend the temporary suspension of duty on mixtures containing methyl...

Sponsor: Bob Etheridge (D-N.C.)

H.R.5415: To suspend temporarily the duty on Sodium Methylate.

Sponsor: Bob Etheridge (D-N.C.)

H.R.5416: To suspend temporarily the duty on Spiroxamine.

Sponsor: Bob Etheridge (D-N.C.)

H.R.5413: To suspend temporarily the duty on Thionyl chloride.

Sponsor: Bob Etheridge (D-N.C.)

H.R.5334: To suspend temporarily the duty on product mixtures containing Methyl...

Sponsor: David E. Price (D-N.C.)

H.R.4592: To suspend temporarily the duty on certain mixtures containing...

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.4593: To extend the temporary suspension of duty on Trichloroacetaldehyde.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.5457: To extend the temporary suspension of duty on Deltamethrin.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.5458: To suspend temporarily the duty on Hydrazine monohydrate.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.5456: To suspend temporarily the duty on Tembotrione.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.5459: To extend the temporary suspension of duty on Triadimefon.

Sponsor: Emanuel Cleaver II (D-Mo.)

H.R.5272: To reduce temporarily the duty on Corvus herbicide.

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.5273: To reduce temporarily the duty on Evergol.

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.5275: To suspend temporarily the duty on Liberty, Rely, and Ignite herbicides.

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.6381: Medical Device Safety Act of 2008

Sponsor: Frank Pallone (D-N.J.)

H.R.5629: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

S.2221: Transparency in Medical Device Pricing Act of 2007

Sponsor: Charles E. Grassley (R-Iowa)

S.2499: Medicare, Medicaid, and SCHIP Extension Act of 2007

Sponsor: Max Baucus (D-Mont.)

H.R.6432: To amend the Federal Food, Drug, and Cosmetic Act to revise and extend...

Sponsor: Frank Pallone (D-N.J.)

S.3335: Jobs, Energy, Families, and Disaster Relief Act of 2008

Sponsor: Max Baucus (D-Mont.)

H.R.5304: To extend the temporary suspension of duty on Sorafenib tosylate.

Sponsor: Bill Pascrell Jr. (D-N.J.)

H.R.5072: To suspend temporarily the duty on Arcol Catalyst 3.

Sponsor: Tim Murphy (R-Pa.)

S.2302: Food and Energy Security Act of 2007

Sponsor: Tom Harkin (D-Iowa)

S.2571: A bill to make technical corrections to the Federal Insecticide,...

Sponsor: Tom Harkin (D-Iowa)

H.R.6124: Food, Conservation, and Energy Act of 2008

Sponsor: Collin C. Peterson (D-Minn.)

H.R.2421: Clean Water Restoration Act of 2007

Sponsor: James L. Oberstar (D-Minn.)

H.R.2784: National Environment and Energy Development Act

Sponsor: John E. Peterson (R-Pa.)

H.R.2337: Energy Policy Reform and Revitalization Act of 2007

Sponsor: Nick J. Rahall II (D-W.Va.)

S.1759: Agriculture Competition Enhancement Act of 2007

Sponsor: Charles E. Grassley (R-Iowa)

H.R.5071: To extend the suspension of duty on Poly(toluene diisocyanate).

Sponsor: Tim Murphy (R-Pa.)

H.R.5082: To suspend temporarily the duty on Desmodur VP LS 2253/1.

Sponsor: Tim Murphy (R-Pa.)

H.R.5076: To suspend temporarily the duty on Mondur M Flaked.

Sponsor: Tim Murphy (R-Pa.)

H.R.1293: Access to Medicare Imaging Act of 2007

Sponsor: Carolyn McCarthy (D-N.Y.)

H.R.3841: SNAP Vitamin and Mineral Improvement Act of 2017

Sponsor: Mike D. Rogers (R-Ala.)

S.2108: Miscellaneous Tariff Bill Act of 2017

Sponsor: Orrin G. Hatch (R-Utah)

H.R.4318: Miscellaneous Tariff Bill Act of 2018

Sponsor: Kevin Brady (R-Texas)

H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the...

Sponsor: Kevin Brady (R-Texas)

S.1528: Genetically Engineered Salmon Labeling Act

Sponsor: Lisa Murkowski (R-Alaska)

H.R.1625: Consolidated Appropriations Act, 2018

Sponsor: Edward Royce (R-Calif.)

H.R.3204: On-the-Job Training Tax Credit Act of 2017

Sponsor: Pete Aguilar (D-Calif.)

S.2434: Animal Drug and Animal Generic Drug User Fee Amendments of 2018

Sponsor: Lamar Alexander (R-Tenn.)

H.R.4618: To amend the Internal Revenue Code of 1986 to provide for a temporary...

Sponsor: Lynn Jenkins (R-Kan.)

H.R.4170: Disclosing Foreign Influence Act

Sponsor: Mike Johnson (R-La.)

S.2039: Disclosing Foreign Influence Act

Sponsor: Charles E. Grassley (R-Iowa)

S.2098: Foreign Investment Risk Review Modernization Act of 2018

Sponsor: John Cornyn (R-Texas)

H.R.2932: Foreign Investment and Economic Security Act of 2017

Sponsor: Rosa DeLauro (D-Conn.)

H.R.4311: Foreign Investment Risk Review Modernization Act of 2017

Sponsor: Robert Pittenger (R-N.C.)

H.R.2810: National Defense Authorization Act for Fiscal Year 2018

Sponsor: William M. Thornberry (R-Texas)

H.R.5515: John S. McCain National Defense Authorization Act for Fiscal Year 2019

Sponsor: William M. Thornberry (R-Texas)

S.483: Pesticide Registration Improvement Extension Act of 2018

Sponsor: Pat Roberts (R-Kan.)

H.R.1029: Space Resources Institute Act

Sponsor: Scott Tipton (R-Colo.)

H.R.1337: Saving America’s Pollinators Act of 2019

Sponsor: Earl Blumenauer (D-Ore.)

H.R.1783: Keep Food Safe from Glyphosate Act of 2019

Sponsor: Rosa DeLauro (D-Conn.)

H.J.RES.31: Consolidated Appropriations Act, 2019

Sponsor: Lucille Roybal-Allard (D-Calif.)

H.J.RES.28: Further Additional Continuing Appropriations Act, 2019

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.863: DXM Abuse Prevention Act of 2019

Sponsor: Doris Matsui (D-Calif.)

H.R.965: CREATES Act of 2019

Sponsor: David Cicilline (D-R.I.)

H.R.985: FAST Generics Act of 2019

Sponsor: Peter Welch (D-Vt.)

H.R.1344: Competitive DRUGS Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

H.R.1503: Orange Book Transparency Act of 2020

Sponsor: Robin Kelly (D-Ill.)

H.R.1520: Further Extension of Continuing Appropriations Act, 2021

Sponsor: Anna G. Eshoo (D-Calif.)

S.340: CREATES Act of 2019

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1046: Medicare Negotiation and Competitive Licensing Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

S.377: Medicare Negotiation and Competitive Licensing Act of 2019

Sponsor: Sherrod Brown (D-Ohio)

H.R.1922: Restoring Access to Medication Act of 2019

Sponsor: Ron Kind (D-Wis.)

S.287: Bicameral Congressional Trade Authority Act of 2019

Sponsor: Patrick J. Toomey (R-Pa.)

H.R.940: Bicameral Congressional Trade Authority Act of 2019

Sponsor: Mike Gallagher (R-Wis.)

H.R.1: For the People Act of 2019

Sponsor: John Sarbanes (D-Md.)

S.949: For the People Act of 2019

Sponsor: Tom Udall (D-N.M.)

H.R.1834: Defending Our National Marine Sanctuaries from Damaging Chemicals Act of...

Sponsor: Francis Rooney (R-Fla.)

H.R.5: Equality Act

Sponsor: David Cicilline (D-R.I.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.748: CARES Act

Sponsor: Joe Courtney (D-Conn.)

H.R.6800: The Heroes Act

Sponsor: Nita M. Lowey (D-N.Y.)

S.3756: Renewable Fuel Feedstock Reimbursement Act of 2020

Sponsor: Charles E. Grassley (R-Iowa)

S.3894: Growing Climate Solutions Act of 2020

Sponsor: Mike Braun (R-Ind.)

H.R.2: Moving Forward Act

Sponsor: Peter A. DeFazio (D-Ore.)

H.R.7022: Rural Broadband Acceleration Act.

Sponsor: James E. Clyburn (D-S.C.)

H.R.7940: Protect America’s Children from Toxic Pesticides Act

Sponsor: Joe Neguse (D-Colo.)

S.4406: Protect America’s Children from Toxic Pesticides Act

Sponsor: Tom Udall (D-N.M.)

H.R.133: Consolidated Appropriations Act, 2021

Sponsor: Henry Cuellar (D-Texas)

S.278: Emergency Relief for Farmers of Color Act of 2021

Sponsor: Raphael Warnock (D-Ga.)

H.R.1319: American Rescue Plan Act of 2021

Sponsor: John Yarmuth (D-Ky.)

S.193: Adopt GREET Act

Sponsor: John Thune (R-S.D.)

H.R.1052: Grand Canyon Protection Act

Sponsor: Raúl M. Grijalva (D-Ariz.)

S.984: Break Free From Plastic Pollution Act of 2021

Sponsor: Jeff Merkley (D-Ore.)

H.R.2238: Break Free From Plastic Pollution Act of 2021

Sponsor: Alan Lowenthal (D-Calif.)

H.R.5: Equality Act

Sponsor: David Cicilline (D-R.I.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.1251: Growing Climate Solutions Act of 2021

Sponsor: Mike Braun (R-Ind.)

H.R.2820: Growing Climate Solutions Act of 2021

Sponsor: Abigail Spanberger (D-Va.)

H.R.3684: Infrastructure Investment and Jobs Act

Sponsor: Peter A. DeFazio (D-Ore.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

S.CON.RES.14: A concurrent resolution setting forth the congressional budget for the...

Sponsor: Bernard Sanders (ID-Vt.)

H.R.7253: Clarifying Remanufacturing to Protect Patient Safety Act of 2022

Sponsor: Scott Peters (D-Calif.)

H.R.5089: Next Generation Fuels Act of 2021

Sponsor: Cheri Bustos (D-Ill.)

S.4348: FDASLA Act of 2022

Sponsor: Patty Murray (D-Wash.)

H.R.7667: Food and Drug Amendments of 2022

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

Sponsor: Angie Craig (D-Minn.)

H.R.7752: Plant Biostimulant Act of 2022

Sponsor: Jimmy Panetta (D-Calif.)

H.R.2617: Consolidated Appropriations Act, 2023

Sponsor: Gerald E. Connolly (D-Va.)

S.2774: Pride in Patent Ownership Act

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.8404: Respect for Marriage Act

Sponsor: Jerrold Nadler (D-N.Y.)

H.R.1472: Plant Biostimulant Act

Sponsor: Jimmy Panetta (D-Calif.)

S.802: Plant Biostimulant Act of 2023

Sponsor: Mike Braun (R-Ind.)

H.R.4288: Agricultural Labeling Uniformity Act

Sponsor: Dusty Johnson (R-S.D.)

H.R.4368: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Andy Harris (R-Md.)

S.2131: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Martin Heinrich (D-N.M.)

H.R.3086: Find It Early Act

Sponsor: Rosa DeLauro (D-Conn.)

H.R.2670: National Defense Authorization Act for Fiscal Year 2024

Sponsor: Mike D. Rogers (R-Ala.)

H.R.3935: Securing Growth and Robust Leadership in American Aviation Act

Sponsor: Sam Graves (R-Mo.)

S.1939: FAA Reauthorization Act of 2024

Sponsor: Maria Cantwell (D-Wash.)

H.R.4821: Department of the Interior, Environment, and Related Agencies...

Sponsor: Mike Simpson (R-Idaho)

S.2605: Department of the Interior, Environment, and Related Agencies...

Sponsor: Jeff Merkley (D-Ore.)

S.2226: National Defense Authorization Act for Fiscal Year 2024

Sponsor: Jack Reed (D-R.I.)

H.R.4366: Consolidated Appropriations Act, 2024

Sponsor: John Carter (R-Texas)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Christopher Leahy	Policy Coordinator & Counsel, House Energy &
Matthew Perin	Subcommittee Staff Dir., House Ag Committee
James McVaney	Leg. Asst./Leg. Corres., Rep. John Linder (1993-1995)
Ursula Wojciechowski	Staff Member, House Oversight Feder. Subcommittee '05-'06; Staff Member, House Oversight Tech. Subcommittee '04; Clerk, House Oversight Tech. Subcommittee '03; Staff Assistant, House Oversight Govt. Efficiency Subcommittee '02
Edward Barron	Dep. Chief Counsel, Senate Judiciary Cmte. 04-07; Dep. Staff Dir., Senate Cmte. on Env. and Pub. Works 02-04; Dep. Chief Counsel, Senate Judiciary Cmte. 98-02; Chief of Staff/Chief Counsel (Majority/Minority), Senate Agriculture Cmte. 87-98.
Brian Nagle	Legislative Director, Sen. Kay Hagan '12-'14; Legislative Director, Sen. Ernest Hollings '04-05; Legislative Assistant, Sen. Ernest Hollings '00-'04; Legislative Correspondent, Sen. Ernest Hollings '99-'00.
Lindsay Morris	Professional Staff Member, U.S. Senate Committee on Health, Education, Labor, and Pensions (2003-2006); Professional Staff Member, U.S. Senate Special Committee on Aging (2007-2008).
Hallie Utley	Sr. Legislative Asst., Rep. Phil Crane 03-05; Sr. Legislative Asst./Legislative Asst., Rep. Jo Ann Emerson 00-03; Legislative Correspondent, Rep. Judy Biggert (R-IL) 99-00; Staff Asst., Rep. Jo Ann Emerson 98-'99.
Brian McCullough	Sr. Prof. Staff, House Energy and Commerce Cmte (1995-2014)
Lucas Tomanelli	2015-2017, Dpty Staff Dir., Senate Comm. on Small Business and Entrepreneurship; 2006-2012, Leg. Asst./Subcom. Staff Dir./ Leg. Corr./Leg. Aide, Sen. Mike Crapo; 2005-2006, Staff Asst., House Comm. on Ways and Means, Subcom. on Oversight
Peter Stehouwer	2013-2017, Leg. Dir./Sr. Leg. Asst., Rep. Billy Long; 2011-2012, Sen. Leg. Asst., Rep. Bill Huizenga; 2006-2010, Leg. Asst./Leg. Corr./Staff Asst., Rep. Pete Hoekstra
Glenn Kelly	Deputy Chief of Staff, Rep. Jo Ann Emerson 97-99.
Christopher (cont'd) Leahy (cont'd)	Commerce Committee, 2004-2006
Michael Holland	Counsel, Rep. Devin Nunes (CA-21), (2009-2011); Legislative Director and Counsel, Rep. John M. McHugh (NY-23) (2007-2009); Legislative Director, Rep. William M. Thomas (CA-22) (2001-2007); Legislative Assistant, Sen. Tim Hutchinson (AR) (1998-2001)
Scott Kuschmider	Min. Staff(11), Subcom. Staff Dir.(10-11), Prof. Staff(07-10) - H. Ag. Com; Press Sec., Rep. D. Kildee(05-07); Press Sec. & Leg. As.(04-05), Sys.Ad./Mail Mgr.(01-04) for Rep. K. Lucas; PT Emp., Rep. C. Shays(02); Int., Rep. D. Moore(01)
Michael Parrish	Executive Assistant, Congressman Sam Farr (2001-2002); Staff Asst., US Department of State (1999-2001)
Stephanie Murphy	Director for Agricultural Affairs, Office of the United States Trade Representative (2009-2014)
James Travis	Rep. Cal Dooley (CA-20): Senior Advisor, Agriculture Policy & Water Resources (1999-2003)
Kasey Gillette	Sen. Pol. Adv., Sen. H. Reid(09-14); Dep. Leg. Dir., Sen. B. Casey(07-09); Pol. Adv., Sen. D. Stabenow(05-07); Sen. Pol. Adv.(02-04), Leg. Asst.(01-02), Leg. Corr.(00-01), Staff Asst.(00), Intern(99) -- Sen. B. Graham
Kellie Adesina	H. Ag. Cmte. (Chief Coun., 19; Sr. Coun., 16-19); USDA (Sr. Coun., 15-16); Rep. Marcia Fudge (Leg. Dir., 12-15); Rep. Judy Chu (Coun., 11-12); Sen. Bob Menendez (Dep. Coun. & Dir. African Amer. Outreach, 11; Leg. Corr., 09-11; Staff As., 09)
Erick Lutt	Office of Sen. Ben Nelson -- Legislative Asst., Deputy Legislative Asst., Staff Asst. (2005-2013)
Julie Corcoran	n/a
Chris Leahy	n/a
Donna Stephens	n/a
Jean Reimers	n/a
Julie Van Egmond	n/a
Dakotah Smith	n/a
THOMAS LILBURN	n/a
Matt Perin	n/a
Robert Thomas	n/a
Thoms Lilburn	n/a
Jean D. Reimers	n/a
Jennifer Spurgat	n/a
ROBERT D. THOMAS	n/a
Ronald F. Docksai	n/a
Juliane H. Van Egmond	n/a
Thomas B. Lilburn	n/a
Ron F. Docksai	n/a
Juliane H. Van Egmongd	n/a
Thomas B Lilburn	n/a
Jean D. Reimers Ms.	n/a
Jennifer Spurgat Ms.	n/a
Donna Stephens Ms.	n/a
Ronald F. Docksai Dr.	n/a
Robert D. Thomas Mr.	n/a
Julie Corcoran Ms.	n/a
Donna Stephens Ms	n/a
Juliane H. Van Egmond Ms.	n/a
Juliane H. Van Egmond Ms	n/a
Thomas B. Lilburn Mr.	n/a
Karen Niedermeyer Ms.	n/a
Lori Wallace	n/a
Jean D Reimers Ms	n/a
Thoms B. Lilburn Mr.	n/a
Dakotah J. Smith	n/a
Ron Docksai	n/a
Julie A. Corcoran Ms.	n/a
Jean D. Reimers Ms	n/a
Jennifer Spurgat Ms	n/a
Thomas B. Lilburn Mr	n/a
Ronald F. Docksai Mr.	n/a
Karen Niedermeyer Ms	n/a
William H. Hensley Mr.	n/a
Juliane. H. Van Egmond Ms.	n/a
Juliane H. Van Egmond Mrs.	n/a
Usula Wojciechowski	n/a
Duane Simpson	n/a
Trent Clark	n/a
Katharine Emerson	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 22. Original Filing: 301572976.xml

Lobbying Issues

Monitor and engage on legislative and administrative action related to pollinator health and habitat promotion. Monitor and engage on legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor and engage on legislative and administrative action related to the Endangered Species Act and related reforms. Monitor and engage on legislative and administrative action related to 7 CFR Part 340. Monitor and engage on the implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor and engage on legislative and administrative action related to biotech innovation and regulation. Monitor and engage on legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor and engage on legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor and engage on legislative and administrative action related to food security and nutrition. Monitor and engage on legislative and administrative action related to the International Union for the Protection of New Varieties of Plants (UPOV). Monitor and engage on legislative and administrative action related to the reauthorization of the Pesticide Registration Improvement Act. Monitor and engage on legislative and administrative action related to biofuels, including ethanol, the RFS, and sustainable aviation fuel. Monitor and engage on legislative and administrative action related to Pesticides: Exemptions of Certain Plant-Incorporated Protectants Derived from Newer Technologies (Final Rule). Monitor and engage on legislative and administrative action related to reauthorization of Foundation for Food and Agriculture Research (FFAR). Monitor and engage on legislative and administrative action related to the Farm Bill. H.R. 1472, Plant Biostimulant Act. H.R. 3935, Securing Growth and Robust Leadership in American Aviation Act. H.R. 4288, Agricultural Labeling Uniformity Act. S. 802, Plant Biostimulant Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on the implementation of the Infrastructure Investment and Jobs Act (P.L. 117-58), and the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on a FY 2025 National Defense Authorization Act (NDAA). H.R. 4288, Labeling Uniformity Act. H.R. 4366, Consolidated Appropriations Act, 2024 (Pub. Law 118-42). H.R. 4368, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024. H.R. 4821, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2024, including Section 461. S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024. S. 2605, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2024.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. Monitor and engage on legislative and administrative action related to DEA-determined pseudoephedrine quotas. H.R. 3086, Find It Early Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor and engage on legislative and federal activity related to tax reform. Monitor and engage on legislative and administrative action related to corporate and international tax, including issues related to tax code sections 245A, 951A, 59A, 163(j), 174, and 965. Monitor and engage on legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor and engage on legislative and administrative action related to including dietary supplements as reimbursable expenses in tax-preferred savings accounts. Monitor and engage on legislative and administrative issues related to foreign tax credit regulations. Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169), including the section 45Z tax credit and the sustainable aviation fuel tax credit.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor and engage on legislative and administrative action related to trade. Monitor and engage on legislative and administrative action related to foreign regulation of chemicals, pesticides, pharmaceuticals, and health care products. Monitor and engage on legislative and administrative action related to China import approvals, and foreign direct investment prohibitions and restrictions. Monitor and engage in administrative action related to maximum residue levels (MRLs) in the EU, EU biotech import approvals, and EU Green Deal. Monitor and engage on legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor and engage on legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor and engage on legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor and engage on legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor and engage on the administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor and engage on legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor and engage on legislative and administrative action related to Russian and Ukraine food security. Monitor and engage on legislative and administrative action related to Ukraine reconstruction and investment. Monitor and engage on legislative and administrative action related to World Trade Organization (WTO) digital trade rules.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 22. Original Filing: 301539557.xml

Lobbying Issues

Monitor and engage on legislative and administrative action related to pollinator health and habitat promotion. Monitor and engage on legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor and engage on legislative and administrative action related to the Endangered Species Act and related reforms. Monitor and engage on legislative and administrative action related to 7 CFR Part 340. Monitor and engage on the implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor and engage on legislative and administrative action related to biotech innovation and regulation. Monitor and engage on legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor and engage on legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor and engage on legislative and administrative action related to White House Conference on Hunger. Monitor and engage on legislative and administrative action related to food security and nutrition. Monitor and engage on legislative and administrative action related to the International Union for the Protection of New Varieties of Plants (UPOV). Monitor and engage on legislative and administrative action related to the reauthorization of the Pesticide Registration Improvement Act. Monitor and engage on legislative and administrative action related to biofuels. Monitor and engage on legislative and administrative action related to Pesticides: Exemptions of Certain Plant-Incorporated Protectants Derived from Newer Technologies (Final Rule). Monitor and engage on legislative and administrative action related to reauthorization of Foundation for Food and Agriculture Research (FFAR). Monitor and engage on legislative and administrative action related to the Farm Bill. H.R. 1472, Plant Biostimulant Act. H.R. 3935, Securing Growth and Robust Leadership in American Aviation Act. H.R. 4288, Agricultural Labeling Uniformity Act. S. 802, Plant Biostimulant Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. Monitor and engage on legislative and administrative action related to DEA-determined pseudoephedrine quotas. H.R. 3086, Find It Early Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 20, 2023. Original Filing: 301511765.xml

Lobbying Issues

Monitor and engage on legislative and administrative action related to pollinator health and habitat promotion. Monitor and engage on legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor and engage on legislative and administrative action related to the Endangered Species Act and related reforms. Monitor and engage on legislative and administrative action related to 7 CFR Part 340. Monitor and engage on the implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor and engage on legislative and administrative action related to biotech innovation and regulation. Monitor and engage on legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor and engage on legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor and engage on legislative and administrative action related to White House Conference on Hunger. Monitor and engage on legislative and administrative action related to food security and nutrition. Monitor and engage on legislative and administrative action related to the International Union for the Protection of New Varieties of Plants (UPOV). Monitor and engage on legislative and administrative action related to the reauthorization of the Pesticide Registration Improvement Act. Monitor and engage on legislative and administrative action related to biofuels. Monitor and engage on legislative and administrative action related to Pesticides: Exemptions of Certain Plant-Incorporated Protectants Derived from Newer Technologies (Final Rule). Monitor and engage on legislative and administrative action related to reauthorization of Foundation for Food and Agriculture Research (FFAR). Monitor and engage on legislative and administrative action related to the Farm Bill. H.R. 1472, Plant Biostimulant Act. H.R. 3935, Securing Growth and Robust Leadership in American Aviation Act. H.R. 4288, Agricultural Labeling Uniformity Act. S. 802, Plant Biostimulant Act. S. 1939, FAA Reauthorization Act of 2023.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 20, 2023. Original Filing: 301490771.xml

Lobbying Issues

Monitor and engage on legislative and administrative action related to pollinator health and habitat promotion. Monitor and engage on legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor and engage on legislative and administrative action related to the Endangered Species Act and related reforms. Monitor and engage on legislative and administrative action related to 7 CFR Part 340. Monitor and engage on the implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor and engage on legislative and administrative action related to biotech innovation and regulation. Monitor and engage on legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor and engage on legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor and engage on legislative and administrative action related to White House Conference on Hunger. Monitor and engage on legislative and administrative action related to food security and nutrition. Monitor and engage on legislative and administrative action related to the International Union for the Protection of New Varieties of Plants (UPOV). Monitor and engage on legislative and administrative action related to the reauthorization of the Pesticide Registration Improvement Act. Monitor and engage on legislative and administrative action related to the Farm Bill. Monitor and engage on legislative and administrative action related to biofuels. Monitor and engage on legislative and administrative action related to Pesticides: Exemptions of Certain Plant-Incorporated Protectants Derived from Newer Technologies (Final Rule). H.R. 1472, Plant Biostimulant Act. H.R. 4288, To clarify the application of a certain provision of the FIFRA with respect to the uniformity of pesticide labeling, consistent with the text of such Act, and for other purposes. S. 802, Plant Biostimulant Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to a WTO IP waiver. Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. H.R. 3086, Find It Early Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 20, 2023. Original Filing: 301465225.xml

Lobbying Issues

Monitor and engage on legislative and administrative action related to pollinator health and habitat promotion. Monitor and engage on legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor and engage on legislative and administrative action related to the Endangered Species Act and related reforms. Monitor and engage on legislative and administrative action related to 7 CFR Part 340. Monitor and engage on the implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor and engage on legislative and administrative action related to biotech innovation and regulation. Monitor and engage on legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor and engage on legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor and engage on legislative and administrative action related to White House Conference on Hunger. Monitor and engage on legislative and administrative action related to food security and nutrition. Monitor and engage on legislative and administrative action related to the International Union for the Protection of New Varieties of Plants (UPOV). Monitor and engage on legislative and administrative action related to the reauthorization of the Pesticide Registration Improvement Act. Monitor and engage on legislative and administrative action related to the Farm Bill. Monitor and engage on legislative and administrative action related to biofuels. H.R. 1472, Plant Biostimulant Act. S. 802, Plant Biostimulant Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to telehealth. Monitor legislative and administrative action related to a WTO IP waiver. Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 20, 2023. Original Filing: 301442528.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to agricultural chemistry. Monitor legislative and administrative action related to biotechnology. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor legislative and administrative action related to White House Conference on Hunger. Monitor legislative and administrative action related to food security and nutrition. Monitor legislative and administrative action related to Russian and Ukraine food security. Monitor legislative and administrative action related to the International Union for the Protection of New Varieties of Plants (UPOV). Monitor legislative and administrative action related to the reauthorization of the Pesticide Registration Improvement Act. H.R. 5376, Inflation Reduction Act of 2022. H.R. 7752, Plant Biostimulant Act of 2022.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to copay assistance. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. Monitor legislative and administrative action related to telehealth expansion. Monitor legislative and administrative action related to a WTO IP waiver. S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 2617, Consolidated Appropriations Act, 2023 (P.L. 117-328), including FDA provisions. H.R. 5376, Inflation Reduction Act of 2022. H.R. 7253, Clarifying Remanufacturing to Protect Patient Safety Act of 2022. H.R. 7667, Food and Drug Amendments of 2022.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals, pesticides, pharmaceuticals, and health care products. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation. Monitor legislative and administrative action related to Russian and Ukraine food security.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 20, 2022. Original Filing: 301414849.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to copay assistance. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. Monitor legislative and administrative action related to telehealth expansion. Monitor legislative and administrative action related to a WTO IP waiver. S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 5376, Inflation Reduction Act of 2022. H.R. 7253, Clarifying Remanufacturing to Protect Patient Safety Act of 2022. H.R. 7667, Food and Drug Amendments of 2022.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 20, 2022. Original Filing: 301393364.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to agricultural chemistry. Monitor legislative and administrative action related to biotechnology. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor legislative and administrative action related to White House Conference on Hunger. Monitor legislative and administrative action related to food security and nutrition. Monitor legislative and administrative action related to Russian and Ukraine food security. Build Back Better proposals, including H.R. 5376, the Build Back Better Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to copay assistance. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. Monitor legislative and administrative action related to telehealth expansion. Monitor legislative and administrative action related to a WTO IP waiver. S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. Build Back Better proposals, including H.R. 5376, the Build Back Better Act. H.R. 7253, Clarifying Remanufacturing to Protect Patient Safety Act of 2022. H.R. 7667, Food and Drug Amendments of 2022.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 20, 2022. Original Filing: 301369286.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to agricultural chemistry. Monitor legislative and administrative action related to biotechnology. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor legislative and administrative action related to White House Conference on Hunger. Monitor legislative and administrative action related to food security and nutrition. Monitor legislative and administrative action related to Russian and Ukraine food security. Build Back Better proposals, including H.R. 5376, the Build Back Better Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to copay assistance. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. Monitor legislative and administrative action related to telehealth expansion. Monitor legislative and administrative action related to a WTO IP waiver. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. Build Back Better proposals, including H.R. 5376, the Build Back Better Act. H.R. 7253, Clarifying Remanufacturing to Protect Patient Safety Act of 2022.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 20, 2022. Original Filing: 301335809.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to agricultural chemistry. Monitor legislative and administrative action related to biotechnology. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Build Back Better proposals, including H.R. 5376, the Build Back Better Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to copay assistance. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. Monitor legislative and administrative action related to telehealth expansion. Monitor legislative and administrative action related to a WTO IP waiver. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. Build Back Better proposals, including H.R. 5376, the Build Back Better Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 20, 2021. Original Filing: 301311613.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to copay assistance. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. Monitor legislative and administrative action related to telehealth expansion. Monitor legislative and administrative action related to a WTO IP waiver. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 1319, American Rescue Plan Act of 2021. Build Back Better proposals, including those in potential budget reconciliation packages.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals, pesticides, pharmaceuticals, and health care products. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 20, 2021. Original Filing: 301287305.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to copay assistance. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. Monitor legislative and administrative action related to telehealth expansion. Monitor legislative and administrative action related to a WTO IP waiver. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 1319, American Rescue Plan Act of 2021.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to corporate and international tax, including issues related to tax code sections 172, 245A, 951A, and 965. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Monitor legislative and administrative action related to net operating loss (NOL) tax issue. Monitor legislative and administrative action related to including dietary supplements as reimbursable expenses in tax-preferred savings accounts. H.R. 1319, American Rescue Plan Act of 2021.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals, pesticides, pharmaceuticals, and health care products. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 20, 2021. Original Filing: 301264334.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals, pesticides, pharmaceuticals, and health care products. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 21, 2021. Original Filing: 301244823.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to agricultural chemistry. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to the Pet and Womens Safety Act, as authorized in the 2018 Farm Bill. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Monitor legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. H.R. 7940, Protect Americas Children from Toxic Pesticides Act. S. 4406, Protect Americas Children from Toxic Pesticides Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to implementation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation. S. 287, Bicameral Congressional Trade Authority Act of 2019. H.R. 940, Bicameral Congressional Trade Authority Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 20, 2020. Original Filing: 301220176.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to agricultural chemistry. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to the Pet and Womens Safety Act, as authorized in the 2018 Farm Bill. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Monitor legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). H.R. 7940, Protect Americas Children from Toxic Pesticides Act. S. 3756, Renewable Fuel Feedstock Reimbursement Act of 2020. S. 4406, Protect Americas Children from Toxic Pesticides Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the negotiation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation. S. 287, Bicameral Congressional Trade Authority Act of 2019. H.R. 940, Bicameral Congressional Trade Authority Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 20, 2020. Original Filing: 301200688.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to agricultural chemistry. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to the Pet and Womens Safety Act, as authorized in the 2018 Farm Bill. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). S. 3756, Renewable Fuel Feedstock Reimbursement Act of 2020.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector and glyphosate. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the negotiation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation. S. 287, Bicameral Congressional Trade Authority Act of 2019. H.R. 940, Bicameral Congressional Trade Authority Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q12020 on April 20, 2020 Original Filing: 301179848.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Address administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to the Pet and Womens Safety Act, as authorized in the 2018 Farm Bill. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1337, Saving Americas Pollinators Act of 2019. H.R. 1783, Keep Food Safe from Glyphosate Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector and glyphosate. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the negotiation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation. S. 287, Bicameral Congressional Trade Authority Act of 2019. H.R. 940, Bicameral Congressional Trade Authority Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 20, 2020. Original Filing: 301175505.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector and glyphosate. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to Mexico import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to maximum residue levels (MRLs) generally and within the context of the proposed EU-US FTA. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the negotiation of the United States-Mexico-Canada Agreement (USMCA), including Mexico biotechnology and glyphosate import permits. Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation. S. 287, Bicameral Congressional Trade Authority Act of 2019. H.R. 940, Bicameral Congressional Trade Authority Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 21, 2020. Original Filing: 301125209.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Address administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to the Pet and Womens Safety Act, as authorized in the 2018 Farm Bill. H.R. 1337, Saving Americas Pollinators Act of 2019. H.R. 1783, Keep Food Safe from Glyphosate Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to repealing the medical device tax. Monitor legislative and administrative action related to sunscreen issues. Monitor legislative and administrative action related to P.L. 113-195, The Sunscreen Innovation Act. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the negotiation of the United States-Mexico-Canada Agreement (USMCA). Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. Monitor legislative and administrative action related to seed importation. S. 287, Bicameral Congressional Trade Authority Act of 2019. H.R. 940, Bicameral Congressional Trade Authority Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 21, 2019. Original Filing: 301077890.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Address administrative action related to pesticide registration and approval issues. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to the Pet and Womens Safety Act, as authorized in the 2018 Farm Bill. H.R. 1337, Saving Americas Pollinators Act of 2019. H.R. 1783, Keep Food Safe from Glyphosate Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to repealing the medical device tax. Monitor legislative and administrative action related to sunscreen issues. Monitor legislative and administrative action related to P.L. 113-195, The Sunscreen Innovation Act. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to EU import approvals and MRLs. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the negotiation of the United States-Mexico-Canada Agreement (USMCA). Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. S. 287, Bicameral Congressional Trade Authority Act of 2019. H.R. 940, Bicameral Congressional Trade Authority Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 22, 2019. Original Filing: 301058336.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to genetically modified labeling. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to the Pet and Womens Safety Act, as authorized in the 2018 Farm Bill. Communication on status of Bayer activities related to agricultural chemistries. H.R. 1337, Saving Americas Pollinators Act of 2019. H.R. 1783, Keep Food Safe from Glyphosate Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to trade. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector. Monitor legislative and administrative action related to China import approvals. Monitor legislative and administrative action related to EU import approvals. Monitor legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the negotiation of the United States-Mexico-Canada Agreement (USMCA). Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM. Monitor legislative and administrative action related to Venezuela sanctions. Monitor legislative and administrative action related to intellectual property issues and regulations in Brazil, India, and Ukraine. S. 287, Bicameral Congressional Trade Authority Act of 2019. H.R. 940, Bicameral Congressional Trade Authority Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 22, 2019. Original Filing: 301036059.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration. Monitor legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor legislative and administrative action related to genetically modified labeling. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Monitor legislative and administrative action related to biotech innovation and regulation. Monitor legislative and administrative action related to the Pet and Womens Safety Act, as authorized in the 2018 Farm Bill. S. 483, Pesticide Registration Improvement Extension Act of 2018, Public Law No: 116-8 (enacted into law H.R. 1029, 115th Congress, as passed by the Senate). H.R. 1337, Saving Americas Pollinators Act of 2019. H.R. 1783, Keep Food Safe from Glyphosate Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 22, 2019. Original Filing: 301014345.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration. Monitor legislative and administrative action related to biotechnology deregulation. Monitor legislative and administrative action related to genetically modified labeling. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to reauthorization of the farm bill. Monitor legislative and administrative action related to reauthorization of Animal Drug User Fee Act (ADUFA). Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Various issues related to corporate acquisition. S. 322, Pet and Women Safety Act of 2017. S. 629, Preventing Antibiotic Resistance Act of 2017. S. 1528, Genetically Engineered Salmon Labeling Act. H.R. 909, Pet and Women Safety Act of 2017. H.R. 953, Reducing Regulatory Burdens Act of 2017. H.R. 1029, Pesticide Registration Enhancement Act of 2017. H.R. 3040, Saving Americas Pollinators Act of 2017.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action on appropriations and budget. Monitor legislative and administrative action related to U.S. Department of Agriculture appropriations. S.Con.Res.3, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026. S. 1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018. H.R. 1625, Vehicle for Consolidated Appropriations Act, 2018. H.R. 2810, National Defense Authorization Act for Fiscal Year 2018. H.R. 3268, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018. H.R. 5515, John S. McCain National Defense Authorization Act for Fiscal Year 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to FDA enforcement of prescription to over-the-counter switches of medicine. Monitor legislative and administrative action related to allowed purchases under the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to opioids. Monitor legislative and administrative action related to implementation of H.R. 3204, Drug Quality and Security Act. S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. S. 934, FDA Reauthorization Act of 2017. S. 2434, Animal Drug and Animal Generic Drug User Fee Amendments Act of 2018. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act. H.R. 2164, Medical Device Safety Act. H.R. 2430, FDA Reauthorization Act of 2017. H.R. 3841, SNAP Vitamin and Mineral Improvement Act of 2017. H.R. 3921, HEALTHY KIDS Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector. Monitor legislative and administrative action related to North American Free Trade Agreement renegotiation. Monitor legislative and administrative action related to duty drawbacks. Monitor legislative and administrative action related to European Union regulation of nutritionals, vitamins and minerals, and dietary supplements. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the renegotiation of the North American Free Trade Agreement (NAFTA). Monitor legislative and administrative action related to the negotiation of the United States-Mexico-Canada Agreement (USMCA). Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor administrative action related to the Review of Controls for Certain Emerging Technologies ANPRM.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 19, 2018. Original Filing: 300992272.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration. Monitor legislative and administrative action related to biotechnology deregulation. Monitor legislative and administrative action related to genetically modified labeling. Monitor legislative and administrative action related to the Endangered Species Act and related reforms. Monitor legislative and administrative action related to reauthorization of the farm bill. Monitor legislative and administrative action related to reauthorization of Animal Drug User Fee Act (ADUFA). Monitor legislative and administrative action related to 7 CFR Part 340. Monitor implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor legislative and administrative action related to the regulation of biostimulants. Various issues related to corporate acquisition. S. 322, Pet and Women Safety Act of 2017. S. 629, Preventing Antibiotic Resistance Act of 2017. S. 1528, Genetically Engineered Salmon Labeling Act. H.R. 909, Pet and Women Safety Act of 2017. H.R. 953, Reducing Regulatory Burdens Act of 2017. H.R. 1029, Pesticide Registration Enhancement Act of 2017. H.R. 3040, Saving Americas Pollinators Act of 2017.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to FDA enforcement of prescription to over-the-counter switches of medicine. Monitor legislative and administrative action related to allowed purchases under the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to opioids. Monitor legislative and administrative action related to implementation of H.R. 3204, Drug Quality and Security Act. S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. S. 934, FDA Reauthorization Act of 2017. S. 2434, Animal Drug and Animal Generic Drug User Fee Amendments Act of 2018. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act. H.R. 2164, Medical Device Safety Act. H.R. 2430, FDA Reauthorization Act of 2017. H.R. 3841, SNAP Vitamin and Mineral Improvement Act of 2017. H.R. 3921, HEALTHY KIDS Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q22018 on Oct. 19, 2018 Original Filing: 300992290.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to FDA enforcement of prescription to over-the-counter switches of medicine. Monitor legislative and administrative action related to allowed purchases under the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to opioids. Monitor legislative and administrative action related to implementation of H.R. 3204, Drug Quality and Security Act. S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. S. 934, FDA Reauthorization Act of 2017. S. 2434, Animal Drug and Animal Generic Drug User Fee Amendments Act of 2018. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act. H.R. 2164, Medical Device Safety Act. H.R. 2430, FDA Reauthorization Act of 2017. H.R. 3841, SNAP Vitamin and Mineral Improvement Act of 2017. H.R. 3921, HEALTHY KIDS Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector. Monitor legislative and administrative action related to North American Free Trade Agreement renegotiation. Monitor legislative and administrative action related to duty drawbacks. Monitor legislative and administrative action related to European Union regulation of nutritionals, vitamins and minerals, and dietary supplements. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the renegotiation of the North American Free Trade Agreement (NAFTA). Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 20, 2018. Original Filing: 300978097.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to FDA enforcement of prescription to over-the-counter switches of medicine. Monitor legislative and administrative action related to allowed purchases under the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to opioids. Monitor legislative and administrative action related to implementation of H.R. 3204, Drug Quality and Security Act. S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. S. 934, FDA Reauthorization Act of 2017. S. 2434, Animal Drug and Animal Generic Drug User Fee Amendments Act of 2018. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act. H.R. 2164, Medical Device Safety Act. H.R. 2430, FDA Reauthorization Act of 2017. H.R. 3841, SNAP Vitamin and Mineral Improvement Act of 2017. H.R. 3921, HEALTHY KIDS Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector. Monitor legislative and administrative action related to North American Free Trade Agreement renegotiation. Monitor legislative and administrative action related to duty drawbacks. Monitor legislative and administrative action related to European Union regulation of nutritionals, vitamins and minerals, and dietary supplements. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the renegotiation of the North American Free Trade Agreement (NAFTA). Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q12018 on July 20, 2018 Original Filing: 300978082.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to FDA enforcement of prescription to over-the-counter switches of medicine. Monitor legislative and administrative action related to allowed purchases under the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to opioids. Monitor legislative and administrative action related to implementation of H.R. 3204, Drug Quality and Security Act. S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. S. 934, FDA Reauthorization Act of 2017. S. 2434, Animal Drug and Animal Generic Drug User Fee Amendments Act of 2018. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act. H.R. 2164, Medical Device Safety Act. H.R. 2430, FDA Reauthorization Act of 2017. H.R. 3841, SNAP Vitamin and Mineral Improvement Act of 2017. H.R. 3921, HEALTHY KIDS Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector. Monitor legislative and administrative action related to North American Free Trade Agreement renegotiation. Monitor legislative and administrative action related to duty drawbacks. Monitor legislative and administrative action related to European Union regulation of nutritionals, vitamins and minerals, and dietary supplements. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the renegotiation of the North American Free Trade Agreement (NAFTA). Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 20, 2018. Original Filing: 300956853.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to FDA enforcement of prescription to over-the-counter switches of medicine. Monitor legislative and administrative action related to allowed purchases under the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to opioids. Monitor legislative and administrative action related to implementation of H.R. 3204, Drug Quality and Security Act. S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. S. 934, FDA Reauthorization Act of 2017. S. 2434, Animal Drug and Animal Generic Drug User Fee Amendments Act of 2018. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act. H.R. 2164, Medical Device Safety Act. H.R. 2430, FDA Reauthorization Act of 2017. H.R. 3841, SNAP Vitamin and Mineral Improvement Act of 2017. H.R. 3921, HEALTHY KIDS Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to foreign regulation of chemicals and pesticides. Monitor legislative issues and administrative action related to trade discussions with China, including those related to the ag biotech sector. Monitor legislative and administrative action related to North American Free Trade Agreement renegotiation. Monitor legislative and administrative action related to duty drawbacks. Monitor legislative and administrative action related to European Union regulation of nutritionals, vitamins and minerals, and dietary supplements. Monitor legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor legislative and administrative action related to the renegotiation of the North American Free Trade Agreement (NAFTA). Monitor legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 22, 2018. Original Filing: 300936203.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to FDA enforcement of prescription to over-the-counter switches of medicine. Monitor legislative and administration action related to allowed purchases under the Supplemental Nutrition Assistance Program (SNAP). S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. S. 934, FDA Reauthorization Act of 2017. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act. H.R. 2164, Medical Device Safety Act. H.R. 2430, FDA Reauthorization Act of 2017. H.R. 3841, SNAP Vitamin and Mineral Improvement Act of 2017. H.R. 3921, HEALTHY KIDS Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 20, 2017. Original Filing: 300915305.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to FDA enforcement of prescription to over-the-counter switches of medicine. Monitor legislative and administration action related to allowed purchases under the Supplemental Nutrition Assistance Program (SNAP). S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. S. 934, FDA Reauthorization Act of 2017. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act. H.R. 2164, Medical Device Safety Act. H.R. 2430, FDA Reauthorization Act of 2017. H.R. 3921, HEALTHY KIDS Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 20, 2017. Original Filing: 300895426.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to womens health issues. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to companion labeling. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the repeal of the Affordable Care Act. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. S. 404, A bill to amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications. S. 469, Affordable and Safe Prescription Drug Importation Act. H.R. 749, Lower Drug Costs through Competition Act. H.R. 1628, American Health Care Act of 2017. H.R. 2009, To amend the Federal Food, Drug, and Cosmetic Act to provide clarity with respect to the regulation of diagnostic imaging devices intended for use with contrast agents. H.R. 2118, Medical Device Servicing Safety and Accountability Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 20, 2017. Original Filing: 300877213.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q42016 on March 9, 2017 Original Filing: 300861252.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration. Monitor legislative and administrative action related to biotechnology deregulation. Monitor legislative and administrative action related to genetically modified labeling. Monitor legislative and administrative action related to the International Treaty on Plant Genetic Resource for Food and Agriculture (ITPGRFA). Various issues related to proposed corporate acquisition. S. 511, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. S. 621, Preventing Antibiotic Resistance Act of 2015. S. 1559, Pet and Women Safety Act of 2015. S. 2609, An original bill to amend the Agricultural Marketing Act of 1946 to require the Secretary of Agriculture to establish a national voluntary labeling standard for bioengineered foods, and for other purposes. H.R. 897, Reducing Regulatory Burdens Act of 2015. H.R. 913, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. H.R. 1258, Pet and Women Safety Act of 2015. H.R. 1284, Saving Americas Pollinators Act of 2015. H.R. 1599, Safe and Accurate Food Labeling Act of 2015. H.R. 3714, Small Agriculture Producer Size Standards Improvements Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Trans-Pacific Partnerships. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to Environmental Goods Agreement. S. 1015, Enforcing Orders and Reducing Customs Evasion Act of 2015. S. 1200, Fairness to Pet Owners Act of 2015. H.R. 644, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 1891, To extend the African Growth and Opportunity Act, the Generalized System of Preferences, the preferential duty treatment program for Haiti, and for other purposes. H.R. 1907, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 2146, Defending Public Safety Employees' Retirement Act (Title 1 -Bipartisan Congressional Trade Priorities and Accountability Act of 2015). H.R. 3174, Fairness to Pet Owners Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 19, 2017. Original Filing: 300851380.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration. Monitor legislative and administrative action related to biotechnology deregulation. Monitor legislative and administrative action related to genetically modified labeling. Monitor legislative and administrative action related to the International Treaty on Plant Genetic Resource for Food and Agriculture (ITPGRFA). Various issues related to proposed corporate acquisition. S. 511, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. S. 621, Preventing Antibiotic Resistance Act of 2015. S. 1559, Pet and Women Safety Act of 2015. S. 2609, An original bill to amend the Agricultural Marketing Act of 1946 to require the Secretary of Agriculture to establish a national voluntary labeling standard for bioengineered foods, and for other purposes. H.R. 897, Reducing Regulatory Burdens Act of 2015. H.R. 913, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. H.R. 1258, Pet and Women Safety Act of 2015. H.R. 1284, Saving Americas Pollinators Act of 2015. H.R. 1599, Safe and Accurate Food Labeling Act of 2015. H.R. 3714, Small Agriculture Producer Size Standards Improvements Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q32016 on March 9, 2017 Original Filing: 300861250.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration. Monitor legislative and administrative action related to biotechnology deregulation. Monitor legislative and administrative action related to genetically modified labeling. Monitor legislative and administrative action related to the International Treaty on Plant Genetic Resource for Food and Agriculture (ITPGRFA). Various issues related to proposed corporate acquisition. S. 511, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. S. 621, Preventing Antibiotic Resistance Act of 2015. S. 1559, Pet and Women Safety Act of 2015. S. 2609, An original bill to amend the Agricultural Marketing Act of 1946 to require the Secretary of Agriculture to establish a national voluntary labeling standard for bioengineered foods, and for other purposes. H.R. 897, Reducing Regulatory Burdens Act of 2015. H.R. 913, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. H.R. 1258, Pet and Women Safety Act of 2015. H.R. 1284, Saving Americas Pollinators Act of 2015. H.R. 1599, Safe and Accurate Food Labeling Act of 2015. H.R. 3714, Small Agriculture Producer Size Standards Improvements Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Trans-Pacific Partnerships. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to Environmental Goods Agreement. H.R. 644, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 1891, To extend the African Growth and Opportunity Act, the Generalized System of Preferences, the preferential duty treatment program for Haiti, and for other purposes. H.R. 1907, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 2146, Defending Public Safety Employees' Retirement Act (Title 1 -Bipartisan Congressional Trade Priorities and Accountability Act of 2015). S. 1015, Enforcing Orders and Reducing Customs Evasion Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 20, 2016. Original Filing: 300838509.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. Monitor legislative and administrative action related to pesticide registration. Monitor legislative and administrative action related to biotechnology deregulation. Monitor legislative and administrative action related to genetically modified labeling. Monitor legislative and administrative action related to the International Treaty on Plant Genetic Resource for Food and Agriculture (ITPGRFA). Various issues related to proposed corporate acquisition. S. 511, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. S. 621, Preventing Antibiotic Resistance Act of 2015. S. 1559, Pet and Women Safety Act of 2015. S. 2609, An original bill to amend the Agricultural Marketing Act of 1946 to require the Secretary of Agriculture to establish a national voluntary labeling standard for bioengineered foods, and for other purposes. H.R. 897, Reducing Regulatory Burdens Act of 2015. H.R. 913, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. H.R. 1258, Pet and Women Safety Act of 2015. H.R. 1284, Saving Americas Pollinators Act of 2015. H.R. 1599, Safe and Accurate Food Labeling Act of 2015. H.R. 3714, Small Agriculture Producer Size Standards Improvements Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Trans-Pacific Partnerships. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to Environmental Goods Agreement. H.R. 644, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 1891, To extend the African Growth and Opportunity Act, the Generalized System of Preferences, the preferential duty treatment program for Haiti, and for other purposes. H.R. 1907, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 2146, Defending Public Safety Employees' Retirement Act (Title 1 -Bipartisan Congressional Trade Priorities and Accountability Act of 2015). S. 1015, Enforcing Orders and Reducing Customs Evasion Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 20, 2016. Original Filing: 300817987.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Trans-Pacific Partnerships. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to Environmental Goods Agreement. H.R. 644, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 1891, To extend the African Growth and Opportunity Act, the Generalized System of Preferences, the preferential duty treatment program for Haiti, and for other purposes. H.R. 1907, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 2146, Defending Public Safety Employees' Retirement Act (Title 1 -Bipartisan Congressional Trade Priorities and Accountability Act of 2015). S. 998, American Manufacturing Competitiveness Act of 2015. S. 1015, Enforcing Orders and Reducing Customs Evasion Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q12016 on March 3, 2017 Original Filing: 300861093.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Trans-Pacific Partnerships. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to Environmental Goods Agreement. H.R. 644, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 1891, To extend the African Growth and Opportunity Act, the Generalized System of Preferences, the preferential duty treatment program for Haiti, and for other purposes. H.R. 1907, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 2146, Defending Public Safety Employees' Retirement Act (Title 1 -Bipartisan Congressional Trade Priorities and Accountability Act of 2015). S. 998, American Manufacturing Competitiveness Act of 2015. S. 1015, Enforcing Orders and Reducing Customs Evasion Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q12016 on April 28, 2016 Original Filing: 300804516.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Trans-Pacific Partnerships. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to Environmental Goods Agreement. H.R. 644, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 1891, To extend the African Growth and Opportunity Act, the Generalized System of Preferences, the preferential duty treatment program for Haiti, and for other purposes. H.R. 1907, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 2146, Defending Public Safety Employees' Retirement Act (Title 1 -Bipartisan Congressional Trade Priorities and Accountability Act of 2015). S. 998, American Manufacturing Competitiveness Act of 2015. S. 1015, Enforcing Orders and Reducing Customs Evasion Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 20, 2016. Original Filing: 300797862.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to Trans-Pacific Partnerships. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to Environmental Goods Agreement. H.R. 644, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 1891, To extend the African Growth and Opportunity Act, the Generalized System of Preferences, the preferential duty treatment program for Haiti, and for other purposes. H.R. 1907, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 2146, Defending Public Safety Employees' Retirement Act (Title 1 -Bipartisan Congressional Trade Priorities and Accountability Act of 2015). S. 998, American Manufacturing Competitiveness Act of 2015. S. 1015, Enforcing Orders and Reducing Customs Evasion Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 20, 2016. Original Filing: 300782682.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative issues and administrative action related to trade. Monitor legislative and administrative action related to trade promotion authority negotiations. Monitor legislative and administrative action related to Trans-Pacific Partnerships. Monitor legislative and administrative action related to Transatlantic Trade and Investment Partnership. Monitor legislative and administrative action related to Environmental Goods Agreement. H.R. 644, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 1890, Bipartisan Congressional Trade Priorities and Accountability Act of 2015. H.R. 1891, To extend the African Growth and Opportunity Act, the Generalized System of Preferences, the preferential duty treatment program for Haiti, and for other purposes. H.R. 1907, Trade Facilitation and Trade Enforcement Act of 2015. H.R. 2146, Defending Public Safety Employees' Retirement Act (Title 1 -Bipartisan Congressional Trade Priorities and Accountability Act of 2015). S. 995, Bipartisan Congressional Trade Priorities and Accountability Act of 2015. S. 998, American Manufacturing Competitiveness Act of 2015. S. 1009, AGOA Extension and Enhancement Act of 2015. S. 1015, Enforcing Orders and Reducing Customs Evasion Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q32015 on Oct. 21, 2015 Original Filing: 300766027.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 19, 2015. Original Filing: 300758396.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q22015 on Oct. 19, 2015 Original Filing: 300758097.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 20, 2015. Original Filing: 300745943.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 20, 2015. Original Filing: 300727100.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 20, 2015. Original Filing: 300705750.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. S. 809, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. S. 1256, Preventing Antibiotic Resistance Act of 2013. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 4432, Safe and Accurate Food Labeling Act of 2014. Provisions related to pollinator issues. H.R. 2692, Saving America's Pollinators Act of 2013. H.R. 5447, To amend the Federal Insecticide, Fungicide, and Rodenticide Act to increase the availability of pesticides for the management of parasitic pests that adversely impact the health of managed pollinator bees, and for other purposes.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action on appropriations and budget. Draft, House Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015. Draft, Senate Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015. Draft, House Energy and Water Development and Related Agencies Appropriations Act, 2015. Draft, Senate Energy and Water Development and Related Agencies Appropriations Act, 2015. Draft, House Interior and Environment Appropriations Act, 2015. Draft, Senate Interior and Environment Appropriations Act, 2015. Draft, House Departments of Labor, Health and Human Services and Related Agencies Appropriations Act, 2015. Draft, Senate Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015. Draft, House National Defense Authorization Act, 2015. Draft, Senate National Defense Authorization Act, 2015. Monitor the passage of FY2014 omnibus appropriations legislation (P.L. 113-76). H.R. 2217, Department of Homeland Security Appropriations Act, 2014. Funding for national biodefense and agriculture funding. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. S. 761, Energy Savings and Industrial Competitiveness Act of 2013. All measures related to energy efficiency. S. 1020, All-Of-The-Above Federal Building Energy Conservation Act of 2013. All measures pertaining to requirements to eliminate fossil fuels by 2030. S. 1392, Energy Savings and Industrial Competitiveness Act of 2013. S. 2074, Energy Savings and Industrial Competitiveness Act of 2014. S. 2262, Energy Savings and Industrial Competitiveness Act of 2014. All provisions pertaining to the Shaheen Portman Act (S. 761) regarding grants to federal facilities wishing to improve energy efficiency and to update the national model building standards. H.R. 1616, Energy Savings and Industrial Competitiveness Act of 2013. All provisions pertaining to the Shaheen Portman Act (S. 761) regarding grants to federal facilities wishing to improve energy efficiency and to update the national model building standards.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug user fees. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to drug safety and drug counterfeiting (track and trace). Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to federal preemption for prescription drugs. Monitor legislative and administrative action related to point-of-care instruments. Monitor legislative and administrative action related to streamlined pathways to market for breakthrough technologies. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor activities related to House Energy and Commerce Committees 21st Century Cures Initiative. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213. S. 1256, Preventing Antibiotic Resistance Act of 2013. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. H.R. 4771, Designer Anabolic Steroid Control Act of 2014. S. 2012, Designer Anabolic Steroid Control Act of 2014. Monitor the implementation of the Patient Protection and Affordable Care Act, P.L. 111-148. H.R. 1295, Medical Device Tax Elimination Act. S. 2917, Adding Ebola to the FDA Priority Review Voucher Program Act. H.R. 3969, Preventing Abuse of Cough Treatments Act of 2014 or the PACT Act. S. 644, Preventing Abuse of Cough Treatments Act of 2013 or the PACT Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Monitor enforcement of Medicares imaging equipment preventative maintenance policy. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to Medicare payment for diabetes testing strips, drug rebates for Medicare Part D, and the Independent Payment Advisory Board (IPAB). Monitor legislative and administrative action related to CMS Competitive Bidding. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 20, 2014. Original Filing: 300688502.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug user fees. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to drug safety and drug counterfeiting (track and trace). Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to federal preemption for prescription drugs. Monitor legislative and administrative action related to point-of-care instruments. Monitor legislative and administrative action related to streamlined pathways to market for breakthrough technologies. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor activities related to House Energy and Commerce Committees 21st Century Cures Initiative. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213. S. 959, Pharmaceutical Quality, Security, and Accountability Act. Provisions related to drug distribution. S. 1256, Preventing Antibiotic Resistance Act of 2013. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. H.R. 1528, Veterinary Medicine Mobility Act of 2014. H.R. 4771, Designer Anabolic Steroid Control Act of 2014. S. 2012, Designer Anabolic Steroid Control Act of 2014. Monitor the implementation of the Patient Protection and Affordable Care Act, P.L. 111-148. H.R. 1295, Medical Device Tax Elimination Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Monitor enforcement of Medicares imaging equipment preventative maintenance policy. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to Medicare payment for diabetes testing strips, drug rebates for Medicare Part D, and the Independent Payment Advisory Board (IPAB). Monitor legislative and administrative action related to CMS Competitive Bidding. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213.

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q22014 on Oct. 20, 2014 Original Filing: 300688470.xml

Lobbying Issues

Monitor legislative and administrative action related to pollinator health and habitat promotion. S. 954, Agriculture Reform, Food, and Jobs Act of 2013. Provisions related to National Pollutant Elimination System (NPDES) permits, Endangered Species, Winter Wheat Cereals Project and Pollinators. H.R. 2642, Federal Agriculture Reform and Risk Management Act 2013 (P.L. 113-79). H.R. 1947, Federal Agriculture Reform and Risk Management Act of 2013. Provisions related to National Pollutant Elimination System (NPDES) permits, Endangered Species, Winter Wheat Cereals Project and Pollinators. S. 809, Genetically Engineered Food Right-to-Know Act. Provisions related to labeling. S. 1256, Preventing Antibiotic Resistance Act of 2013. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 4432, Safe and Accurate Food Labeling Act of 2014. Provisions related to pollinator issues. H.R. 2692, Saving America's Pollinators Act of 2013.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug user fees. Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Issues of tranparency on the CMS preventative maintenance directive for medical equipment. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to drug safety and drug counterfeiting (track and trace). Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to federal preemption for prescription drugs. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213. S. 959, Pharmaceutical Quality, Security, and Accountability Act. Provisions related to drug distribution. S. 1256, Preventing Antibiotic Resistance Act of 2013. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. H.R. 1528, Veterinary Medicine Mobility Act of 2014. H.R. 4771, Designer Anabolic Steroid Control Act of 2014. S. 2012, Designer Anabolic Steroid Control Act of 2014. Monitor the implementation of the Patient Protection and Affordable Care Act, P.L. 111-148. H.R. 1295, Medical Device Tax Elimination Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Issues of tranparency on the CMS preventative maintenance directive for medical equipment. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to Medicare payment for diabetes testing strips, drug rebates for Medicare Part D, and the Independent Payment Advisory Board (IPAB). S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 21, 2014. Original Filing: 300669742.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug user fees. Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Issues of tranparency on the CMS preventative maintenance directive for medical equipment. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to drug safety and drug counterfeiting (track and trace). Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to federal preemption for prescription drugs. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213. S. 959, Pharmaceutical Quality, Security, and Accountability Act. Provisions related to drug distribution. S. 1256, Preventing Antibiotic Resistance Act of 2013. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. H.R. 1528, Veterinary Medicine Mobility Act of 2014. H.R. 4771, Designer Anabolic Steroid Control Act of 2014. S. 2012, Designer Anabolic Steroid Control Act of 2014. Monitor the implementation of the Patient Protection and Affordable Care Act, P.L. 111-148. H.R. 1295, Medical Device Tax Elimination Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Amendment

Bayer Corporation (consolidated report) amended a lobbying report for in-house lobbying in Q12014 on Oct. 20, 2014 Original Filing: 300688436.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. S. 761, Energy Savings and Industrial Competitiveness Act of 2013. All measures related to energy efficiency. S. 1020, All-Of-The-Above Federal Building Energy Conservation Act of 2013. All measures pertaining to requirements to eliminate fossil fuels by 2030. S. 1392, Energy Savings and Industrial Competitiveness Act of 2013. All provisions pertaining to the Shaheen Portman Act (S. 761) regarding grants to federal facilities wishing to improve energy efficiency and to update the national model building standards. H.R. 1616, Energy Savings and Industrial Competitiveness Act of 2013. All provisions pertaining to the Shaheen Portman Act (S. 761) regarding grants to federal facilities wishing to improve energy efficiency and to update the national model building standards.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug user fees. Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Issues of transparency on the CMS preventative maintenance directive for medical equipment. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to drug safety and drug counterfeiting (track and trace). Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. oMonitor legislative and administrative action related to federal preemption for prescription drugs. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213. S. 959, Pharmaceutical Quality, Security, and Accountability Act. Provisions related to drug distribution. S. 1256, Preventing Antibiotic Resistance Act of 2013. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. Monitor the implementation of the Patient Protection and Affordable Care Act, P.L. 111-148.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Issues of transparency on the CMS preventative maintenance directive for medical equipment. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to Medicare payment for diabetes testing strips, drug rebates for Medicare Part D, and the Independent Payment Advisory Board (IPAB). S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 21, 2014. Original Filing: 300648928.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to commercial building energy efficiency and building materials technology. S. 761, Energy Savings and Industrial Competitiveness Act of 2013. All measures related to energy efficiency. S. 1020, All-Of-The-Above Federal Building Energy Conservation Act of 2013. All measures pertaining to requirements to eliminate fossil fuels by 2030.S. 1392, Energy Savings and Industrial Competitiveness Act of 2013. All provisions pertaining to the Shaheen Portman Act (S. 761) regarding grants to federal facilities wishing to improve energy efficiency and to update the national model building standards. H.R. 1616, Energy Savings and Industrial Competitiveness Act of 2013. All provisions pertaining to the Shaheen Portman Act (S. 761) regarding grants to federal facilities wishing to improve energy efficiency and to update the national model building standards.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug user fees. Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Issues of tranparency on the CMS preventative maintenance directive for medical equipment.Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to drug safety and drug counterfeiting (track and trace). Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to federal preemption for prescription drugs. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213. S. 959, Pharmaceutical Quality, Security, and Accountability Act. Provisions related to drug distribution. S. 1256, Preventing Antibiotic Resistance Act of 2013. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. Monitor the implementation of the Patient Protection and Affordable Care Act, P.L. 111-148.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action related to sustainable growth rate and SGR repeal. Issues of tranparency on the CMS preventative maintenance directive for medical equipment. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment.Monitor legislative and administrative action related to Medicare payment for diabetes testing strips, drug rebates for Medicare Part D, and the Independent Payment Advisory Board (IPAB). S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. HR 3204, Drug Quality and Security Act. Provisions related to drug distribution. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor legislative and administrative action on appropriations and budget. Draft, House Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015. Draft, Senate Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015. Draft, House Energy and Water Development and Related Agencies Appropriations Act, 2015.Draft, Senate Energy and Water Development and Related Agencies Appropriations Act, 2015. Draft, House Interior and Environment Appropriations Act, 2015. Draft, Senate Interior and Environment Appropriations Act, 2015. Draft, House Departments of Labor, Health and Human Services and Related Agencies Appropriations Act, 2015. Draft, Senate Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015. Draft, House National Defense Authorization Act, 2015. Draft, Senate National Defense Authorization Act, 2015. Monitor the passage of FY2014 omnibus appropriations legislation (P.L. 113-76). H.R. 2217, Department of Homeland Security Appropriations Act, 2014. Funding for national biodefense and agriculture funding. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 21, 2014. Original Filing: 300625284.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 21, 2013. Original Filing: 300604843.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on July 22, 2013. Original Filing: 300582035.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Discussions related to passage of an omnibus MTB. U.S. Job Creation and Manufacturing Competitiveness Act of 2013 H.R. 6727 (112th Congress) sections related to MTBduty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent duty on Desmodur BL 1100/1 duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane , 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin). duty on D-Mannose. duty on propoxur (2-(1-methylethoxy)phenol methylcarbamate).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on April 22, 2013. Original Filing: 300564150.xml

Lobbying Issues

H.R. 1150 The Federal Food, Drug, Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases. title II. General provisions in the bill S.10 Agriculture Reform, Food, and Jobs Act of 2013 Provisions related to National Pollutant Elimination System (NPDES) permits, Endangered Species and Pollinators H.R.935 Reducing Regulatory Burdens Act of 2013 Provisions related to National Pollutant Elimination System (NPDES) permits S.175 A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides. Provisions related to National Pollutant Elimination System (NPDES) permits H.R.933 Consolidated and Further Continuing Appropriations Act, 2013 Provisions related to pesticide fees (PRIA) and agriculture appropriations H.R.8 American Taxpayer Relief Act of 2012 Provisions related to extension of the Farm Bill. Bee Health Discussions on EPA regulatory actions involving pollinator protection and bee health Biotech Labeling Discussions related to biotech labeling of food. Farm Bill Discussions related to pesticide registrations under the Endangered Species Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

U.S. Job Creation and Manufacturing Competitiveness Act of 2013 H.R. 6727 (112th Congress) sections related to MTBduty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on 1,6-Hexanediol-dimethyl carbonate copolymer duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent duty on Desmodur BL 1100/1 duty on Bayhydur BL 5335 duty on Desmodur VP LS 2078/2 duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked. duty on Bayhydur XP 2547 duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane , 2-ethyl-1-hexanol-blocked duty on Desmodur R-E duty on Desmodur E 14 duty on Poly(toluene diisocyanate) duty on Desmodur RF-E duty on Desmodur HL BA. duty on o-Acetylsalicylic acid (Aspirin). duty on D-Mannose. duty on propoxur (2-(1-methylethoxy)phenol methylcarbamate).

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Jan. 18, 2013. Original Filing: 300534810.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 5250/S 2763 To suspend temporarily the rate of duty on dimethyl carbonate polymer with 1,6 hexanediol copolymer and 2-oxepanone; (Provisions realted to the reduction of tariffs) HR 5251/S 2765 To supsend temporarily the rate of duty on 1,6 hexanediol-dimethyl carbonate copoloymer; (Provisions realted to the reduction of tariffs) HR5250/S 2767 To supsend temporarily the rate of duty on 1,6-Hexanediol-dimethyl carbonate copolymer; (Provisions related ot the reduction of tariffs.) HR 5253/S 2770/S 2778 To supsend temporarily the rate of duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent; (privisions related ot the reduction of tariffs.) HR 5236/S 2772 To supsend temporarily the duty on Desmodur BL 1100/1; (Provisions related to the reduction of tariffs). HR 5235/S 2773 To supsend temporarily the duty on on Bayhydur BL 5335; (Provisions related to the reduction of tariffs.) HR 5233/S 2775 To supsend temporarily the duty on Desmodur VP LS 2078/2; (Provisions related to the reduction of tariffs.) HR 5229/S 2779 To supsend temporarily the duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked (Provision related to the reduction of tariffs.) HR 5234/S 2781 To supsend temporarily the duty on Bayhydur XP 2547; (Provision related to the reduction of tariffs.) HR 5246/S 2783 To extend the temporary suspension of duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane , 2-ethyl-1-hexanol-blocked; (Provisions related to the reduction of tariffs.) HR 5247/S 2788 To extend and modify the temporary suspenion of dutry on Desmodur R-E; (Provisions related to the reduction of tariffs.) HR 5230/S 2784 To extend the temporary suspension of duty on Desmodur E 14; (Provision related to the reduction of tariffs.) HR 5248/S 2760 To extend and modify the temporary suspension of duty on Poly(toluene diisocyanate); (Provisions related to the reduction of tariffs.) HR 5249/S 2762 To extend and modify the temporary suspension of duty on Desmodur RF-E; (Provisions related to the reduction of tariffs.) HR 5231/S 2786 To extend and modify the temporary suspension of duty on Desmodur HL BA; (Provisions related to the reduction of tariffs.) HR 5276/S 2758 To extend and modify the temporary reduction of duty on o-Acetylsalicylci acid (Aspirin); (Provision related to the reduction of tariffs.) HR 5277/S 3028 To extend the temporary suspension of duty on D-Mannose; (Provisions related to the reduction of tariffs.) HR 5278/S 3026 To extend the temporary suspension of duty on propoxur (2-(1-methylethoxy)phenol methlcarbamate); (Provisions related to the reduction of tariffs.) S. 3292: Temporary Duty Suspension Process Act of 2012. Provisions related to tariffs (TAR) Senate H.R. 6727: United States Job Creation and Manufacturing Competitiveness Act of 2013. Provisions related to tariffs. House H.R.4459 and S. 2725: To suspend temporarily the duty on Thidiazuron. H.R.4460 and S. 3135 : To extend the suspension of duty on Fenamidone. H.R.4461 and S.2702 : To extend the suspension of duty on Spirodiclofen. H.R.4462 and S.3137 : To extend the suspension of duty on 2,4-dichloroaniline. H.R.4463 and S.2723: To suspend temporarily the duty on Thiacloprid. H.R.4464 and S. 2700: To extend the suspension of duty on Pyrimethanil. H.R.4465 : To suspend temporarily the duty on Pyrasulfotole. H.R.4466 and S.2704: To suspend temporarily the duty on Fosetyl-Al. H.R.4538 and S.3020 : To extend the temporary suspension of duty on Permethrin. H.R.4575 : To modify and extend the temporary reduction of duty on Isoxaflutole. H.R.4576 and S.3015 : To modify and extend the temporary reduction of duty on Clothianidin. H.R.4578 and S. 3016: To supsend temporarily the duty on Triadimefon. H.R.4657 : To suspend temporarily the duty on mixtures containing ?-cyfluthrin. H.R.4658 : To extend the temporary reduction of duty on Deltamethrin. H.R.4660 : To reduce temporarily the duty on Thiencarbazone-methyl. H.R.4661 and S.3017: To extend the temporary suspension of duty on Spiromesifen. H.R.4662 : To suspend temporarily the duty on Trifloxystrobin. H.R.4663 and S. 2703: To modify and extend the temporary reduction of duty on 2-Acetylbutyrolactone. H.R.4664 : To suspend temporarily the duty on 1,3-Cyclohexanedione. H.R.4665 and S. 3132: To suspend temporarily the duty on Flubendiamide. H.R.4666 and S.2722 : To suspend temporarily the duty on Spirotetramat. H.R.4667 : To extend the temporary suspension of duty on Isoxadifen-Ethyl. H.R.4668 and S. 3024: To extend the temporary suspension of duty on Cyfluthrin. H.R.4669 : To modify and extend the temporary reduction of duty on ?-cyfluthrin. H.R.4670 : To reduce temporarily the duty on mixtures contaning Trifloxystrobin and Prothioconazole. H.R.4671 : To suspend temporarily the rate of duty on certain mixtures containing Trifloxystrobin. H.R.4672 and S.2726 : To reduce temporarily the duty on mixtures containing Spirotetramat. H.R.4673 : To suspend temporarily the duty on mixtures containing Trifloxystrobin and Propiconazole. H.R.4675 and S. 2678: To reduce temporarily the duty on 1H-[1,2,4]Triazole. H.R.4676 and S. 3161 : To suspend temporarily the duty on mixtures of Indaziflam. H.R.4677 and S. 3162: To suspend temporarily the duty on mixtures of Flubendiamide. H.R.4678 and S. 2681: To suspend temporarily the duty on mixtures containing Fluopyram. H.R.4679 and S. 2719: To suspend temporarily the duty on mixtures containing Fluopyram and Prothioconazole. H.R.4680 and S.2720: To suspend temporarily the duty on mixtures containing Fluopyram and Trifloxystrobin. H.R.4681 and S.2721 : To suspend temporarily the duty on mixtures containing Fluopyram and Pyrimethanil. H.R.4682 and S. 3133: To suspend temporarily the duty on Fenhexamid. H.R.4683 and S.3134: To suspend temporarily the duty on Fluopicolide. H.R.4684 and S 3130: To suspend temporarily the duty on Fluopyram. H.R.4685 and S. 3131 : To suspend temporarily the duty on Indaziflam. H.R.4686 and S. 3021 : To extend the temporary suspension of duty on 4-Chlorobenzaldehyde. H.R.4687 and S.2701 : To extend the temporary suspension of duty on Phenmedipham. H.R.4694 and S.3160 : To reduce temporarily the duty on product mixtures containing Spiromesifen. H.R.4696 : To suspend temporarily the duty on product mixtures containing Clothianidin. H.R.4698 : To extend the suspension of duty on product mixtures containing ethofumesate. H.R.4699 : To suspend temporarily the duty on cyprosulfamide. H.R.4735 and S.2355 : To extend and modify the temporary reduction of duty on ACM. H.R.4736 and S.2356: To reduce temporarily the duty on Glufosinate-Ammonium (GA). H.R.4737 and S.2354 : To extend and modify the temporary reduction of duty on Oxadiazon. H.R.4876 and S. 3136: To extend the temporary reduction of duty on Imidacloprid. H.R.4878 and S. 2587 : To suspend temporarily the duty on 1-Naphthyl, N-methylcarbamate. H.R.4879 and S.2386 : To reduce temporarily the duty on Penflufen. H.R.4883 and S. 2385 : To suspend temporarily the duty on IMIDACLOPRID. H.R.4914 and S. 2680: To suspend temporarily the duty on mixtures containing Fluopyram and Tebuconazole. H.R.5592 and S. 3023 : To suspend temporarily the duty on mixtures containing beta-cyfluthrin. H.R.5591 and S. 3025 To modify and extend the temporary reduction of duty on beta-cyfluthrin. H.R.4695 and S. 3008 To reduce temporarily the duty on product mixtures containing Clothianidin and Bacillus Firmus strain I-1582.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.840 : Safe Exploration Coming from Underwater Reserves of Energy Act or the SECURE Act Expedites drilling for oil or natural gas, if already permitted by the Minerals Management Service before May 3, 2010. Eliminates need for review by the Bureau of Ocean Energy Management, Regulation and Enforcement; and the National Environmental Policy Act of 1969 or any other similar statutes such as the Federal Water Pollution Control Act or the Marine Mammal Protection Act of 1972. Provisions related to offshore drilling and exploration. S 352- American Energy Independence and Security Act of 2011. A bill to allow leases and exploration of oil and gas from the coastal plain. All provisions related to increased supply of natural gas. S.629 : A bill to improve hydropower, and for other purposes. All provisions related to the advancement of alternative energy S.630 : A bill to promote marine and hydrokinetic renewable energy research and development, and for other purposes. All provisions related to advancement of alternative energy S.631 : A bill to extend certain Federal benefits and income tax provisions to energy generated by hydropower resources. All provisions related to provision of incentives for alternative power. S398: A bill to increase energy efficiency and other purposes. The bill would reduce regulatory burden on appliance manufacturers, create energy and water savings and reduce the environmental impacts of energy production. All provisions related to enhancing energy efficiency. H.R.2962 : Roofing Efficiency Jobs Act of 2011-a bill to amend the Internal Revenue Code to classify any qualified energy-efficient cool roof replacement property as 20-year property for depreciation purposes. All provisions related to incentives to retrofit or build cool roofs. S.1575 : Energy-Efficient Cool Roof Jobs Act-a bill amend the Internal Revenue Code to classify any qualified energy-efficient cool roof replacement property as 20-year property for depreciation purposes. All provisions related to incentives in this bill S.1737 Sensible Accounting to Value Energy Act of 2011 (SAVE Act) a bill to improve the accuracy of mortgage underwriting. All provisions related to the creation of energy efficiency retrofit and construction jobs, and for other purposes. H.R.2599 : PACE Assessment Protection Act of 2011- a bill to prevent Fannie Mae, Freddie Mac, and other Federal residential and commercial mortgage lending regulators from adopting policies that go against State and local property clean energy laws. All provisions related to the bill. S. 3591, the Commercial Building Modernization Act (CBMA) introduced by Senators Snowe, Bingaman, Feinstein and Cardin. All provisions pertaining to extending and enhancing the tax reduction at Section 179D of the Internal Revenue Code for energy efficient commercial and multifamily buildings.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, Bayer Corporation (consolidated report) had in-house lobbyists. The report was filed on Oct. 22, 2012. Original Filing: 300519303.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S3552: Discussions on EPA regarding reauthorization of the Pesticide Registration Improvement Act H.R.872 and S. 3605: Reducing Regulatory Burdens Act of 2011. Provisions related to NPDES permits. S. 3240: Agriculture Reform, Food, and Jobs Act of 2012. Provisions related to NPDES permits. H.R. 965 Title: The Federal Food, Drug, Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases. title II. General provisions in the bill. S 1211 Companion bill to to HR 965 S 1053 Title: Veterinary Services Investment Act. General support of the bill. Farm bill - Discussion draft of House Farm bill. Provisions related to NPDES, PRIA, Pollinators. ESA - Discussions on biological opinions and impact on agriculture, and need for streamlined consultation process with National Marine Fisheries, and Fish and Wildlife Service. Spray Drift - Discussions on proposed EPA guidance for pesticide label language on preventing spray drift.

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 3292: Temporary Duty Suspension Process Act of 2012. Provisions related to tariffsHouse and Senate H.R.4459 and S. 2725: To suspend temporarily the duty on Thidiazuron. H.R.4460 and S. 3135 : To extend the suspension of duty on Fenamidone. H.R.4461 and S.2702 : To extend the suspension of duty on Spirodiclofen. H.R.4462 and S.3137 : To extend the suspension of duty on 2,4-dichloroaniline. H.R.4463 and S.2723: To suspend temporarily the duty on Thiacloprid. H.R.4464 and S. 2700: To extend the suspension of duty on Pyrimethanil. H.R.4465 : To suspend temporarily the duty on Pyrasulfotole. H.R.4466 and S.2704: To suspend temporarily the duty on Fosetyl-Al. H.R.4538 and S.3020 : To extend the temporary suspension of duty on Permethrin. H.R.4575 : To modify and extend the temporary reduction of duty on Isoxaflutole. H.R.4576 and S.3015 : To modify and extend the temporary reduction of duty on Clothianidin. H.R.4578 and S. 3016: To supsend temporarily the duty on Triadimefon. H.R.4657 : To suspend temporarily the duty on mixtures containing ?-cyfluthrin. H.R.4658 : To extend the temporary reduction of duty on Deltamethrin. H.R.4660 : To reduce temporarily the duty on Thiencarbazone-methyl. H.R.4661 and S.3017: To extend the temporary suspension of duty on Spiromesifen. H.R.4662 : To suspend temporarily the duty on Trifloxystrobin. H.R.4663 and S. 2703: To modify and extend the temporary reduction of duty on 2-Acetylbutyrolactone. H.R.4664 : To suspend temporarily the duty on 1,3-Cyclohexanedione. H.R.4665 and S. 3132: To suspend temporarily the duty on Flubendiamide. H.R.4666 and S.2722 : To suspend temporarily the duty on Spirotetramat. H.R.4667 : To extend the temporary suspension of duty on Isoxadifen-Ethyl. H.R.4668 and S. 3024: To extend the temporary suspension of duty on Cyfluthrin. H.R.4669 : To modify and extend the temporary reduction of duty on ?-cyfluthrin. H.R.4670 : To reduce temporarily the duty on mixtures contaning Trifloxystrobin and Prothioconazole. H.R.4671 : To suspend temporarily the rate of duty on certain mixtures containing Trifloxystrobin. H.R.4672 and S.2726 : To reduce temporarily the duty on mixtures containing Spirotetramat. H.R.4673 : To suspend temporarily the duty on mixtures containing Trifloxystrobin and Propiconazole. H.R.4675 and S. 2678: To reduce temporarily the duty on 1H-[1,2,4]Triazole. H.R.4676 and S. 3161 : To suspend temporarily the duty on mixtures of Indaziflam. H.R.4677 and S. 3162: To suspend temporarily the duty on mixtures of Flubendiamide. H.R.4678 and S. 2681: To suspend temporarily the duty on mixtures containing Fluopyram. H.R.4679 and S. 2719: To suspend temporarily the duty on mixtures containing Fluopyram and Prothioconazole. H.R.4680 and S.2720: To suspend temporarily the duty on mixtures containing Fluopyram and Trifloxystrobin. H.R.4681 and S.2721 : To suspend temporarily the duty on mixtures containing Fluopyram and Pyrimethanil. H.R.4682 and S. 3133: To suspend temporarily the duty on Fenhexamid. H.R.4683 and S.3134: To suspend temporarily the duty on Fluopicolide. H.R.4684 and S 3130: To suspend temporarily the duty on Fluopyram. H.R.4685 and S. 3131 : To suspend temporarily the duty on Indaziflam. H.R.4686 and S. 3021 : To extend the temporary suspension of duty on 4-Chlorobenzaldehyde. H.R.4687 and S.2701 : To extend the temporary suspension of duty on Phenmedipham. H.R.4694 and S.3160 : To reduce temporarily the duty on product mixtures containing Spiromesifen. H.R.4696 : To suspend temporarily the duty on product mixtures containing Clothianidin. H.R.4698 : To extend the suspension of duty on product mixtures containing ethofumesate. H.R.4699 : To suspend temporarily the duty on cyprosulfamide. H.R.4735 and S.2355 : To extend and modify the temporary reduction of duty on ACM. H.R.4736 and S.2356: To reduce temporarily the duty on Glufosinate-Ammonium (GA). H.R.4737 and S.2354 : To extend and modify the temporary reduction of duty on Oxadiazon. H.R.4876 and S. 3136: To extend the temporary reduction of duty on Imidacloprid. H.R.4878 and S. 2587 : To suspend temporarily the duty on 1-Naphthyl, N-methylcarbamate. H.R.4879 and S.2386 : To reduce temporarily the duty on Penflufen. H.R.4883 and S. 2385 : To suspend temporarily the duty on IMIDACLOPRID.H.R.4914 and S. 2680: To suspend temporarily the duty on mixtures containing Fluopyram and Tebuconazole. H.R.5592 and S. 3023 : To suspend temporarily the duty on mixtures containing beta-cyfluthrin. H.R.5591 and S. 3025: To modify and extend the temporary reduction of duty on beta-cyfluthrin. H.R.4695 and S. 3008: To reduce temporarily the duty on product mixtures containing Clothianidin and Bacillus Firmus strain I-1582. H.R.4874 and S. 2382: To suspend temporarily the duty on mixtures containing Thiencarbazone-methyl, Isoxaflutole, and Cyprosulfamide. H.R.4659: To suspend temporarily the duty on N-(4-Fluorophenyl)-2-hydroxy-N-(1-methylethyl)acetamide. H.R.4877: To reduce temporarily the duty on mixtures containing Imidacloprid and Cyfluthrin or its ?-Cyfluthrin isomer. H.R.5565 and S.2384: To reduce temporarily the duty on mixtures containing Imidacloprid and Cyfluthrin or its beta-Cyfluthrin isomer. H.R.4875 and S. 2383: To modify and extend the temporary reduction of duty on mixtures of imidacloprid with application adjuvants. H.R.4873 and S.2381: To suspend temporarily the duty on mixtures containing Imidacloprid and Thiodicarb. H.R.4577: To extend and modify the temporary reduction of duty on mixtures containing Isoxaflutole and Cyprosulfamide. H.R.5257 and S.3009: To extend the temporary suspension of duty on product mixtures containing mesosulfuron-methyl. H.R.4537 and S. 3019: To suspend temporarily the duty on Methyl 2-[(4-methyl-5-oxo-3-propoxy-4,5-dihydro-[1,2,4]triazole-1-c arbonyl)sulfamoyl]benzoate, sodium salt. H.R.4536 and S.3018: To extend the temporary suspension of duty on 2-Chlorobenzyl chloride. H.R.5258 and S.3022: To suspend temporarily the rate of duty on certain mixtures containing Fenoxaprop-p-ethyl, Pyrasulfotole, Bromoxynil octanoate, Bromoxynil heptanoate, and Mefenpyr-diethyl. H.R.4697: To reduce temporarily the duty on product mixtures containing Pyrasulfotole, Bromoxynil Octanoate, and Bromoxynil Heptanoate, including application adjuvants. H.R.4574: To modify and extend the temporary reduction of duty on AE 0172747 Ether. H.R.4579: To suspend temporarily the duty on mixtures containing Thiencarbazone-methyl, Isoxadifen-ethyl, and Tembotrione. H.R.4580: To suspend temporarily the duty on mixtures containing Trifloxystrobin, Clothianidin, Carboxin, and Metalaxyl.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, BAYER CORPORATION had in-house lobbyists. The report was filed on July 20, 2012. Original Filing: 300497736.xml

Lobbying Issues

HR 872 Reducing Regulatory Burdens Act of 2011; (Provisions related to NPDES permits.) S 3240 Agriculture Reform, Food and Jobs Act of 2012; (Provisions related to NPDES permits; provisions relating to pesticides, biotechnology, agriculture research and conservation.) S 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013; (Allprovisions related to funding of USDA agencies including APHIS and FAS.) Regulatory Biotech Issues (no bill numbers); (Provisions in proposed regulations regarding the approval of biotech traits and all other issues related to biotech regulations.) ESA (no bill); (NMFS Biological opinions -- Discussions on National Marine Fisheries Biological Opinions and their potential affects on agriculture and the need for a resolution to the consultation process.) Spray Drift (no bill number);Discussions on proposed EPA guidance for pesticide label language on preventing spray drift.) PRIA (no bill number); (Discussions on EPA regarding reauthorization of the Pesticide Registration Improvement Act (PRIA).) Farm Bill (no bill number); Discussion draft of House Farm bill; (Provisions related to NPDES, PRIA, Pollinators.) Bee Health (no bill number); (Discussions on EPA regulatory actions involving pollinator protection and bee health.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 480 Safe Exploration coming from Underwater Reserves of Energy Act, or the SECURE Act: Expedites drilling for oil or natural gas, if already permitted by the Minerals Management Service before May 3, 2010; Eliminates need for review by the Bureau of Ocean Energy Management, Regulation and Enforcement; and the National Environmental Policy Act of 1969 or any other similar statues such as the Federal Water Pollution Control Act or the Marine Mammal Protection Act of 1972; (All provisionsrelated to off-shore drilling and exploration.) S 352 American Energy Independence and Security Act of 2011: A bill to allow leases and exploration of oil and gas from the coastal plain; (All provisions related to increased supply of natural gas.) S 629 A bill to improve hydropower, and for other purposes; (All provisions related to the advancement of alternative energy.) S 630 A bill to promote marine and hydrokinetic renewable energy research and development, and for other purposes; (All provisions related to advancement of alternative energy.) S 631 A bill to extend certain Federal benefits and income tax provisions to energy generated by hydropower resources; (All provisions related to provision of incentives for alternative power.) S 398 A bill to increase energy efficiency and other purposes: The bill would reduce regulatory burden on appliance manufacturers, create energy and water savings and reduce the environmental impacts of energy production; (All provisions related to enhancing energy efficiency.) HR 2962/S 1575 Roofing Efficiency Jobs Act of 2011: A bill to amend the Internal Revenue Code to classify any qualified energy-efficient cool roof replacement property as 20-year property for depreciation purposes. Defines "qualified energy-efficient cool roof replacement property" as any roof system that: (1) is placed in service above conditioned or semi-heated space on an eligible commercial building, (2) replaces an existing roof system, (3) is a low-slope roof, and (4) includes insulation meeting specified standards and a primary roof covering that has a cool roof surface; (All provisions related to the bill.) S 1737 Sensible Accounting to Value Energy Act of 2011: A bill to improve the accuracy of mortgage underwriting used by mortgage agencies by ensuring that energy costs are included in the underwriting process, to reduce the amount of energy consumed by homes, to facilitate the creation of energy efficiency retro-fit and construction jobs, and for other purposes; (All provisions of the bill.) HR 2599 PACE Assessment Protection Act of 2011: A bill to prevent Fannie Mae, Freddie Mac, and other federal residential and commercial mortgage lending regulators from adopting policies that contravene established state and local property assessed clean energy laws; (All provisions of the bill.) S 398 Energy Efficiency National Consensus Appliance Agreement Act; (Provisions related to energy tax credits.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 432/ S136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) HR 4223 The "Safe Doses Act"; (All provisions of the bill.)HR 3668 The "Counterfeit Drug Penalty Enhancement Act of 2011"; (All parts.) HR 4216 The "Foreign Counterfeit Prevention Act"; (All parts.) Draft Discussion of FDA User Fees; (All parts) S 365 Balanced Budget Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.) Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.) HR 2245 the Preserving Access to Life Saving Medications Act; (Provisions relating drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11.) HR 965/S 1211 The Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions of the bill.) HR 436 Health Care Cost Reduction Act of 2012; (Provisions related to medical device taxes.) Safe Injection Practices (no bill number); (Provisions related to safer injection practices.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 4223 The "Safe Doses Act"; (All parts.) HR 3668 The "Counterfeit Drug Penalty Enhancement Act of 2011"; (All provisions.) HR 4216 The "Foreign Counterfeit Prevention Act"; (All provisions.) Draft Discussion on FDA User Fees; (All provisions.)Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic report and stop sale.) HR 2245 The Preserving Access to Life Saving Medications Act; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11.) Meth Lab Elimination Act of 2010, a draft by Senator Wyden; (All parts relating to pseudoephedrine.) Maintaining Consumer Access to Cough Medicine Act of 2011, a draft; (All parts relating to DXM.) HR 525 Veterinary Public Health Amendments Act: An act to amend the Public Health Service Act to enhance and increase the number of veterinarians trained in veterinary public health.) HR 1406 Fairness to Pet Owners Act 2011; (General provisions requiring veterinary prescribing.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 5250/S 2763 To suspend temporarily the rate of duty on dimethyl carbonate polymer with 1,6-hexanediol copolymer and 2-oxepanone; (Provisions related to the reduction of tariffs) HR 5251/S 2765 To suspend temporarily the rate of duty on 1,6-Hexanediol-dimethyl carbonate copolymer; (Provisions related to the reduction of tariffs.)HR 5250/S 2767 To suspend temporarily the rate of duty on 1,6-Hexanediol-dimethyl carbonate copolymer; (Provisions related to the reduction of tariffs.) HR 5253/S 2770/S 2778 To suspend temporarily the duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent; (Provisions related to the reduction of tariffs.) HR 5236/S 2772 To suspend temporarily the duty on Desmodur BL 1100/1; (Provisions related to the reduction of tariffs.) HR 5235/S 2773 To suspend temporarily the duty on Bayhydur BL 5335; (Provisions related to the reduction of tarrifs.) HR 5233/S 2775 To suspend temporarily the duty on Desmodur VP LS 2078/2; (Provisions related to the reduction of tariffs.) HR 5229/S 2779 To suspend temporarily the duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked (Provisions related to the redution of tariffs.) HR 5234/S 2781 To suspend temporarily the duty on Bayhydur XP 2547; (Provisions related to the reduction of tariffs.) HR 5246/S 2783 To extend the temporary suspension of duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane , 2-ethyl-1-hexanol-blocked; (Provisions related to the reduction of tariffs.) HR 5247/S 2788 To extend and modify the temporary suspension of duty on Desmodur R-E; (Provisions related to the reduction of tariffs.) HR 5230/2784 To extend the temporary suspension of duty on Desmodur E 14; (Provisions related to the reduction of tariffs.) HR 5248S 2760 To extend and modify the temporary suspension of duty on Poly(toluene diisocyanate); (Provisions related to the reduction of tariffs.) HR 5249/S 2762 To extend and modify the temporary suspension of duty on Desmodur RF-E; (Provisions related to the reduction of tariffs.) HR 5231/S 2786 To extend and modify the temporary suspension of duty on Desmodur HL BA; (Provisions related to the reduction of tariffs.) HR 5276/S 2758 To extend and modify the temporary reduction of duty on o-Acetylsalicylic acid (Aspirin); (Provisions related to the reduction of tariffs.) HR 5277/S 3028 To extend the temporary suspension of duty on D-Mannose; (Provisions related to the reduction of tariffs.) HR 5278/S 3026 To extend the temporary suspension of duty on propoxur (2-(1-methylethoxy)phenol methylcarbamate); (Provisions related to the reduction of tariffs.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, BAYER CORPORATION had in-house lobbyists. The report was filed on April 20, 2012. Original Filing: 300473644.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S 398 Energy Efficiency National Consensus Appliance Agreement Act; (Provisions related to energy tax credits; provisions related to enhancing energy efficiency.) S 629 A bill to improve hydro-power, and for other purposes; (All provisions related to the advancement of alternative energy.) S 630 A bill to promote marine and hydro-kinetic renewable energy research and development, and for other purposes; (All provisions related to advancement of alternative energy.) S 631 A bill to extend certain federal benefits and income tax provisions to energy generated by hydro-power resources; (All provisions related to provision of incentives for alternative power.) HR 2962/S 1575 Roofing Efficiency Jobs Act of 2011: A bill to amend the Internal Revenue Code to classify any qualified energy efficient cool roof replacement property as 20-year property for depreciation purposes; (All provisions related to the bill.) S 1737 Sensible Accounting to Value Energy Act of 2011 (SAVE Act): A bill to improve the accuracy of mortgage underwriting used by federal mortgage agencies by ensuring that energy costs are included in the underwriting process, to reduce the amount of energy consumed by homes, to facilitate the creation of energy efficiency retrofit and construction jobs, and for other purposes; (All provisions of the bill.) HR 2599 FACE Assessment Protection Act of 2011: A bill to prevent Fannie Mae, Freddie Mac, and other Federal residential and commercial mortgage lending regulators from adopting policies that contravene established state and local property assessed clean energy laws; (All provisions of the bill.) HR 840 Safe Exploration coming from Underwater Reserves of Energy Act or the SECURE Act: Expedites drilling for oil or natural gas, if already permitted by the Minerals Management Service before May 3, 2010. eliminated need for review by the bureau of Ocean Energy Management, Regulation and Enforcement; and the National Environmental Policy Act of 1969 or any other similar statutes such as the Federal Water Pollution Control Act or the Marine Mammal Protection Act of 1972; (All provisions related to off-shore drilling and exploration.) S 352 American Energy Independence and Security Act of 2011: A bill to allow leases and exploration of oil and gas from the coastal plain; (All provisions related to increased supply of natural gas.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 965/S 1211 The Federal Food, Drug and Cosmetic Act to preserve the effectiveness of medially important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions of the bill.) HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-Acontaining products.) HR 436/HR 488/HR 734/S 17/S 262 Medical Device Tax Repeal; (Provisions related to entire bill.) HR 4/HR 60/HR 144/HR 584/HR 705/S 18/S 72 The Small Business Paperwork Mandate Elimination Act of 2011; (Provisions related to the 1099 repeal.) HR 141/HR 145/HR 215/HR 429/HR 636/S 16/S 193 To repeal the Patient Protection and Affordable Care Act and the health Care and Education Reconciliation Act of 2010; (Provisions related to Health Care Reform repeal.) HR 3209 HR 3204/S 1700/PL 107-250 Medical Device User Fee and Modernization Act (MDUFMA); (Provisions related to MDUFMA.) HR 4223 The Safe Doses Act; (All provisions of the bill.) HR 3668 The Counterfeit Drug Penalty Enhancement Act of 2011; (All provisions of the bill.) HR 4216 The Foreign Counterfeit Prevention Act; (All provisions of the bill.) Draft Discussion on FDA User Fees; (All parts.) S 365 Balanced Budget Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.) Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.) HR 2245 The Preserving Access to Life Saving Medications Act; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 908 Full Implementation of the Chemical Facilities Anti-Terrorism Act (CFATS); (All provisions of the bill related to the reauthorization of CFATS through 2017.) HR 901 Full Implementation of the "Chemical Facility Anti-Terrorism Security (CFATS) Authorization Act of 2011"; (All provisions related to implementation of the CFATS program.)S 473 Continuing Chemical facilities Anti-Terrorism Security Act of 2011: A bill to extend the Chemical facilities Anti-Terrorism Standards (CFATS) until October 14, 2014; (All provisions related to implementation of CFATS.) S 709 Secure Chemical Facilities Act: A bill to insure adequate security is employed at chemical plants; (All provisions related to chemical risk management, tiered assessments, audits, standard setting and inspections.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 4223 The Safe Doses Act; (All provisions of the bill.) HR 3668 The Counterfeit Drug Penalty Enhancement Act of 2011; (All provisions of the bill.) HR 4216 The Foreign Counterfeit Prevention Act; (All provisions of the bill.) Draft Discussion on FDA User Fees; (All parts.)Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.) HR 2245 The Preserving Access to Life Saving Medications Act; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11.) "Meth Lab Elimination Act of 2010" a draft by Senator Wyden; (All parts relating to pseudoephedrine.) "Maintaining Consumer Access to Cough Medicine Act of 2011", a draft; (All part relating to DXM.) HR 1406 Fairness to Pet Owners Act 2011; (General provisions requiring Veterinary prescribing.) HR 525 Veterinary Public Health Amendments Act: An act to amend the Public Health Service Act to enhance and increase the number of veterinarians trained in veterinary public health; (General provisions of the bill.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, BAYER CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2012. Original Filing: 300450771.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 480 Safe Exploration Coming from Underwater Reserves of Energy Act of the SECURE Act: Expedites drilling for oil or natural gas, if already permitted by the Minerals Management Service before May 3, 2010. Eliminates need for review by the Bureau of Ocean Energy Management, Regulation and Enforcement; and the National Environment Policy Act of 1969 or any other similar statutes such as the Federal Water Pollution Control Act or the Marine Mammal Protection Act of 1972; (All provisions related to off-shore drilling and exploration.) S 352 American Energy Independence and Security act of 2011; A bill to allow leases and exploration of oil and gas from the coastal plain; (All provisions related to increased supply of natural gas.) S 629 A bill to improve hydropower, and for other purposes; (All provisions related to the advancement of alternative energy.) S 630 A bill to promote marine and hydrokinetic renewable energy research and development, and for other purposes; (All provisions related to advancement of alternative energy.) S 631 A bill to extend certain Federal benefits and income tax provisions to energy generated by hydropower resources; (All provisions related to provision of incentives for alternative power.) S 398 A bill to increase energy efficiency and other purposes: The bill would reduce regulatory burden on appliance manufacturers, create energy and water savings and reduce the environmental impacts of energy production; (All provisions related to enhancing energy efficiency.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 965/S 1211 The Federal Food, Drug and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions in the bill.) S 365 Balanced Budget Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.) Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.)HR 2245 The Preserving Access to Life Saving Medications Act; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11) HR 436/HR 488/HR 734/S 17/S 262 Medical Device Tax Repeal; (Provisions related to entire bill.) HR 4/HR 60/HR 144/HR 584/HR 705/S 18/S 72 The Small Business Paperwork Mandate Elimination Act of 2011; (Provisions related to the 1099 repeal.) HR 141/HR 145/HR 215/HR 429/HR 636/S 16/S 193 To repeal the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010; (Provisions related to Health Care Reform repeal.) PL 107-250 The Medical Device User Fee and Modernization Act; (Provisions related to MDUFMA.) HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic report and stop sale.) HR 2245 The Preserving Access to Life Saving Medications Act; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11) "Meth Lab Elimination Act of 2010", a draft by Senator Wyden; (All parts relating to pseudoephedrine.)"Maintaining Consumer Access to Cough Medicine Act of 2011", a draft; (All parts relating to DXM.) HR 525 Veterinary Public Health Amendments Act: An act to amend the Public Health service Act to enhance and increase the number of veterinarians trained in veterinary public health; (General provisions of the bill.) HR 1406 Fairness to Pet Owners Act 2011; (General provisions requiring veterinary prescribing.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 908 Full Implementation of the Chemical facilities Anti-terrorism Act (CFATS); (All provisions of the bill related to the reauthorization of CFATS through 2017.) HR 901 Full Implementation of the "Chemical Facility Anti-Terrorism Security (CFATS) Authorization Act of 2011"; (All provisions related to implementation of the CFATS program.)S 473 Continuing Chemical Facilities Anti-Terrorism Security Act of 2011: A bill to extend the Chemical Facilities Anti-Terrorism Standards (CFATS) until October 14, 2014; (All provisions related to implementation of CFATS.) S 709 Secure Chemical Facilities Act: A bill to insure adequate security is employed at chemical plants; (All provisions related to chemical risk management, tiered assessments, audits, standard setting and inspections.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, BAYER CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2011. Original Filing: 300428079.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 2112 Agriculture, Rural Development, Food and drug Administration, and Related Agencies Appropriations Act, 2012; (Provisions related to agriculture research and USDA funding and any provisions that could affect biotech regulations; Provisions related to agriculture and farm bill programs.) HR 2584 Department of the Interior, Environment, and Related Agencies Appropriations Act, 2012; (Provisions related to fundingfor agriculture, EPA, NPDES Permits and pesticide fees.) HR 2017 Homeland Security Appropriations for FY 2012; (Provisions related to extension of the CFATS program.) HR 2584 Appropriations Department of the Interior, Environment, and Related Agencies Appropriations Act 2012; (Provisions related to funding for agriculture, EPA, NPDES Permits and pesticide fees.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 840 Safe Exploration coming from Underwater Reserves of Energy Act of the SECURE Act: Expedites drilling for oil or natural gas, if already permitted by the Minerals Management Service before May 3, 2010. Eliminates need for review the Bureau of Ocean Energy Management, Regulations and Enforcement; and the National Environmental Policy Act of 1969 or any other similar statues such as the Federal Water Pollution Control Act or the Marine Mammal Protection Act of 1972; (All provisions related to off-shore drilling and exploration.) S 352 American Energy Independence and Security Act of 2011: A bill to allow leases and exploration of oil and gas from the coastal plain; (All provisions related to increased supply of natural gas.) S 1000 Energy Savings and Industrial Competitiveness Act of 2011: A bill to enact a national energy efficiency strategy; (All provisions related to energy efficiency.) S 937 American Alternative Fuels Act of 2011: A bill to ease pain at the pump and encourage alternative fuels; (all provisions pertaining to energy efficiency.) S 963 Reducing Federal Energy Dollars Act of 2011: A bill to reduce energy costs, improve energy efficiency, and expand the use of renewable energy by Federal agencies, and for other purposes; (All provisions pertaining to energy efficiency.) S 629 A bill to improve hydropower, and for other purposes; (All provisions related to the advancement of alternative energy.) S 398 A bill to increase energy efficiency and other purposes: The bill would reduce regulatory burden on appliance manufacturers, create energy and water savings and reduce the environmental impacts of energy production; (All provisions related to enhancing energy efficiency.) S. 630 A bill to promote marine and hydrokinetic renewable energy research and development, and for other purposes; (All provisions related to advancement of alternative energy.) S 631 A bill to extend certain Federal benefits and income tax provisions to energy generated by hydropower resources; (All provisions related to provision of incentives for alternative power.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 436/HR 488/HR 734/S 17/S 262 Medical Device Tax Repeal; (Provisions related to entire bill.) HR 4/HR 60/HR 144/HR 584/HR 705/S 18/S 72 The Small Business Paperwork Mandate Elimination Act of 2011; (Provisions related to the 1099 repeal.) S 365 Balanced budge Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.)Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.) HR 2245 The Preserving Access to Life Saving Medications Act of 2011; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11) Labor, HHS, and Education Appropriations Bill draft; (sections relating to efforts to defund PPACA.) HR141/HR 145/HR 215/HR 429, HR 636/S 16/S 193 To repeal the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010; (Provisions related to Health Care Reform repeal.) HR 965/S 1211 The Federal food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases.) HR 432/S 136 ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, BAYER CORPORATION had in-house lobbyists. The report was filed on July 20, 2011. Original Filing: 300404351.xml

Lobbying Issues

HR 872 Reducing Regulatory Burdens Act of 2011; (Provisions related to NPDES permits.) ESA Issues; (Discussions on biological opinions and impact on agriculture, need for streamlined consultation process with National Marine Fisheries, and Fish and Wildlife Service, and the need for a resolution to the consultation process.) Bee Health; (Discussions on EPA regulatory actions involving pollinator protection and bee health.)PRIA (no bill numbers); (Discussions on EPA regarding reauthorization of the Pesticide Registration Improvement Act.) HR 1249/S 23 America Invents Act; (Provisions related to false markings and other provisions that could affect agriculture.) HR 2112 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012; (Provisions related to agriculture research and USDA funding and any provisions that could affect biotech regulations.) Regulatory Biotech Issues (no bill numbers); (Provisions in proposed regulations regarding the approval of biotech traits and all other issues related to biotech regulations, including APHIS part 340 regs.) Spray Drift (no bill numbers); (Discussions on proposed EPA guidance for pesticide label language on preventing spray drift.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 840 Safe Exploration Coming from Underwater Reserves of Energy Act; (All provisions related to off-shore drilling and exploration.) S 352 American Energy Independence and Security Act of 2011; A bill to allow leases and exploration of oil and gas from the coastal plain; (All provisions related to increased supply of natural gas.)S 629 A bill to improve hydropower, and for other purposes; (All provisions related to the advancement of alternative energy.) S 630 A bill to promote marine and hydrokinetic renewable energy research and development, and for other purposes; (All provisions related to advancement of alternative energy.) S 631 A bill to extend certain Federal benefits and income tax provisions to energy generated by hydropower resources; (All provisions related to provision of incentives for alternative power.) S 398 A bill to increase energy efficiency and other purposes: The bill would reduce regulatory burden on appliance manufacturers, create energy and water savings and reduce the environmental impacts of energy production; (All provisions related to enhancing energy efficiency.) S 1000 Energy Savings and Industrial Competitiveness Act of 2011; (Provisions related to energy.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) HR 452 Medicare Decisions Accountability Act of 2011; (Provisions relating to entire bill.)South Korean Free Trade Agreement; (Sections pertaining to offsets, including imaging utilization rates.) HR 436/ HR 488/HR 734/S 17/S 262 Medical Device Tax Repeal; (Provisions related to entire bill.) HR 4/HR 60/HR 144/HR 705/HR 584/S 18/S 72 The Small Business Paperwork Mandate Elimination Act of 2011; (Provisions related to the 1099 repeal.) HR 141/HR 145/HR 215/HR 429/HR 636/S 16/S 193 To repeal the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010; (Provisions related to Health Care Reform repeal.) PL 107-250 The Medical Device User Fee and Modernization Act (MDUFMA); (provisions related to MDUFMA.) HR 965/S 1211 The Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions in the bill.) HR 605 Patients' Freedom to Choose Act; (General provisions in the bill.) Medicare Part D (no bill number); (Provisions related to Medicare Part D)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, BAYER CORPORATION had in-house lobbyists. The report was filed on April 20, 2011. Original Filing: 300377930.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S 4 Make America the World's Leader in Clean Energy Act, a bill to expand incentives for clean energy; (All provisions related to advancement of clean energy solutions.) HR 840 Safe Exploration Coming from Underwater Reserves of Energy Act, a bill to allow drilling off-shore under the authority of Minerals and Mine leases issued previously; (All provisions related to off-shore drilling and exploration.)S 352 American Energy Independence and Security Act of 2011, a bill to allow leases and exploration of oil and gas from the coastal plain; (All provisions related to increased supply of natural gas.) S 629 A bill to improve hydropower, and for other purposes; (All provisions related to the advancement of alternative energy.) S 630 A bill to promote marine and hydrokinetic renewable energy research and development, and for other purposes; (All provisions related to advancement of alternative energy.) S 631 A bill to extend certain Federal benefits and income tax provisions to energy generated by hydropower resources; (All provisions related to provisions of incentives for alternative power.) HR 910 Energy Tax Prevention Act of 2011; (Provisions relating to corporate extension process.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 432/S 136 Ban Poisonous Addiditives Act of 2011, a bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) HR 965 The Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (title II. General provision in the bill.) S 17/S 262/ HR 436/HR 488/HR 734 Medical Device Access and Innovation Protection Act; (Provisions related to the medical device tax repeal.) S 18/S 72/HR 4/HR 60/HR 144/HR 584/HR 705 Small Business Paperwork Mandate Elimination Act of 2011; (Provisions related to the 1099 repeal.) S 16/S 193/HR 141/HR 145/HR 429/HR 636 Patient Choice Restoration Act; (Provisions related to healthcare reform repeal.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, BAYER CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2011. Original Filing: 300352599.xml

Lobbying Issues

HR 2868/S 2996 To amend the Homeland Security Act of 2002 to extend, modify, and recodify the authority of the Secretary of Homeland Security to enhance security and protect against acts of terrorism against chemical facilities, and for other purposes; (Provisions related to issues that could affect farmers and those relating to extending CFATS regulations, IST provisions and citizen enforcement provisions.)S 787 A bill to amend the Federal Water Pollution Control Act to clarify the jurisdiction of the United States over waters of the United States; (Provisions related to agriculture activites and the section changing the definition of U.S. Waters.) HR 5504/S 3307 Healthy, Hunger-Free Kids Act of 2010; (Provisions related to organic food.) S 3606 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2011; (All provisions related to APHIS and BRS funding.) HR 6273 To amend the Federal Insecticide, Fungicide, and Rodenticide Act to exempt the application of pesticides subject to that Act, when applied in conformance with that Act, from certain permit requirements under the Federal Water Pollution Control Act, and for other purposes; (Provisions related to NPDES permits for agriculture.) S 3735 A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides; (Provisions related to NPDES permits for agriculture.) HR 6087 To amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides; (Provisons related to NPDES permits for agriculture.) EPA/Environment Appropriations (no bill number): Seeking funding for the FY2011 appropriations; (All provisions related to agriculture, EPA and pesticide fees.) Regulatory Biotech Issues (No bill numbers); (Provisions in proposed regulations regarding the approval of biotect traits and all other issues related to biotect regulations, including APHIS part 340 regs.) ESA Issues (No bill number) NMFS Biological opinions; (Discussions on National Marine Fisheries Biological Opinions that were recently released and their potential affects on agriculture.) EPA Regulations (No bill number): Guidance on spray drift; (Provisions in the guidance related to "may cause harm" and changes to FIFRA.) PRIA -- pesticide fees; (Provisions regarding reauthorization.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S 787 A bill to amend the Federal Water Pollution Control Act to clarify the jurisdiction of the United States over waters of the United States; (Provisions related to agriculture activities and the section changing the definition of U.S. Waters.) HR 6273 To amend the Federal Insecticide, Fungicide, and Rodenticide Act to exempt the application of pesticides subject to that Act, when applied in conformance with that Act, from certain permit requirements under the Federal Water Pollution Control Act, and for other purposes; (Provisions related to NPDES permits for agriculture.) S 3735 A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides; (Provisions related to NPDES permits for agriculture.) HR 6087 To amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides; (Provisions related to NPDES permits for agriculture.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S 1462 American Clean Energy Leadership Act of 2009: A bill to promote clean energy technology development; (All provisions related to enhanced energy efficiency and clean energy development.) HR 2454 The American Clean Energy and Security Act: A bill to set up a Cap and Trade system for greenhouse gas emission and to provide enhancements to programs and initiatives designed to foster green jobs, clean energy, wind, solar, geothermal and other renewables; (All provisions pertaining to enhancements to energy efficiency programs.) HR 1749 Energy Efficient Manufacturing Housing Act 2009: a bill to provide rebates and grants to the states to implement a retrofit program for houses built before 1976; (All provisions related to Energy Star rebates and credits.) HR 5476 Building Star Energy Efficiency Act of 2010: A bill to provide incentives for building owners to receive credits and rebates for using energy efficient materials and green technology in constructing commercial buildings; (All provisions related to enhancing energy efficient commercial development and retrofit.) S 3079 Building Star Energy Efficiency Act of 2010: A bill to provide incentives for building owners to receive credits and rebates for using energy efficient materials and green technology in constructing commercial buildings; (All provisions related to enhancing energy efficient commercial develpment and retrofit.) HR 5019 Home Star Energy Retrofit Act of 2009: A bill to provide rebates for energy efficient retrofits of residential housing; (All provisions related to improving energy efficiency.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 1523/S 593 Ban Poisonous Additives Act of 2009: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act: A ban on food contact materials for children and infants (3 years and under); (All provisionsand amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A Consumer Information Act of 2009: A bill to amend the Food Drug and Cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part, or Bisphenol-A or could release Bisphenol-A into the food; (All provisions relating to the scicne, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009: A reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) S 510 Food Safety Modernization Act: A bill to modernize the Food and Drug Administration's regulation of food safety; (All provisions related to adding an amendment on Bisphenol-A.) HR 2789 Food Safety Enhancement Act 2009: A bill to amend various provisions of the act to make the food supply safer; (All provisions related to Bisphenol-A in food contact applications.) HR 1332 Safe FEAST Act of 2009: A bill to to empower the Food and Drug Administration to more thoroughtly protect the food supply. (Provisions relating to BPA)

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 1549/S 619 To amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions in the bill.) HR 2749 Food Safety Enhancement Act of 2009 to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food in the global market, and for other purposes; (Title 1 Food Safety. Monitoring food safety provisions.)S 510 FDA food Safety Modernization Act: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the safety of the food supply; (Monitoring provisions of the bill; All sections.) HR 2400 Strategies to address antimicrobial resistance; (Section 3 (c) relating to authorities over antimicrobial drug data collection.) HR 3519/S 1709 Veterinary Services Investment Act; (Support legislation.) HR 4341 Bisphenol-A Consumer Information Act 2009: A bill to amend the Food Drug and Cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol-A into the food; (All provisions relating to the science, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009: A reform of the law on food safety protection; (all provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) S 753 the Children's Safe Chemical Act: A ban on food contact materials for children and infants (3 years and under); (All provisions and amendments pertaining to the ban and the testing are relevant.) HR 1523/S 593 The Ban Poisonous Additives Act of 2009: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) HR 4994 Medicare and Medicaid Extenders Act of 2010; (Sections pertaining to competitive bidding of DME.) S 3653 Health Care Bureaucrats Elimination Act; (Sections pertaining to the IPAB.) HR 2751 FDA Food Safety Modernization Act; (Sections pertaining to inspections.) HR 3590 Patient Protections and Affordable Care Act; (All provisions relating to healthcare) HR 4872 The Healthcare and Education Reconciliation Act of 2010; (Provisions relating to healthcare.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S 146 Railroad Anti-Trust Enforcement Act: A bill to amend the Federal antitrust laws to provide expanded coverage and to eliminate exemptions from such laws that are contrary to the public interest with respect to railroads; (All provisions pertaining to the "common carrier" provisions of the Staggers Act and injunctive relief for exemptions contrary to the public interest. S 2889 Surface Transportation Reauthorization Act 2009: A bill to reauthorize the Surface Transportation Act and for other purposes; (All provisions related to bottleneck provisions, common carrier, injunctive relief, rate quotation, competition, and service necessary to business and public interest.) HR 233 The Railroad Antitrust Enforcement Act of 2009: A bill to amend Federal anti-trust laws to provide expanded coverage and to eliminate exemptions from such laws that are contrary to the public interest with respect to railroads; (All provisions pertaining to the "common carrier" provisions of the Staggers Act and injunctive relief for exemptions contrary to the public interest.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, BAYER CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2010. Original Filing: 300327379.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S 787 A bill to amend the Federal Water Pollution Control Act to clarify the jurisdiction of the United States over waters of the United States; (Provisions related to agriculture activities and the section changing the definition of U.S. Waters.) HR 6273 To amend the Federal Insecticide, Fungicide, and Rodenticide Act to exempt the applicaiton of pesticides subject to that Act, when applied in conformace with that Act, from certain permit requirements under the Federal Water PollutionControl Act, and for other purposes; (Provisions related to NPDES permits for agriculture.) S 3735 A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certin registered pesticides; (Provisions related to NPDES permits for agriculture.) HR 6087 To amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides; (Provisions related to NPDES permits for agriculture.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S 1462 American Clean Energy Leadership Act of 2009: A bill to promote clean energy technology development; (All provisions related to enhanced energy efficiency and clean energy development.) HR 2454 Clean Energy and Security Act: A bill to set up a Cap and Trade system for greenhouse gas emmission and to provide enhancements to programs and initiatives designed to foster green jobs, clean energy, wind, solar, geothermal and other renewables; (All provisions pertaining to enhancements to energy efficiency programs.) HR 1749 Energy Efficient Manufacturing Housing Act 2009: A bill to provide rebates and grants to the states to implement a retrofit program for houses built before 1976; (All provisions related to Energy Star rebates and credits.) HR 5476/S 3079 Building Star Energy Efficiency Act of 2010: A bill to provide incentives for building owners to receive credits and rebates for using energy efficient materials and green technology in constructing commercial buildings; (All provisions related to enhancing energy efficient commercial development and retrofit.) HR 5019 Home Star Energy Retrofit Act of 2009: A bill to provide rebates for energy efficient retro-fits of residential housing; (All provisions related to improving energy efficiency.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 6228/S 593 The Ban Poisonous Additives Act of 2009: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act: A ban on food contact material for children and infants (3 years and under); (All provisionsand amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A Consumer Information Act 2009: A bill to amend the Food, Drug, and Cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol-A into the food; (All provisions relating to the science, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009, a reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) S 510 Food Safety Modernization Act: A bill to modernize the Food and Drug Administration's regulation of food safety; (All provisions related to adding and amendment on Bisphenol-A.) HR 2789 Food Safety Enhancement Act 2009: A bill to amend various provisions of the Act to make the food supply safer; (All provisions related to Bisphenol-A in food contact applications.) HR 1523/S 593 Ban Poisonous Addititives Act of 2009: A bill to ban Bisphenol-A from all food contact uses; (All provisions related to banning Bisphenol-A.) HR 1332 Safe FEAST Act of 2009: A bill to empower the Food and Drug Administration to more thoroughly protect the food supply; (Provisions relating to Bispehenol-A.)

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 1549/S 619 The Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions in the bill.) HR 2749 Food Safety Enhancement Act 2009: To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food in the global market, and for other purposes; (Title I Food Safety. Monitoring food safety provisions. All provisions pertaining to theFDA mandate to make a safety determination on BPA before the end of the year.) S 510 FDA Food Safety Modernization Act: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the safety of the food supply; (Monitoring provisions of the bill.) HR 2400 Strategies to Address Antimicrobial Resistance; (Section 3 (c) relating to authorities over antimicrobial drug data collection.) HR 3519/S 1709 Veterinary Services Investment Act; (Support legislation.) HR 4213 "American Jobs and Closing Tax Loopholes Act of 2010"; (Sections pertaining to AMP, and allocations systems.) S.AMDT 4369 to HR 4213 In the nature of a substitute; (Sections pertaining to AMP, and allocations systems.) HR 6228/S 593 The Ban Poinsonous Additives Act of 2009: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphneol-A containing products.) S 753 the Children's Safe Chemical Act: A ban on food contact materials for children and infants (3years and under); (All provisions and amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A Consumer Information Act 2009: A bill to amend the Food, Drug and cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol-A into the food; (All provisions relating to the science, restrictions on use and applications of Bisphnol-A in food applications.) HR 3590 Patient Protection and Affordable Care Act; (Sections relating to health insurance and drugs; All provisions relating to healthcare.) HR 4872 The Healthcare and Education Reconciliation Act of 2010; (Provisions relating to healthcare.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 4380 To amend the Haromonized Tariff Schedule and temporarily suspend or modify current rates of tariff; (All provisions related to the tariff bills introduced below) A bill to extend the temporary suspension of duty on o-Acetylsalicylic acid (Aspirin). S 2712 A bill to extend the temporary suspension of duty on D-MannoseS 2169 A bill to extend the suspension of duty on Mixtures of Methyl o-toluenesulonate and methyl p-toluenesulfonate (TSME). S 2169 A bill to extend the suspension of duty on Trimethylopropane tris(3-aziridinylpropanoate) (Xama 2) 2166 A bill to extend the suspension of duty on Polyfunctional aziridine (Xama 7). S 2187 A bill to extend the suspension of duty on 1,3-Diisocyanatomethylbenzene, polymer with 1,6-diisocyanatohexane (Desmondur VP HL). S 2189 A bill to extend the suspension of duty on A linear aromatic polyurethane prepolymer based on toluene diisocyanate. (Desmondur E 14 S 2188 A bill to extend the suspension of duty on Poly(toluene diisocyanate) (Desmondur IL BA). S 2190 A bill to extend the suspension of duty on Polyisocyanate cross linking agent products containing triphenylmethane triisocyanate in solvents, (Desmondur R-E). S 2185 A bill to extend suspension of duty on Mixtures of tris(4-isocyanatophenyl)thiophosphate) in solvents, (Desmondur RF-E). S 2167 A bill to extend the suspension of duty on hexane 1,6, diisocynato-, homopolymer, 3,5, dimethyl-1H-pyrazole-blocked solvents.( Desmodur VP LS 2253) S2186 A bill to extend the suspension of duty on Copolymer of methyl ethyl ketoximine and toluene diisocyanate (Desmondur BL XP). S 2165) A bill to extend the suspension of duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked (Crelan). A bill to suspend temporarily the duty on Propoxur (Sedran Technical).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, BAYER CORPORATION had in-house lobbyists. The report was filed on July 20, 2010. Original Filing: 300300581.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 6228/S 593 The Ban Poisonous Additives Act of 2009: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act: a ban on food contact materials for children and infants (3 years and under); (All provisions and amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A Consumer Information Act 2009: A bill to amend the Food, Drug and Cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol-A into the food; (All provisions relating to the science, restricitons on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009, a reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) S 510 Food Safety Modernization Act: A bill to modernize the Food and Drug Administration's regulation of food safety; (All provisions related to adding an amendment on Bisphenol-A.) HR 1332 Safe FEAST Act of 2009: A bill to empower the Food and Drug Administration to more thoroughly protect the food supply.) S 510 Food Safety and Modernization Act; (All sections.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 1549/S 619 To amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II General provisions in the bill.) HR 2749 Food Safety Enhancement Act of 2009 to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food in the global market, and for other purposes; (Title 1 Food Safety. Monitoring food safety provisions.)HR 2400 Strategies to Address Antimicrobial Resistance; (Section 3(c) relating to authorities over Antimicrobial drug data collection.) HR 3519/S 1709 Veterinary Services Investment Act; (Support legislation.) HR 6228/S 593 The Ban Poisonous Additives Act of 2009: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act: A ban on food contact materials for children and infants (3 years and under); (All provisions and amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A Consumer Information Act 2009: A bill to amend the Food Drug and Cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part of Bisphenol-A or could release Bisphenol-a into the food; (All provisions relating to the science, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009, a reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) HR 3962 Affordable Health Care for America Act; (Provisions related to subtitle, A,B,C, and D.) HR 4213 "American Jobs and Closing Tax Loopholes Act of 2010" (Sections pertaining to AMP, and allocation systems; all provisions related to pharmaceuticals and medical devices) S.Amdt 4369 to HR 4213 In the Nature of a substitute; (Sections pertaining to AMP, and allocation systems.) HR 1427 Promoting Innovation and Access to Life-Saving Medicine Act; (All relating to follow on biologics.) S 1142 the "Informed Health Care Decisions Making Act of 2009; (sections pertaining to comparative effectiveness.) HR 1321 Healthy Americans Act; (Relating to Medicare) HR 3590 Patient Protection and Affordable Care Act; (Sections relating to health insurance and drugs; All provisions relating to healthcare.) HR 3962 Affordable Health Care for America Act; (Sections relating to health insurance and drugs; All provisions related to pharmaceuticals and medical devices.) HR 4899 Making Emergency Supplemental Appropriations for Fiscal Year 2010; (All provisions related to pharmaceuticals and medical devices.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 233 The Railroad Antitrust Enforcement Act of 2009: A bill to amend Federal anti-trust laws to provide expanded coverage and to eliminate exceptions from such laws that are contrary to the public interest with respect to railroads. (All provisions pertaining to the "common carrier" provisions of the Staggers Act and injunctive relief for exemptions contrary to the public interest.) S 146 Railroad Anti-Trust Enforcement Act: A bill to amend the Federal anti-trust laws to provide expanded coverageand to eliminate exceptions from such laws that are contrary to the public interest with respect to railroads; (All provisions pertaining to the "common carrier" provisions of the Staggers Act and injunctive relief for exemptions contrary to the public interest.) S 2889 Surface Transportation Reauthorization Act 2009: A bill to reauthorize the Surface Transportation Act and for other purposes; (All provisions related to bottleneck provisions, common carrier, injunctive relief, rate quotation, competition, and service necessary to business and public interest.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 2868/S 2996 To amend the Homeland Security Act of 2002 to extend, modify, and recodify the authority of the Secretary of Homeland Security to enhance security and protect against acts of terrorism against chemical facilities, and for other purposes; (Provisions related to issues that could affect farmers and those relating to extending CFATS regulations, IST provisions and citizen enforcement provisions.)S 787 A bill to amend the Federal Water Pollution Control Act to clarify the jurisdiction of the United States over waters of the United States; (Provisions related to agriculture activities and the section changing the definition of U.S. Waters.) HR 2454 To create clean energy jobs, achieve energy independence, reduce global warming pollution and transition to a clean energy economy; (All provisions related to agriculture activities, allowances/offsets and credits and the "cap and trade" system for agriculture.) S 1733 A bill to create clean energy jobs, promote energy independence, reduce global warming pollution, and transition to a clean energy economy; (All provisions related to agriculture, allowances and offsets.) HR 4159 A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to require local educational agencies and schools to implement integrated pest management programs to minimize the use of pesticides in schools and to provide parents, guardians, and employees with notice of the use of pesticides in schools, and for other purposes; (Provisions relating to pesticides.) S 3535 A bill to enhance the energy security of the United States; (All provisions related to agriculture.) S 3464 A bill to establish an energy and climate framework; (All provisions related to agriculture.) Appropriations: Seeking funding for the FY 2011 appropriations; (All provisions related to agriculture, EPA and pesticide fees.) NPDES permitting issues; (Permitting issues concerning agriculture applications.) PRIA: pesticide fees; (Reauthorization.) Regulatory Biotech Issues; (Provisions in proposed regulations regarding the approval of biotech traits and all other issues related to biotech regulations, including APHIS part 340 regs.) ESA Issues: NMFS Biological opinions; (Discussions on National Marine Fisheries Biological Opinions that we recently released and their potential affects on agriculture.) ESA Spray Drift: Guidance on spray drift; (Provisions in the guidance related to "may cause harm" and changes to FIFRA.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Amendment

BAYER CORPORATION amended a lobbying report for in-house lobbying in Q12010 on July 27, 2010 Original Filing: 300305339.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 6228/S 593 The Ban Poisonous Act of 2009, a bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act, a ban on food contact materials for children and infants (3 years and under); (All provisions and amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A consumer Information Act 2009, a bill to amend the Food, Drug, and Cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol-A into the food; (All provisions relating to the science, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009, a reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) S 510 Food Safety Modernization Act, a bill to modernize the Food and Drug Administrations regulation of food safety; (All provisions related to adding an amendment on Bisphenol-A.) HR 1332 Safe FEAST Act of 2009, a bill to empower the Food and Drug Administration to more thoroughly protect the food supply; (All provisions relating to BPA.) S 510 Food Safety and Modernization Act; (All sections.)

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 6228/S 593 the Ban Poisonous act of 2009, a bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act, a ban on food contact materials for children and infants (3 years and under); (All provisionsand amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A Consumer Information Act 2009, a bill to amend the Food, Drug, and Cosmetic Act to require a warning on the lable of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol-A into the food; (All provisions relating to the science, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009, a reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) HR 1549/S 619 To amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal disease; (Title II. General provisions in the bill.) HR 2749 Food Safety Enhancement Act of 2009 To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food in the global market, and for other puposes; (Title I food Safety,; Monitoring food safety provisions.) HR 2400 Strategies to Address Antimicrobial Resistance; (Section 3 (c) relating to authorities over antimicrobial drug data collection.) HR 3519/S 1709 Veterninary Services Investment Act; (Support of legislation.) HR 1427 Promoting Innovation and Access to Life-Saving Medicine Act; (all relating to follow-on biologics.) S 1142 The "Informed Health Care Decision Making" Act of 2009; (Sections pertaining to comparative effectiveness.) HR 1321 Healthy Americans Act; (Relating to Medicare) Senate Finance Committee Chairman's Mark, America's Healthy Future Act of 2009 (All provisions.) HR 3590 Patient Protection and Affordable Care Act; (Sections relating to health insurance and drugs, all provsions relating to healthcare; all provisions related to competitive acquisition for durable medical equipment and prosthetics, orthotics, and supplies.).) HR 3962 Affordable Health Care for America Act; (Sections relating to health insurance and drugs; provisions related to subtitles A, B, C, and D.) HR 4872 The Health Care and Education Afforability Reconciliation Act; (All provisions dealing with phramaceuticals and medical devices.) S 1796 America's Healthy Future Act of 2009; (Provisions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.) S 1679 Affordable Health Choices Act; (Provsions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.) HR 3200 America's Affordable Health Choices Act of 2009; (Provisions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.) HR 3790 To Amend Title XVIII of the Social Security Act to repeal the Medicare competitive aquisition program for durable medical equipment and prosthetics, orthotics, and supplies (DMEPOS); (All provisions related to competitive acquistionf for durable medical equipment and prosthetics, orthotcs, and supplies.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 1321 Healthy Americans Act; (Provisions relating to Medicare) Senate Finance Committee Chairman's Mark, America's healthy Future Act of 2009; (All provisions.) HR 3962 Affordable health Care for America Act; (Sections relating to health insurance and drugs.)HR 3790 To Amend Title XVIII of the Social Security Act to repeal the Medicare competitive aquisition program for durable medical equipment and prosthetics, orthotics, and supplies (DMEPOS); (All provisions related to competitive acquistionf for durable medical equipment and prosthetics, orthotcs, and supplies.) HR 3590 Patient Protection and Affordable Care Act of 2010; (All provisions related to competitive acquisition for durable medical equipment and prosthetics, orthotics, and supplies.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 233 The Railroad Antitrust Enforcement Act of 2009, a bill to amend Federal anti-trust laws to provide expanded coverage and to eliminate exemptions from such laws that are contrary to the public interest with respect to railroads; (All provisions pertaining to the "common carrier" provisions of the Staggers Act and injunctive relief for exemptions contrary to the public interest.)S 146 Railroaad Anti-Trust Enforcement Act, a bill to amend the Federal anti-trust laws to provide expanded coverage and to eliminate exemptions from such laws that are contrary to the public interest with respect to railroads; (All provisions pertaining to the "common carrier" provisions of the Staggers Act and injunctive relief for exemptions contrary to the public interest.) S 2889 Surface Transportation Reauthorization Act 2009, a bill to reauthorize the Surface Trasportation Act and for other purposes; (All provisions related to bottleneck provisions, common carrier, injunctive relief, rate quotation, competition, and service necessary to business and public interest.)

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 4380 A bill to amend the Harmonized Tariff Schedule of the United States to modify temporarily certain rates of duty, and for other purposes; (All provisions related to chemicals listed below) A bill to suspend temporarily the duty on Olympus WG70 A bill to reduce temporarily the duty on SpirotetramatA bill to suspend temporarily the duty on Flubendiamide A bill to reduce temporarily the duty on AE 0172747 Ether A bill to suspend temporarily the duty on 1,3-Cyclohexanedione. A bill to extend the temporary suspension of duty on Trichloroacetaldehyde (Chloral) A bill to extend the temporary suspension of duty on p-chlorobenzaldehyde A bill to suspend temporarily the duty on mixtures containing 5-Cyclospropyl-4-2(2-Methylsulfonyl-4-Trifluoromethylbenoxyl)Isoxazole (BALANCE PRO) A bill to suspend temporarily the duty on Isoxaflutole A bill to extend the reduction of duty on product mixtures containing Iprodione: 3-(3-5,dicholorophenyl)-N-(1-methylethyl)-2,4-dioxo-1-imidazolidinecarboxamide and application adjuvants (ROVRAL) A bill to extend the temporary suspension of duty on 2-Acetylbutyrolactone A bill to extend the temporary reduction in duty on Beta-cyfluthrin A bill to extend the temporary suspension of duty on Cyfluthrin A bill to temporary suspend the general rate of duty on Clothianidin A bill to extend the temporary suspension of duty on Ethoprop A bill to extend the temporary suspension of duty on product mixtures containing Foramsulfuron and Iodosulfuronmethyl-sodium (Equip) A bill to extend the temporary suspension of duty on Isoxadifen-Ethyl A bill to extend the temporary reduction of duty on Trifloxystrobin A bill to extend the temporary suspension of duty on Spiromesifen A bill to suspend temporarily the duty on Thiencarbazone-methyl A bill to extend the temporary suspension of duty on FOE Hydroxy A bill to reduce temporarily the duty on product mixtures containing Tembotrione and application adjuvants ( LAUDIS) A bill to suspend temporarily the duty on products containing (E)-N-[(2-Chloro-1,3-thiazol-5-yl) methyl]-N-methyl[oxido(oxo)hydrazono] methanediamine or N-[(2-Chloro-1,3-thiazol-5-yl)methyl]-N-{(E)-(methylamino) [oxido(oxo)hydrazono] methyl}amine and application adjucants (PONCHO) A bill to suspend temporarily the duty on 2(Methylthio)-4-(trifluoromethyl) benzoic acid CAS [142994-05-6] A bill to suspend temporarily the duty on 2-Chloro-6-(methylthio)toluene (CAS [82961-52-2]) A bill to suspend temporarily the duty on products containing 3-Mesityl-2-oxo-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutyrate and application adjuvants (OBERON & FORBID) A bill to suspend temporarily the duty on mixtures containing Pyrasulfotole: 5-Hydroxy-1,3-dimethylpyrazol-4-yl 2-mesyl-4-(trifluoromethyl)phenyl ketone; and Bromoxynil Octanoate: 2,4-Dibromo-6-cyanophenyl octanoate; and Bromoxynil Heptanoate: 2,4-Dibromo-6-cyanophenyl heptanoate (HUSKIE) A bill to suspend temporarily the duty on 1,3-Dimethyl-1H-pyrazol-5-ol and 1,3-Dimethylpyrazol-5-one (CAS [5203-77-0], [2749-59-9]) A bill to reduce temporarily the duty on product mixtures containing Thiencarbazone-methyl: Methyl 4-({[(3-methoxy-4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)carbonyl]amino}sulfonyl)-5-methylthiophene-3-carboxylate and Isoxadifen-ethyl: ethyl 4,5-dihydro-5,5-diphenyl-1,2-oxazole-3-carboxylate and Tembotrione: 2-{2-Chloro-4-mesyl-3-[(trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione and application adjuvants (HTSUS 3808.93.15; CAS: 317815-83-1, 163520-33-0, 335104-84-2) (CAPRENO) A bill to suspend temporarily the duty on Cyprosulfamide: N-({4-[(Cyclopropylamino) carbonyl]phenyl}sulfonyl)-2-methoxybenzamide (CAS No. Cyprosulfamide: 221667-31-8) A bill to extend the temporary reduction of duty on ACM A bill to reduce temporarily the duty on Oxadiazon A bill to extend the temporary suspension of duty on mixtures of methyl 4-iodo-2-[3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)ureidosulfonyl] benzoate, sodium salt (Iodosulfuron methyl, sodium salt) and application adjuvants (AUTUMN) A bill to extend the temporary suspension of duty on Mesosulfuronmethyl (OSPREY & SILVERADO) A bill to suspend temporarily the duty on mixtures containing Ethyl(R)-2-[4-(6-chloro-1,3-benzoxazol-2-yloxy)phenoxy]propionate (Fenoxaprop Ethyl), (CAS No. 71283-80-2), 5-hydroxy-1,3-dimethylpyrazol-4-yl 2-mesyl-4-(trifluoromethyl)phenyl ketone (Pyrafulfotole) (CAS No. 365400-11-9), 2,6-dibromo-4-cyanophenyl octanoate (Bromoxynil octanoate) (CAS No. 1689-99-2), and 2,6-dibromo-4-cyanophenyl heptanoate (Bromoxynil heptanoate) (CAS No. 56634-95-8) (WOLVERINE) A bill to suspend temporarily the duty on 1,2,4 Triazole A bill to suspend temporarily the duty on Fluopicolide A bill to suspend temporarily the duty on Fenhexamid A bill to suspend temporarily the duty on BELT & SYNAPSE A bill to extend the temporary suspension of duty on Phenmedipham A bill to extend the temporary suspension of duty on Propiconazole A bill to extend the temporary suspension of duty on PREVICUR A bill to extend the temporary suspension of duty on 2,4-dichloroaniline A bill to extend the temporary reduction in duty of Aluminum tris (O-ethylphosphonate) whether or not mixed with application adjuvants (FOSETYL-AL) A bill to suspend temporarily the duty on 2,2-Dimethylbutanoic acid 3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro(4.5)dec-3-en-4-yl ester (Spirodiclofen) A bill to extend the temporary suspension of duty on Fenamidone A bill to temporarily suspend the duty on cyclopropane-1,1-dicarboxylic acid, dimethyl ester A bill to suspend temporarily the duty on Pyrasulfotole A bill to extend the temporary suspension of duty on Pyrimethanil A bill to reduce temporarily the duty on CORVUS herbicide A bill to reduce temporarily the duty on EVERGOL A bill to reduce temporarily the duty on Imidacloprid Pesticides A bill to suspend temporarily the duty on LIBERTY, RELY and IGNITE herbicides A bill to reduce the temporarily the duty on Imidacloprid Technical A bill to extend the temporary suspension of duty on OPTION & REVOLVER Herbicides A bill to extend the temporary suspension of duty on 2,6-dibromo-4-cyanophenyl octanoate/heptanoate (Bromoxynil Octanoate / Heptanoate) A bill to suspend temporarily the product mixtures containing Methyl 2-[({[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl}amino)sulfonyl]-4- [(mesylamino)methyl]benzoate (Mesosulfuron-methyl) and Methyl 4-iodo-2-[3-(4-methoxy -6-methyl-1,3,5-triazin-2-yl)ureidosulfonyl]benzoate, sodium salt (Iodosulfuron-methyl-sodium), whether or not mixed with application adjuvants (HTSUS 3808.93.15; CAS 208465-21-8 144550-36-7) (ATLANTIS) A bill to suspend temporarily the duty on certain mixtures containing [3-[(6-chloro-3-pridinyl)methyl]-2-thiazolidinylidene]cyanamide (CALYPSO) A bill to extend the temporary suspension of duty on Permethrin A bill to extend the temporary suspension of duty on 2-Chlorobenzyl chloride (O-Chlorobenzylchloride) A bill to suspend temporarily the duty on product mixtures containing Imidacloprid: 1-(6-Chloro-3-pyridinyl)methyl-N-nitroimidazolidin-2-ylidene amine Z9: (9Z)-9-Tricosene (MAXFORCE WG10 & GR0.5) A bill to extend the temporary suspension of duty on Resmethrin A bill to extend the temporary suspension of duty on N-3[3-(1-methylethoxy)phenyl]-2-(trifluoromethyl)benzamide (Flutolanil) A bill to extend the temporary suspension of duty on product mixtures containing 2-(4,5-dihydro-4-methyl-5-oxo-3-propoxy-1H-1,2,4-triazol-1-yl)carboxamidosulfonylbenzoate; sodium (4,5-dihydro-4-methyl-5-oxo-3-propoxy-1H-1,2,4-triazol-1-ylcarbonyl)(2-methoxycarbonylphenylsulfonyl)azanide & methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-a-(methanesulfonamido)-p-toluate (HTSUS 3808.93.15 AND 9902.24.42; CAS 181274-15-7, 208465-21-8) (RIMFIRE & OLYMPUS FLEX) To suspend temporarily the duty on Tembotrione A bill to extend the temporary suspension of duty on Deltamethrin A bill to suspend temporarily the duty on Hydrazine Hydrate Solution A bill to extend the temporary reduction of duty on Triadimefon (Bayleton Technical) A bill to extend the temporary reduction of duty on Ethofumesate in bulk or mixtures. A bill to reduce temporarily the duty on product mixtures containing Imidacloprid: 1-[(6-chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine and Cyfluthrin: Cyano(4-fluoro-3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclo-propanecarboxylate and application adjuvants (HTSUS 3808.91.25; CAS 138261-41-3, 68359-37-5) (LEVERAGE ) A bill to reduce temporarily the duty on product mixtures containing Imidacloprid: 1-[(6-chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine and Beta-Cyfluthrin: (RS)-a-cyano-4-fluro-3-phenoxybenzyl(1RS,3RS;1RS,3SR)-2-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate and application adjuvants (HTSUS 3808.91.25; CAS 138261-41-3, 68359-37-5) (LEVERAGE 360) A bill to reduce temporarily the duty on Benzamide, N-[2-[3-chloro-5 (trifluoromethyl) 2-pyridinyl]ethyl]-2-(trifluoromethyl) (FLUOPYRAM) whether or not mixed with application adjuvants (FLUOPYRAM) A bill to suspend temporarily the duty on 1,3,5-Triazine-2,4-diamine, N-[(1R,2S)-2,3-dihydro-2,6-dimethyl-1H-inden-1-yl]-6-(1-fluoroethyl) (INDAZIFLAM) whether or not mixed with application adjuvants (HTSUS 2933.69.60; CAS 950782-86-2) ) (INDAZIFLAM) A bill to extend the temporary suspension of duty on Phosphorus Thiochloride (PSCL3) A bill to extend the temporary suspension of duty on Desmedipham in bulk or mixtures A bill to extend the temporary suspension of duty on Phenmedipham Miscellaneous Tarrif Bill: To seek introduction and passage of a bill in the Senate (similar to HR 4380) that would encompass the following bills already introduced in the Senate into a larger package: S.2691A bill to reduce temporarily the duty on AE 0172747 Ether. S.1972 A bill to extend the temporary suspension of duty on mixtures of methyl 4-iodo-2-[3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)ureidosulfonyl] benzoate, sodium salt (Iodosulfuron methyl, sodium salt) and application adjuvants. S.2689 A bill to reduce the temporary suspension of duty on B-Cyfluthrin. S.1903 A bill to suspend temporarily the duty on 1,3-Dimethyl-1H-pyrazol-5-ol and 1,3-Dimethylpyrazol-5-one. S.2489 A bill to suspend temporarily the duty on 2-Chloro-6-(methylthio)toluene. S.2252 A bill to extend the temporary suspension of duty on Clothianidin. S.1902 A bill to reduce temporarily the duty on Corvus herbicide. S.2686 A bill to extend and modify the temporary reduction of duty on cyclopropane-1,1-dicarboxylic acid, dimethyl ester. S.2257 A bill to extend the temporary suspension of duty on Deltamethrin. S.1901 A bill to reduce temporarily the duty on Evergol. S.2684 A bill to extend the temporary suspension of duty on Fenamidone. S.2069 A bill to extend the temporary suspension of duty on flutolanil. S.2687 A bill to extend and modify the temporary suspension of duty on Aluminum tris (O-ethylphosphonate). S.1900 A bill to reduce temporarily the duty on Liberty, Rely, and Ignite herbicides. S.1971 A bill to extend the suspension of duty on Mesosulfuronmethyl. S.2253 A bill to extend the temporary suspension of duty on Permethrin. S.2683 A bill to suspend temporarily the duty on Pyrasulfotole. S.2262 A bill to extend the temporary suspension of duty on Resmethrin. S.2690 A bill to reduce and modify the temporary suspension of duty on Iprodione. S.2688 A bill to extend the temporary suspension of duty on Triadimefon. S.1970 A bill to suspend temporarily the duty on mixtures containing ethyl (R)-2-[4-(6-chloro-1,3-benzoxazol-2-yloxy)phenoxy]propionate (Fenoxaprop-p-ethyl) (CAS No. 71283-80-2), 5-hydroxy-1,3-dimethylpyrazol-4-yl 2-mesyl-4-(trifluoromethyl)phenyl ketone (Pyrasulfotole) (CAS No. 365400-11-9), 2,6-dibromo-4-cyanophenyl octanoate (Bromoxynil octanoate) (CAS No. 1689-99-2_, and 2,6-dibromo-4-cyanophenyl heptanoate (Bromoxynil heptanoate) (CAS No. 56634-95-8) (provided for in subheading 3808.93.15). S.2109 A bill to reduce temporarily the duty on mixtures of imidacloprid ((1-[(6-Chloro-3-pyridinyl)methly]-N-nitro-2-imidazolidinimine) with cyfluthrin ((R)-cyano-(4-fluoro-3-phenoxyl)phenyl)methyl (1R,3R)-3-(2.,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate) or its beta-cyfluthrin isomer. S.2110 A bill to reduce temporarily the duty on Fluopyram. S.2111 A bill to suspend temporarily the duty on Indaziflam. Miscellaneous Tariff Bill: Bayer CropScience had previously requested several chemicals to be included in the Miscellaneous Tariff Bill that are no longer part of the companys request. Bayer Crop Science has asked that the following bills or chemicals not be included in the Miscellaneous Tariff Bill on the companys behalf. A bill to suspend temporarily the duty on Thionyl chloride A bill to suspend the temporary duty suspension on Sodium Methylate Solution A bill to suspend temporarily the duty on Spiroxamine A bill to extend the temporary duty suspension on NORTRON SC

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, BAYER CORPORATION had in-house lobbyists. The report was filed on April 20, 2010. Original Filing: 300273468.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 6228/S 593 the Ban Poisonous act of 2009, a bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act, a ban on food contact materials for children and infants (3 years and under); (All provisionsand amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A Consumer Information Act 2009, a bill to amend the Food, Drug, and Cosmetic Act to require a warning on the lable of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol-A into the food; (All provisions relating to the science, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009, a reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) HR 1549/S 619 To amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal disease; (Title II. General provisions in the bill.) HR 2749 Food Safety Enhancement Act of 2009 To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food in the global market, and for other puposes; (Title I food Safety,; Monitoring food safety provisions.) HR 2400 Strategies to Address Antimicrobial Resistance; (Section 3 (c) relating to authorities over antimicrobial drug data collection.) HR 3519/S 1709 Veterninary Services Investment Act; (Support of legislation.) HR 1427 Promoting Innovation and Access to Life-Saving Medicine Act; (all relating to follow-on biologics.) S 1142 The "Informed Health Care Decision Making" Act of 2009; (Sections pertaining to comparative effectiveness.) HR 1321 Healthy Americans Act; (Relating to Medicare) Senate Finance Committee Chairman's Mark, America's Healthy Future Act of 2009 (All provisions.) HR 3590 Patient Protection and Affordable Care Act; (Sections relating to health insurance and drugs, all provsions relating to healthcare.) HR 3962 Affordable Health Care for America Act; (Sections relating to health insurance and drugs; provisions related to subtitles A, B, C, and D.) HR 4872 The Health Care and Education Afforability Reconciliation Act; (All provisions dealing with phramaceuticals and medical devices.) S 1796 America's Healthy Future Act of 2009; (Provisions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.) S 1679 Affordable Health Choices Act; (Provsions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.) HR 3200 America's Affordable Health Choices Act of 2009; (Provisions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, BAYER CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2010. Original Filing: 300245017.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 6228/S 593 the Ban Poisonous Act of 2009 A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act a ban on food contact materials for children and infants (3 years and under); (All provisionsand amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol-A Consumer Information Act of 2009, a bill to amend the Food Drug and Cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol A into the food; (All provisions relating to the science, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009, a reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) S 510 Food Safety Modernization Act; (Provisions relating to all sections, provisions relating to strategy for comments.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 6228/S 593 The Ban Poisonous Act of 2009, A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (all provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) S 753 The Children's Safe Chemical Act a ban on food contact materials for children and infants (3 years and under); (All provisionsand amendments pertaining to the ban and the testing are relevant.) HR 4341 Bisphenol -A Consumer Information Act of 2009, a bill to amend the Food Drug and Cosmetic Act to require a warning on the label of any food container that is composed, in whole or in part, of Bisphenol-A or could release Bisphenol A into the food; (All provisions relating to the science, restrictions on use and applications of Bisphenol-A in food applications.) HR 2749 Food Safety Enhancement Act of 2009, a reform of the law on food safety protection; (All provisions pertaining to the FDA mandate to make a safety determination on BPA before the end of the year.) HR 1427 Promoting Innovation and Access to Life-Saving Medicine Act; (All provisions relating to follow on biologics.) S 1142 The "Informed Health Care Decisions Making Act of 2009; (Sections pertaining to comparative effectiveness.) HR 1321 Healty Americans Act; (Provisions relating to Medicare.) Senate Finance Committee Chairman's Mark, America's Healthy Future Act of 2009; (All provisions.) HR 3590 Patient Protection and Affordable Care Act; (Sections relating to health insurance and drugs, all provisions relating to healthcare) HR 3962 Affordable Health Care for America Act; (Sections relating to health insurance and drugs, provisions related to subtitles A,B, C and D.) Senate: Patient Protection & Affordable Care Act; (All provisions relating to health care.) S 1796 America's Healthy Future Act of 2009; (Provisions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.) S 1679 Affordable Health Choices Act; (Provisions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.) HR 3200 America's Affordable Health Choices Act of 2009; (Provisions relating to medical device excise tax, medicare reimbursement rates for medical imaging, comparative effectiveness research.) HR 1549/S 619 the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisons in the bill.) HR 2749 Food Safety Enhancement Act of 2009 To amend the Federal Food, Drug, and cosmetic act to improve the safety of food in the global market, and for other purposes.) HR 3519/S 1709 Veterinary Services Investment Act (Support for legislation.) HR 2400 Strategies to Address Antimicrobial Resistance; (Section 3(c) relating to authorities over antimicrobial drug data collection.) S 510 Food Safety Modernization Act; (Provisions relating to strategy for comments.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 146 Railroad Anti-Trust Enforcement Act, a bill to amend the Federal anti-trust laws to provide expanded coverage and to eliminate exemptions from such laws that are contrary to the public interest with respect to railroads; (All provisions pertaining to the "commoncarrier" provisions of the Staggers Act and injuctive relief for exemptions contrary to the public interest.) S 2889 Surface Transportation Reauthorization Act of 2009, a bill to reauthorize the Surface Transportaion Act and for otherpurposes; (All provisions related to bottleneck provisions, common carrier, injunctive relief, rate quotation, competition, and service necessary to business and public interest.) HR 233 The Railroad Antitrust Enforcement Act of 2009, a bill to amend Federal anti-trust laws to provide expanded coverage and to eliminate exemptions from such laws that are contrary to the public interest with respect to railroads; (all provisions pertaining to the "common carrier" provision of the Staggers Act and injunctive relief for exemptions contrary to the public interest.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Miscellaneous Tariff Bill (No number yet): To seek introduction of bills to provide duty suspension or duty reduction on chemicals as listed below, similar to bill introduced in the 110th congress: A bill to extend the temporary suspension of duty on o-Acetylsalicylic acid (Aspirin). A bill to extend the temporary suspension of duty on D-Mannose.A bill to extend the suspension of duty on Mixtures of Methyl o-toluenesulonate and methyl p-toluenesulfonate (TSME). A bill to extend the suspension of duty on Trimethylopropane tris(3-aziridinylpropanoate) (Xama 2) A bill to extend the suspension of duty on Polyfunctional aziridine (Xama 7). A bill to extend the suspension of duty on 1,3-Diisocyanatomethylbenzene, polymer with 1,6-diisocyanatohexane (Desmondur VP HL). A bill to extend the suspension of duty on A linear aromatic polyurethane prepolymer based on toluene diisocyanate. (Desmondur E 14 A bill to extend the suspension of duty on Poly(toluene diisocyanate) (Desmondur IL BA). A bill to extend the suspension of duty on Polyisocyanate cross linking agent products containing triphenylmethane triisocyanate in solvents, (Desmondur R-E). A bill to extend suspension of duty on Mixtures of tris(4-isocyanatophenyl)thiophosphate) in solvents, (Desmondur RF-E). A bill to extend the suspension of duty on hexane 1,6, diisocynato-, homopolymer, 3,5, dimethyl-1H-pyrazole-blocked solvents.( Desmodur VP LS 2253) A bill to extend the suspension of duty on Copolymer of methyl ethyl ketoximine and toluene diisocyanate (Desmondur BL XP). A bill to extend the suspension of duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked (Crelan). A bill to suspend temporarily the duty on Propoxur (Sedran Technical).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, BAYER CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2009. Original Filing: 300216276.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Miscellaneous Tariff Bill (no number yet): To seek introduction of bills (no numbers yet); (To provide duty suspension or duty reduction on chemicals as listed below: A bill to extend the temporary suspension of duty on o-Acetylsalicylic acid (Asprin). A bill to suspend temporarily the duty on Propoxur (Sedran Technical). A bill to extend the suspension of duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked (Crelan). A bill to extend suspension of duty on Mixtures of tris(4-isocyanatophenyl)thiophosphate) in solvents (Desmondur RF-E). A bill to extend the suspension of duty on Copolymer of methyl ethyl ketoximine and toluene diisocyanate (Desmondur BL XP). A bill to extend the suspension of duty on 1,3-Diisocyanatomethylbenzene, polymer with 1,6-diisocyanatohexane (Desmondur VP HL). A bill to extend the suspension of duty on Poly(toluene diisocyanate) (Desmondur IL BA). A bill to extend the suspension of duty on A linear aromatic polyurethane prepolymer based on toluene diisocyanate. (Desmondur E 14). A bill to extend the suspension of duty on Polyisocyanate cross linking agent products containing triphenylmethane triisocyanate in solvents (Desmondur R-E). A bill to extend extend the suspension of duty on Hexane, 1-6-diisocyanato-,homopolymer, 3,5-dimethyl-1H-pyrazole-blocked in solvents (Desmondur VP LS 2253). A bill to extend the suspension of duty on Mixtures of Methyl o-toluenesulonate and methyl p-toluenesulfonate (TSME). A bill to extend the suspension of duty on Trimethylopropane tris(3-aziridinylpropanoate) (Xama 2). A bill to extend the suspension of duty on Polyfunctional aziridine (Xama 7). A bill to extend the temporary suspension of duty on D-Mannose.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, BAYER CORPORATION had in-house lobbyists. The report was filed on July 20, 2009. Original Filing: 300189365.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HealthCare Reform: House Tri Committee Discussion Draft/Senate HELP Draft; (All provisions relating to pharmaceuticals and medical devices.) HR 1427/S 1695/S 726 To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes; (All provisions.)S 1213 A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revene Code of 1986 to establish a Patient-Centered Outcomes Research Trust Fund, and for other purposes; (All provisions.) HR 2824 A bill to enhance the conduct and support of federally funded comparative effectiveness research to health care, and for other purposes; (All provisions.) HR 2502 To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revene Code of 1986 to establish a Comparative Effectiveness Research Trust Fund; (All provisions.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HJ Res 18 Providing for congressional disapproval of the rule submitted by the Department of the Interior and the Department of Commerce under chapter 8 of title 5, United States Code relating to interagency cooperation under the Endangered Species Act of 1973; (Provisions relaing to the Endangered Species Act.) HR 21 To establish a national policy for our oceans, to strengthen the National Oceanic and Atmospheric Administration, to establish a national and regional ocean governance structure, and for other purposes; (Provisions related to regulations/changes to upsteam activities that could affect agriculture.) S 787 A bill to amend the Federal Water Pollution Control Act to clarify the jurisdiction of the United States over waters of the United States; (Provisions related to agriculture activities and the section removing the word "navigable" from the definition of US Waters.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, BAYER CORPORATION had in-house lobbyists. The report was filed on April 20, 2009. Original Filing: 300160708.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1 American Recovery and Reinvestment Act; (All provisions having to do with energy, infrastructure and science and retroffitting schools, government buildings and medical facilities.)HR 5301-To temporarily suspend the duty of Acetyl Salicylic acid.(All provisions.) HR 5304- To temporarily suspend the duty of Sorafenib-Bay54.(All provisions.) HR 5072- To temporarily suspend the duty of Arcol Catalyst 3. (All provisions.) HR 5302- To temporarily suspend the duty of D-Mannose. (All provisions.) HR 5303- To temporarily suspend the duty of Sedran Technical. (All provisions.) HR 5073- To temporarily suspend the duty of Crelan VP LS 2147. (All provisions.) HR 5074- To temporarily suspend the duty of Desmodur RF-E. (All provisions.) HR 5078- To temporarily suspend the duty of Desmodur BL XP 2468. (All provisions.) HR 5080- To temporarily suspend the duty of Desmodur HL BA. (All provisions.) HR 5083- To temporarily suspend the duty of Desmodur E 14. (All provisions.) HR 5075- To temporarily suspend the duty of Desmodur RE. (All provisions.) HR 5081- To temporarily suspend the duty of VP LS 2253. (All provisions.) HR 5077- To temporarily suspend the duty of TSME. (All provisions.) HR 5079- To temporarily suspend the duty of Xama 2. (All provisions.) HR 5070- To temporarily suspend the duty of Xama 7. (All provisions.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, BAYER CORPORATION had in-house lobbyists. The report was filed on Jan. 17, 2009. Original Filing: 300125414.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1650/S. 772 The Railroad Anti-Trust Enforcement Act; (All provisions relating to amendments that will provide expanded coverage to the Federal Anti-Trust laws to eliminate exemptions from such laws that are contrary to the public interest with respect to railroalds.) H.R. 2125/S. 953 The Rail Competition and Service Improvement Act of 2007; (All provisions relating to amendments that willensure the competition in the rail industry, enable rail customers to obtain reliable rail servie, and provide those customers with a reasonable process for challenging rate and service disputes.) S. 1125 The Freight Rail Capacity Expansion Act of 2007; (All provisions pertaining to incentives to encourage investment in the expansion of freight rail infrastructure capacity through changes to the Internal Revenue Code of 1986 and to enhance modal tax equity.)

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.4653 To extend the temporary suspension of duty on ACM; (Provisions relating to the reduction of tariffs.) H.R.4654 To extend the temporary suspension of duty on Oxadiazon; (Provisions relating to the reduction of tariffs.) H.R.4635 To suspend temporarily the duty on Product mixtures containing Thiencarbazone-methyl (Methyl 4-({Y(3-methoxy-4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-tria zol-1-yl)carbonyl?amino} sulfonyl)-5-methylthiophene-3-caroxylate) & Isoxadifen-ethyl (ethyl 4,5-dihydro-5,5-diphenyl-1,2-oxazole-3-carboxylate) & Isoxaflutole(5-Cyclospropyl-4-(2-Methylsulfonyl-4-Trifluorom ethylbenxoyl)Isoxazole)); (Provisions relating to the reduction of tariffs.) H.R.4636 To suspend temporarily the duy on Cyprosulfamide: N-( {4-YCyclopropylamino) carbonyl?phenyl}sulfonyl)-2-methoxybenzamide (CAS No. Cyprosulfamide: 221667-31-8); (Provisions relating to the reduction of tariffs.) H.R.4630 To suspend temporarily the duty on 2-Chloro-6-(methylthio)toluene; (Provisions relating to the reduction of tariffs.) H.R.4629 To suspend temporarily the duty on 2-(Methylthio)-4-(trifluoromethyl) benzoic acid; (Provisions relating to the reduction of tariffs.) H.R.4633 To suspend temporarily the duty on 1,3-Dimethyl-1H-pyrazol-5-ol and 1,3-Dimethylpyrazol-5-one; (Provisions relating to the reduction of tariffs.) H.R.4631 To suspend temporarily the duty on products containing 3-Mesityl-2-oxo-1-oxaspiroY4.4?non-3-en-4-yl 3,3-dimethylbutyrate; (Provisions relating to the reduction of tariffs.) H.R.4632 To suspend temporarily the duty on mixtures containing Pyrasulfotole: 5-Hydroxy-1,3-dimethylpyrazol-4-yl 2-mesyl-4-(trifluoromethyl)phenyl ketone; and Bromoxynil Octanoate: 2,4-Dibromo-6-cyanophenyl octanoate; and Bromoxynil Heptanoate: 2,4-Dibromo-6-cyanophenyl heptanoate; (Provisions relating to the reduction of tariffs.) H.R.4634 To suspend temporarily the duty on Products containing ( ) -2-ethoxy-2,3-dihydro-3,3-diemthylbenzofuran-5-yl methansulfonate; (Provisions relating to the reduction of tariffs.) H.R.4628 To suspend temporarily the duty on products containing (E)-N-Y(2-Chloro-1,3-thiazol-5-yl) methyl?-N-methylYoxido(oxo)hydrazono? methanediamine or N-Y(2-Chloro-1,3-thiazol-5-yl)methyl?-N-{(E)-(methylamino) Yoxido(oxo)hydrazono? methyl}-amine; (Provisions relating to the reduction of tariffs.) H.R.4591 To suspend temporarily the duty on 1,3-Cyclohexanedione; (Provisions relating to the reduction of tariffs.) H.R.4599 To extend the temporary suspension of duty on 2-Acetylbutyrolactone; (Provisions relating to the reduction of tariffs.) H.R.4590 To suspend temporarily the duty on AE 0172747 Ether; (Provisions relating to the reduction of tariffs.) H.R.4595 To suspend temporarily the duty on Mixtures containing 4-(2-Methylsulfonyl-4-trifluoromethyl-benzoyl)-5-cyclopropyl soxazole; (Provisiosn relating to the reduction of tariffs.) H.R.4600 To extend the temporary suspension of duty on -Cyfluthrin; (Provisions relating to the reduction of tariffs.) H.R.4602 To extend the temporary suspension of duty on Clothianidin; (Provisions relating to the reduction of tariffs.) H.R.4601 To extend the temporary suspension of duty on Cyfluthrin; (Provisions relating to the reduction of tariffs.) H.R.4604 To extend the temporary suspension of duty on product mixtures containing Foramsulfuron and Iodosulfuronmethyl-sodium; (Provisions relating to the reduction of tariffs.) H.R.4603 To extend the temporary suspension of duty on Ethoprop; (Provisions relating to the reduction of tariffs.) H.R.4589 To suspend temporarily the duty on Flubendiamide; (Provisions relating to the reduction of tariffs.) H.R.4609 To extend the temporary suspension of duty on FOE Hydroxy; (Provisions relating to the reduction of tariffs.) H.R.4605 To extend the temporary suspension of duty on Isoxadifen-Ethyl; (Provisions relating to the reduction of tariffs.) H.R.4597 To suspend temporarily the duty on Isoxaflutole; (Provisions relating to the reduction of tariffs.) H.R.4587 To suspend temporarily the duty on Olympus WG70; (Provisions relating to the reduction of tariffs.) H.R.4594 To extend the temporary suspension of duty on 4-Chlorobenzaldehyde; (Provisions relating to the reduction of tariffs.) H.R.4598 To extend the temporary suspension of duty on Iprodione; (Provisiosn relating to the reduction of tariffs.) H.R.4607 To extend the temporary suspension of duty on Spiromesifen; (Provisions relating to the reduction of tariffs.) H.R.4588 To suspend temporarily the duty on Spirotetramat; (Provisions relating to the reduction of tariffs.) H.R.4610 To suspend temporarily the duty on Tembotrione; (Provisions relating to the reduction of tariffs.) H.R.4608 To suspend temporarily the duty on Thiencarbazone-methyl; (Provisions relating to the reduction of tariffs.) H.R.4606 To extend the temporary suspension of duty on Trifloxystrobin; (Provisions relating to the reduction of tariffs.) H.R.5117 To extend the temporary suspension of duty on 2,4-Dichloroaniline; (Provisions relating to the reduction of tariffs.) H.R.5398 To suspend temporarily the duty on certain mixtures containing Y3-Y(6--chloro-3-pridinyl)methyl?-2-thiazolidinylidene?cyana ide; (Provisions relating to the reduction of tariffs.) H.R.5121 To extend the temporary reduction of duty on cyclopropane-1,1-dicarboxylic acid, dimethyl ester; (Provisions relating to the reduction of tariffs.) H.R.5118 To extend the temporary suspension of duty on Aluminum tris (O-ethylphosphonate); (Provisions relating to the reduction of tariffs.) H.R.5122 To suspend temporarily the duty on Pyrasulfotole; (Provisions relating to the reduction of tariffs.) H.R.5123 To extend the temporary suspension of duty on Pyrimethanil; (Provisions relating to the reduction of tariffs.) H.R.5278 To extend the temporary suspension of duty on Option and Revolver herbicides; (Provisions relating to the reduction of tariffs.) H.R.5274 To reduce temporarily the duty on Imidacloprid Pesticides; (Provisions relating to the reduction of tariffs.) H.R.5277 To extend the temporary suspension of duty on Imidacloprid Technical; (Provisions relating to the reduction of tariffs.) H.R.5039 To suspend temporarily the duty on 1,2,4 Triazole; (Provisions relating to the reduction of tariffs.) H.R.5042 To suspend temporarily the duty on Belt & Synapse; (Provisions relating to the reduction of tariffs.) H.R.5041 To suspend temporarily the duty on Fenhexamid; (Provisions relating to the reduction of tariffs.) H.R.5040 To suspend temporarily the duty on Fluopicolide; (Provisions relating to the reduction of tariffs.) H.R.5045 To extend the temporary suspension of duty on Previcur; (Provisions relating to the reduction of tariffs.) H.R.5044 To extend the temporary suspension of duty on Propiconazole; (Provisions relating to the reduction of tariffs.) H.R.5419 To suspend temporarily the duty on product mixtures containing Imidacloprid: 1-(6-Chloro-3-pyridinyl)methyl-N-nitroimidazolidin-2-ylidene amine Z9: (9Z)-9-Tricosene; (Provisions relating to the reduction of tariffs.) H.R.5418 To extend the temporary suspension of duty on 2-Chloro benzyl chloride; (Provisions relating to the reduction of tariffs.) H.R.5417 To extend the temporary suspension of duty on Permethrin; (Provisions relating to the reduction of tariffs.) H.R.5414 To suspend temporarily the duty on Phosphorus Thiochloride; (Provisions relating to the reduction of tariffs.) H.R.5120 To extend the temporary suspension of duty on Fenamidone; (Provisions relating to the reduction of tariffs.) H.R.5119 To suspend temporarily the duty on 2,2-Dimethylbutanoic acid 3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro(4.5)dec-3-en-4-yl ester; (Provisions relating to the the reduction of tariffs.) H.R.5333 To extend the temporary suspension of duty on 2,6-dibromo-4-cyanophenyl octanoate/heptanoate; (Provisions relating to the reduction of tariffs.) H.R.5332 To extend the temporary suspension of duty on Desmedipham in bulk or mixtures; (Provisions relating to the reduction of tariffs.) H.R.5043 To extend the temporary suspension of duty on Phenmedipham; (Provisions relating to the reduction of tariffs.) H.R.4998 To extend the temporary suspension of duty on mixtures of methyl 4-iodo-2-Y3-(4-methoxy-6-methyl-1,3,5- triazin-2-yl)ureidosulfonyl? benzoate, sodium salt(Iodosulfuron methyl, sodium salt) and application adjuvants; (Provisions relating to the reduction of tariffs.) H.R.4999 To extend the temporary suspension of duty on Mesosulfuronmethyl; (Provisions relating to the reduction of tariffs.) H.R.5000 To suspend temporarily the duty on mixtures containing (R)-2-Y4-(6-chloro-1,3-benzoxazol-2-yloxy)phenoxy?propionate (Fenoxaprop Ethyl), (CAS No. 71283-80-2), 5-hydroxy-1,3-dmiethylpyrazol-4-yl 2-mesyl-4-(trifluoromethyl)phenyl ketone (Pyrafulfotole) (CAS No. 365400-11-9), 2,6-dibromo-4-cyanophenyl octanoate (Bromoxynil octanoate) (CAS No. 1689-99-2), and 2,6-dibromo-4-cyanophenyl heptanoate (Bromoxynil heptanoate) (CAS No. 56634-95-8); (Provisions relating to the reduction of tariffs.) H.R.5421 To extend the temporary suspension of duty on N-3Y3-(1-methylethoxy)phenyl?-2-(trifluoromethyl)benzamide; (Provisions relating to the reduction of tariffs.) H.R.5420 To extend the temporary suspension of duty on Resmethrin; (Provisions relating to the reduction of tariffs.) H.R.5422 To extend the temporary suspension of duty on mixtures containing methyl 2-(4,5-dihydro-4-methyl-5-oxo-3-propoxy-1H-1,2,4-triazol-1-y l)carboxamidosulfonylbenzoate; sodium (4,5-dihydro-4-methyl-5-oxo-3-propoxy-1H-1,2,4-triazol-1-ylc arbonyl)(2-methoxycarbonylphenylsulfonyl)azanide & methyl 4-iodo-2-Y3-(4-methoxy-6-methy; (Provisions relating to the reduction of tariffs.) H.R.5415 To suspend temporarily the duty on Sodium Methylate; (Provisions relating to the reduction of tariffs.) H.R.5416 To suspend temporarily the duty on Spiroxamine; (Provisions relating to the reduction of tariffs.) H.R.5413 To suspend temporarily the duty on Thionyl chloride; (Provisions relating to the reduction of tariffs.) H.R.5334 To suspend temporarily the duty on product mixtures containing Methyl 2-Y({Y(4,6-dimethoxy-2-pyrimidinyl)amino?carbonyl}amino)sulf onyl?-4-Y(mesylamino)methyl?benzoate Methyl 4-iodo-2-Y3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)ureidosul fonyl?benzoate, sodium salt; (Provisions relating to the reduction of tariffs.) H.R.4592 To suspend temporarily the duty on certain mixtures containing Thiencarbazone-methyl and Isoxadifen-ethyl and Isoxaflutole; (Provisions relating to the reduction of tariffs.) H.R.4593 To extend the temporary suspension of duty on Trichloroacetaldehyde; (Provisions relating to the reduction of tariffs.) H.R.5457 To extend the temporary suspension of duty on Deltamethrin; (Provisions relating to the reduction of tariffs.) H.R.5458 To suspend temporarily the duty on Hydrazine monohydrate; (Provisions relating to the reduction of tariffs.) H.R.5456 To suspend temporarily the duty on Tembotrione; (Provisions relating to the reduction of tariffs.) H.R.5459 To extend the temporary suspension of duty on Triadimefon (Provisions relating to the reduction of tariffs.) H.R.5272 To reduce temporarily the duty on Corvus herbicide; (Provisions relating to the reduction of tariffs.) H.R.5273 To reduce temporarily the duty on Evergol; (Provisions relating to the reduction of tariffs.) H.R.5275 To suspend temporarily the duty on Liberty, Rely, and Ignite herbicides; (Provisions relating to the reduction of tariffs.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, BAYER CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2008. Original Filing: 300105459.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2008

Q2 Report

In Q2, BAYER CORPORATION had in-house lobbyists. The report was filed on July 21, 2008. Original Filing: 300079888.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Q1 Report

In Q1, BAYER CORPORATION had in-house lobbyists. The report was filed on April 21, 2008. Original Filing: 300052349.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1650/S. 772 The Railroad Anti-Trust Enforcement Act; (All provisions relating to amendments that will provide expanded coverage to the Federal Anti-Trust laws to eliminate exemptions from such laws that are contrary to the public interest with respect to railroads.) H.R. 2125/ S. 953 The Rail Competition and Service Improvement Act of 2007; (All provisions relating to amendments that will ensure competition in the rail industry, enable rail customers to obtain reliable rail service, and provide those customers with a resonable process for challenging rate and service disputes.) S. 1125 The Freight Rail Capacity Expansion Act of 2007; (All provisions pertaining to incentives to encourage investment in the expansion of freight rail infrastructure capacity through changes to the Interal Revenue Code of 1986 and to enhance modal tax equity.)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed